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ABSTRACT
Mass spectrometry (MS) has tum out to be a fundamental technology which has
produced tremendous strides in the biological sciences. In the last three decades, MS has
witnessed convincing growth. Mass spectrometry has rapidly evolved to the forefront of
analytical techniques; its ability to analyze proteins, deoxyribonucleic acid (0 A) and
carbohydrate biomolecules has been a major driving force in the field of proteomics,
genomics and glycomics. The level of perfonnance that is achievable with MS today
allows scientists to study various biomolecules in ways that were inconceivable 25 years
ago. In this thesis, two different kinds of biomolecules will be covered: oligonucleotides
and carbohydrate-protein neoglycoconjugates.
First of all, the differentiation and sequencing of three constitutional isobaric 18-
o A oligomers, namely: GATICATAGCTACGAATC 1,
AATICGTAGCTACGAATC 2, and AATICGTACCTACGAATG 3 were investigated
using e1ectrospray ionization (ESI) mass spectrometry with a hybrid QqTOF-MSfMS
instrument. Our main objective was to differentiate and to sequence these
oligonucleotides. The hypothesis was that the single scan ESI-QqTOF-MS analyses of
the DNA oligomers will afford the same series of deprotonated molecular ions and that
low-energy collision tandem mass spectrometric analyses (CID-MSfMS) will allow us to
differentiate and to sequence the three DNA oligomers using the Mongo Oligo Software.
Another objective was also to establish a mass fingerprint of these three oligonucleotides.
This will aid to characterize the structure of covalently linked carcinogens to these three
isobaric oligonucleotides.
The second part of the thesis, which includes several chapters, is concerned with
the use of MS for the localization of the glycation sites of neoglycoconjugate vaccine
models formed by the covalent attachment of specific immunogenic carbohydrates
obtained from different virulent bacteria to the protein carrier bovine serum albumin
(BSA). This can be accomplished using a methodology based on squaric acid chemistry
which was developed to conjugate carbohydrate antigens to lysine residues in proteins.
Three different examples of hapten-BSA glycoconjugate vaccines were used: the Vibrio
cholerae 01 antigenic specific hapten conjugated to the BSA, the tetrasaccharide side
chain of the Bacillus anthracis exosporium conjugated to the BSA, and finally the model
~-D-galactopyranosyl-(l-->4)-~-D-glucopyranoside(~-lactoside) conjugated to the protein
carrier BSA. Initially, the recording of the MALDI-TOF-MS of the different hapten-BSA
glycoconjugate vaccines allowed us to determine the hapten-to-BSA ratios. The
neoglycoconjugates were then digested and analyzed by MALDI-TOFrrOF-MS/MS and
LC-ESI-QqTOF-MS/MS for the determination of the glycation sites. Our hypothesis was
that the trypsin digestion will not allow a complete digestion of the protein, since the
glycated Iysines are not reactive with trypsin. Thus we had to use another protease, the
GluC V8 which is known to digest proteins at the C-terminus of the aspartic acid and
glutamic acid residues. We also suspected that the LC-ESI-QqTOF-MS/MS analysis was
going to afford the identification of a higher number of glycation sites than the MALDI-
TOF/TOF-MS/MS analyses.
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CHAPTER 1: Introduction
The scientific connotation of "biomolecule" denotes any molecule which is
generated by a living organism. Biomolecules can be classified in two categories. The
first is large polymeric biomolecules such as proteins, polysaccharides, lipids, and nucleic
acids. The second is small molecules like the natural products, metabolites and secondary
metabolites. The polymeric oligonucleotides, proteins, and glycoproteins are the main
constituents of the large biomolecules group which are involved in the complex
biochemical mechanisms of life. For example, attempting to understand the functions of
biomolecules and their modification during the development of diseases is tedious,
crucial and necessary for the understanding and design of new medical treatments.
Therefore, researchers and medical practitioners are doing important work in developing
new drugs and the necessary tools for the analysis and characterization of biomolecules,
in a quality control manner. The chemical analysis of these new biomolecular drugs is
necessary for following up the level and excretion of the drugs and finally for measuring
the metabolites produced by the biological system. Accordingly, mass spectrometry (MS)
has been proven to be a well suited technique for the analysis of complex molecules.
In this thesis, MS based methods have been applied for the analysis of
oligonucleotides and carbohydrate-protein glycoconjugate vaccines.
Mass spectrometry has been extensively used for the understanding of
Deoxyribonucleic acid (DNA) alterations which lead to several diseases by means of
discovering genetic mutations as well as DNA adducts. It was found that the gas-phase
fTagmentation of oligonucleotides is challenging and its sequence detennination is limited
by its size. This is why we proposed to study the gas phase fragmentation of isobaric
oligonucleotides and to compare their fragmentation pathway.
The second category of biomolecules that we have analyzed corresponds to
carbohydrate-protein vaccines. Several studies have been carried out to detennine the
carbohydrate-to-protein ratio of synthetic glycoconjugates. However, we are the first in
the literature to have proposed a mass spectrometry-based method for the glycation sites
detennination in different neoglycoconjugates.
1.1. Biomolecules
1.1.1. Oligonucleotides
Nucleic acids are typically linear polymers of nucleotides. When composed of
fifty or less nucleic acid bases, they are called oligonucleotides. The nucleic acids are
constituents of D A, ribonucleic acid (R A) and the messenger ribonucleic acid
(mR A), which play essential roles in several fundamental biological processes. In 1953,
Watson and Crick discovered the molecular structure of D A, which pennitted them to
establish the "central dogma of molecular biology".[I·3] The dogma states that the DNA is
first transcribed to mR A which is then translated to a sequence of amino acids, fomling
proteins. Moreover, the nucleotides contain the genetic infonnation and are the first level
of its transmission.13] They are considered as a key step for the organization and
execution of protein synthesis, and also have a function of secondary messengers,
metabolic regulators, and components of vitamins. 13 .41 Nucleotides are also involved in
thennodynamically unfavourable enzyme-catalyzed reactions by working as high-energy
intennediates. The nucleic acids are divided in two classes of heterocyclic nitrogenous
bases: the purine derivatives adenine (A) and guanine (G), and the pyrimidine derivatives
uracil (U), thymine (T), and cytosine (C). A major challenge for the detection and
analysis of nucleic acids in complex biological samples is their isolation, separation and
purification.[3] In addition, different studies also involve the purification and analysis of
nucleotides, nucleosides and nucleic acids arising from hydrolyzed R A and DNA. 13]
Modified oligonucleotides
Since fifty years, it has been shown that the ability of many substances to bind to
DNA is is one of the causes of their mutagenic activityYl Thus, carcinogenic substances
have been extensively studied and the detection and measurement of carcinogen-DNA
adducts has been found to be reliable for the detennination of the human exposure to
specific carcinogens and for evaluating their presence and incidence in the
environmentY-S] The mass spectrometry (MS) analysis and fragmentation pathway
detennination for simple nucleosides and nucleotides is essential in order to understand
the gas-phase fragmentation of more complex nucleic acids and oligonucleotides.
McCloskey and coworkers developed extensively used MS techniques in nucleic acid
research[3.4.9-11]
Synthetic oligonu/eotides
The introduction of methods for the synthesis of oligonucleotides allowed the
development of several applications, such as the design of DNA vaccines. Indeed,
different DNA vaccines have been produced against infectious pathogensl12] and
cancer.I13.14] Thus, the MS analysis of oligonucleotides became of primary importance
since establishing the size, purity, and sequence of nucleic acids is a prerequisite to their
use as molecular probes in biomedical science. Significant progress in the area of
accurate mass detennination, sequencing, and study of noncovalent interactions has been
made possible by the use of MS ionization techniques such as matrix-assisted-laser-
desorption/ionization coupled to time-of-flight (MALDI-TOF) and electrospray
ionization (ESI) coupled to conventional analyzers and tandem mass spectrometric
(MS/MS) instruments.[2]
1.1.2. Carbohydrates
It is well known that carbohydrates (sugars, saccharides, or glycans) are ever-
present in the cells. Carbohydrates can be observed on all cell surfaces, in the nucleus and
cytosol of eukaryotes, and within the extracellular matrix.[IS] The glycans are involved in
all primordial biological processes such as cell synthesis, structure, and cell-cell
interactions. They also play essential roles in disease.[I6] Thus, it is of outmost importance
to understand the structure and function of all glycans within an organism.[I7] Thus, the
study of the biological functions and structures of complex glycans expressed by cells,
tissues, and organisms is known as "Glycomics". It has been predicted that the structural
characterization of glycans will be the next step used to decode the molecular make-up of
an organism.[I8]
The central dogma of biology is that all biological infonnation flows from the
DNA to the RNA and to the proteins. This dogma has allowed scientists to gain an
understanding of biological organisms at a very fundamentallevel.[I9] When the mRNA is
translated into proteins, a number of chemical modifications occur in the cellsyoJ The
most important post-translational modification is the "glycosylation transfer reaction".
This glycosyaltion reaction occurs when mono- or oligosaccharides are covalently
attached through their anomeric C-I position to other biomolecular aglycones such as the
proteins and/or the lipids forming new biomolecules such as the glycoproteins and the
glycolipids.1211 The glycosylation of proteins may alter the biological function of the
protein and introduce a significant influence on all original biological function. 122,23]
In the last century, glycoproteins have attracted a tremendous scientific interest
due to their diverse structural and biological functions. I22-25] This increased awareness
was partly due to the reality that glycoproteins were discovered to be abundant in all
living organisms. Indeed, glycoproteins are ubiquitous constituents of the cell wall;
connective tissues such as collagen and are also found in gastrointestinal mucus
secretions. Another facet indicating the biological importance of glycoproteins, is they
are used as protective agents and lubricants and are also found abundantly in the blood
plasma. The described diverse functions of glycoproteins are a straight result of their
chemical and geometrical structures. DUe to the tremendous biological importance of
glycoproteins, it is important to reiterate, once more, that glycoproteins are formed by the
glycosylation (covalent association) of one or more carbohydrate moieties to a peptide
chain. This implies that glycoproteins consist of a polypeptide covalently bonded to a
carbohydrate moiety also known as the "Glycan".
It is well known that glycans can exhibit enormous microheterogeneity and
structural diversity. A glycosylated protein can exhibit several different spatial
conformations,126] and could also present structural heterogeneity due to different
"carbohyadrate occupancy" also known as glycosylation sites. Thus, this constant
challenge presented by the presence of the various factors of variations creates a very
large structural diversity of glycan structures and make it a mammoth task to reveal the
glycan structure and map their specific functions.
There are two major classes of glycoprotein structures which are known as the N-
linked and the a-linked glycoproteins.[27] N-linked carbohydrates are attached through N-
acetylglucosamine (GlcNAc) and the amino acid asparagine (Asn). It was found that the
N-Iinked amino acid consensus sequence is Asn-any amino acid (A.A.)-serine (Ser) or
threonine (Thr). Inaddition, the middle amino acid can not be proline (pro).[27] N-Iinked
oligosaccharides of glycoproteins are in most cases complex and branched. They are
involved in the regulation of several cellular proteins, including enzymes and
transcription factors.
The majority of a-linked carbohydrate covalent attachments to proteins engage
a linkage between the monosaccharide N-acetylgalactosamine (GaINAc) and the amino
acids Ser or Thr. At this time there is not an a-linked amino acid consensus
sequence.[28.29] In addition, they playa role in recognition, interaction, and enzyme
regulation.
Figure 1.1 displays a schematic representation of N-Iinked and a-linked
carbohydrates on glycoproteinsYOJ
N-linked O-linked
Figure 1.1. Schematic representation of N-Iinked and a-linked carbohydrates on
glycoproteins. Man = mannose, Gal = galactose, NeuAc = N-acetylneuraminic acid. l30]
[Reproduced with the pennission of Ref. 3D).
Carbohydrates' Role in Biological Function
It is well known and an obvious fact that the carbohydrate chains of glycoproteins
playa role in the spatial confonnation and structure of the polypeptide. Thus, in human
immunoglobulins, the carbohydrate chain coils around one of the protein domains and
prevents contact of this domain with the adjacent domain.[3I) The net result is that this
adjacent domain could no longer perfonn its ordinary function. They are located
throughout matrices and they operate as receptors on cell surfaces to other transported
cells and proteins (collagen), together giving strength and support to a matrix. l32]
Glycoproteins can also cross link to other proteoglycan molecules and fonn complex
ordered structures within ca11ilage tissue. In the nerve tissues, the abundant glycoproteins
appear to be associated with synaptosomes, axons, and microsomes. In addition, it is well
known that the glycoproteins thrombin, prothrombin, and fibrinogen are involved in the
blood clotting mechanism. l33]
Some bacteria possess glycoproteins (called s-layers) fonning a membrane layer
that envelop the outennost constituents of cell walls.[33] Moreover, glycoproteins can act
as bacterial flagella which are a construct of bundles of glycoproteins attached on the
cell's surface.(33) In the Plantae kingdom, the glycoproteins are involved in cell wall
construction, tissue differentiation, embryogenesis, and sexual adhesion[33.34) Mucins are
glycoproteins with a high molecular weight and are present on all the surfaces of the
internal epithelial. They have the apparence of viscous gel and act as protecting agents to
the epithelium from chemical, physical, and microbial damages.l33J51 In addition to being
involved in protection, mucins also have the capacity to function as lubricants.
In immunology, Kabat showed that many immunoglobulins were actually
glycoproteinsY6] He also showed that the interaction of blood group substances with
antibodies was detennined mainly by the presence of the glycoproteins on the
erythrocytes. It was made known that adding or removing one monosaccharide from a
blood group structure could dramatically alter the antigenicity and will alter the
corresponding blood type. Thus, soluble immune mediators for instance helper,
suppressor, and activator cells bind to glycoproteins located on the surface of their target
cells. In effect, Band T cells contain surface glycoproteins that bind these circulating
bacteria. Similarly, glycoproteins can direct phagocytosis.
1.1.3. Bacteria
It is well known that bacteria, viruses and other microbes are all surrounded by a
capsular membrane fonned usually of either complex polysaccharides or
glycoproteinsY7] These glycans are very important for promoting the host pathogen
interactions. In the case of pathogenic Gram positive and/or negative bacteria, usually
either the capsular polysaccharides (CPS) and/or the Iipopolysaccharides (LPS) are
implicated in all virulence factors which prevent phagocytosis and hence promote the
bacterial colonization and persistence on mucosal surfacesYS,39] Therefore, it is well
accepted that the foreign CPS and LPS are recognized by the different receptors of the
innate immune system. This results in the production of cytokines, chemokines and
cellular adhesion molecules.[40] Accordingly, bacterial polysaccharides will induce an
adaptive immune response. In the past century, bacterial glycan structures were employed
successfully for the development of vaccines and immune modulators.[41]
1.1.3.1. Gram negative bacteria
In 1884, Christian Gram invented a staining method (Gram Stain) which allows
differentiating bacteria in two distinct groups. Gram-negative bacteria correspond to
bacteria that do not retain crystal violet dye when tested with the staining method,
contrary to the Gram-positive bacteria which are able to hold the stain.[42] Moreover,
Gram-negative and Gram-positive bacteria are also separated in different groups. As an
example, the proteobacteria correspond to an important family of Gram-negative bacteria
which incorporate Escherichia coli (E. coli), Salmonella and several other bacteria.[43]
Structure ofthe Graflll1egative cell wall
In 1969, the development of the electron microscope allowed Glauert and
Thomley to discover that the Gram-negative cell envelope is composed of three main
layers: the peptidoglycan, the inner and the outer layers.(44) Moreover, the outemlost part
of Gram-negative bacterial membrane is divided into inner and outer portions which
contains a coat of LPS.[4SJ Both inner and outer membranes are composed of
phospholipids (mainly glycerol-phospholipids) and proteins. The peptidoglycan layer is
located within the gelatinous material, called peri plasm, which separates the two layers.
The outer leaflet of the outer membrane is mainly composed of the amphiphilic LPS
moieties that contain a lipid portion (lipid A) embedded into the membrane environment.
(a)
Peptidoglycon
layer
/
(Flogcllum) GRAM POSITIVE
(b)
a-antigen
Core
saccharide
Outer
membrane
Penplasm
Gram-posrtrve Cytoplasm Gram-negatIVe
Figure 1.2. (a) Schematic representation of a Gram-positive (left) and a Gram-negative
(right) bacteria.[46] (b) Representation of the Gram-positive (left) and Gram-negative
(right) cell envelopes (WTA = wall teichoic acid, CAP = covalently attached protein,
IMP = integral membrane protein, LP = lipoprotein, LPS = lipopolysaccharide, LTA =
lipoteichoic acid, OMP = outer membrane protein.[4S] [Reproduced with the permission of
Ref. 45 and 46].
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Figure 1.2 represents the configuration of Gram-positive and negative structures
and also a representation of their cell envelope.[46) The major difference between Gram-
positive and Gram-negative bacteria is the absence of the outer membrane on Gram-
positive bacteria. It has to be noted that the outer membrane plays a protective role for
Gram-negative organisms and its presence allows the stabilization of the inner
membrane.[45)
Lipopolysaccharide (LPS)
Lipopolysaccharides (LPS) are present on the outer membranes in Gram-negative
bacterial cells. Different methods have been developed for the isolation of LPS portions
from bacteria, such as the aqueous phenol method in order to study their structure and
composition.(47) LPS correspond to amphiphillic macromolecules which are composed of
an internal core oligosaccharide covalently linked to the lipid A, and also of an external
core oligosaccharide (O-specific chain, or hydrophilic antigen). Lipopolysaccharides are
characterized by endotoxic properties which are mainly due to the lipid A. Moreover, the
O-specific chain consists of an arrangement of oligosaccharide units and its structure and
composition are dependent on the bacterial serotype. Due to the fact that the
polysaccharide moiety confers the immunological properties to the bacteria, several
portions of LPS have been tested for therapeutic purposes, such as vaccines[48] and
anticancer drugs development.[49)
II
LPS-derived vaccines or LPS-protein neoglycoconjugates
LPS derivatives have been mostly appreciated for their potential use as vaccine
candidates. Bacterial LPS is the major contributor to the host immune reaction and hence,
it has been successfully utilized for vaccination. The significance of LPS can be
illustrated with the use of LPS antibodies which can protect against infection.[50.51] LPS
when injected alone is not immunogenic as it can escape recognition by the immune
system due to its relatively small size.[50] LPS conjugated to a protein carrier, however,
can provoke the desired immunological reaction and can induce prolonged immunity.
The first attempts to test protein conjugates as immunogens dates back to the late 1920s
by Landsteiner's groupY2.53] Shortly after, it was shown that bacterial carbohydrate-
protein conjugates can induce strong antibody response.[54) It is well known that the
sugar portion of a carbohydrate-protein conjugate is always referred to as a hapten, which
emerged from the work of Landsteiner's group.[53,55] Figure 1.3 displays the immune
response induced by protein-polysaccharide conjugate vaccines.l41 ] First of all, the
polysaccharide chain from the neoglycoconjugate vaccine cross links the B cell receptor,
inducing the stimulation of these lymphocytes and the production of immunoglobulins.
During the same time, the protein-polysaccharide conjugate vaccine is recognized by
receptors located at the surface of polysaccharide specific B cells which process the
protein carrier. Peptides specific to this protein are presented to carrier-peptide-specific T
cells. As a consequence, T-cells are involved in the production of memory B cells and
plasma Bcells.
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The covalent linkage between the LPS backbone and the protein carrier can be
completed by either a direct linkage or with the aid of a suitable spacer. Many protein
carriers have been assessed for the production of LPS-derived vaccines such as bacterial
toxoids (e.g. tetanus toxoid),[56] outer bacterial membrane proteins[57.58] and bovine serum
albumin (BSA).[59] Regardless of the nature of the protein carrier, it is necessary to
develop a neoglycoconjugate that is safe and capable of enhancing LPS immunogenicity.
The first commercially available glycoconjugate vaccine was licensed in the late ]980s
against Haemophilus i/?/luenza type b and this work was originally pioneered by
Schneerson and co-workersJ60] The infection has been virtually eliminated in countries
where widespread vaccination among the general public has been executed.[61]
Figure J.3. Molecular mechanisms of the generation of immune responses against
protein-polysaccharide conjugate vaccines.[41] [Reproduced with the pennission of Ref.
41].
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While many studies have focused on using natural LPS for the development of
LPS vaccine conjugates, synthetic carbohydrate chains that mimic LPS epitopes (the part
of an antigen recognized by the immune system) seem to be evolving as a promising
approach for the production of LPS-protein conjugates. Pavol KovaC's group, for
example, has been spearheading the production of hapten-BSA conjugates that bear
synthetic mono-, tetra- and hexa-sugars which mimic the terminal part of the O-specific
polysaccharide of the Vibrio cholerae, serotype Ogawa.[62.63] Their novel conjugate
(bearing the hexa-sugar) has shown protective immunity within mice.[59] However, BSA-
LPS derived from the Vibrio cholerae, serotype Inaba (despite structural similarities to
Ogawa) failed to achieve this protective immunity.[64] This has been attributed to the
possibility that either the tenninal sugars of Inaba are not protective epitopes or the
delivery system was not optimized. The only difference between those two species lies
within the terminal sugar which is characterized by a hydroxyl group at the 2 position in
Inaba but a 2-0-methyl group in Ogawa. The investigators have successfully utilized
surface-enhanced laser desorption/ionization time of flight (SELDI-TOF) MS to evaluate
the degree of BSA-sugar conjugation and have presented very promising results with
respect to controlling the reaction and the degree ofsubstitution.[62.65) These results, based
on MS analysis, can have significant industrial impact during commercial production as it
relates to quality control and quality assurance.
1.1.3.2. Gram positive bacteria
Gram-positive bacteria are characterized by their ability to be stained violet by
Gram staining. They are also divided is numerous groups, including for example the
cocci and the bacillus bacteria.[66.67]
14
Structure ofthe Gram positive cell wall
Several differences can be observed on the cell envelope of Gram-positive and
Gram-negative bacteria (Figure 1.2).[46J First of all, in the Gram-positive bacteria, the
outer membrane is not present. As a consequence, the layers of peptidoglycans that
surround the bacteria is thicker than on Gram-negative bacteria.[45J Moreover, the
peptidoglycans in Gram-positive bacteria are linked to long anionic polymers called
teichoic acids, which are composed of glycosyl phosphate, glycerol phosphate, or ribitol
phosphate repeating units. Another major difference is the presence of covalently
attached proteins at the surface of the Gram-positive bacteria.
Elldospore
Some Gram-positive bacteria are able to develop an endospore in response to
nutrient deprivation and to protect the bacteria from extreme stress (temperature, high
UV irradiation, desiccation, chemical damage and enzymatic destruction).[68] The
endospore is composed of a core, a spore cell wall (or core wall), a cortex, a spore coat,
and an exosporium. It has to be noted that the exosporium is a complex assembly of
proteins, amino and neutral polysaccharides, lipids and ash.f69] The exosporium is also the
first part of the bacteria to be in contact with the host which confers to its constituents a
major importance. It was also reported that spores of the following bacteria include
specific glycoproteins at their surface layer: Bacillus thuringiensispO] Bacillus cereus[71]
and Bacillus anthracis.f72]
Carbohydrate-proteill neoglycocolljugates vaccilles
One of the most studied Gram-positive bacteria is the Bacillus anthracis.[72] This
bacteria causes anthrax disease (infection) mainly on herbivores and cattle. Bacillus
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an/hracis spores can also be used as biochemical warfare agents against humains and
their inhalation are lethal within few days. Contrary to Gram-negative bacteria, Gram-
positive bacteria do not possess LPSs.f46J However, like most bacteria, Bacillus an/hracis
exhibits specific carbohydrates (on the surface of the spore) which can be used for the
design of potential vaccines. Moreover, Sylvestre e/ al. found that the collagen-like spore
surface glycoprotein of Bacillus an/hracis (BelA) is extremely immunogenic and is part
of the filaments of the hairy nap constituents[72J The identification of a tetrasaccharide
antigen of the BelA allowed the synthesis of carbohydrate-protein vaccine models for the
Bacillus an/hracis bacteriump3J
1.1.3.3. Future perspectives in glycomics
It is obvious that scientists must decode the glycome. To decode the glycome,
scientists must perfonn feats such as perfonning stereospecific carbohydrate synthesis,
tedious structural characterization of the complex carbohydrates and associated
glycofonns.
The current methods commonly employed to characterize the glycome inelude
mainly mass spectrometry methods which are used to detennine the structures of
individual glycans located at the cell surface and also to identity sites of attachment of
glycans on proteins.[74J Nuclear magnetic resonance spectroscopy (NMR) is also used
routinely to study the structure and function of glycan assemblies.[75l Other biochemical
methods such as lectin and antibody arrays and other higher throughput techniques can
be used to identify and characterize the glycans used by the microbes which lead to
infection.[761 In addition, recently there have been reports discussing the development of
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specific inhibitors for carbohydrate biosynthetic enzymes and carbohydrate binding
proteins, to reveal their biological functions.
1.2. Mass spectrometry
Mass spectrometry is a technique that allows the detection of charged particles in
the form of their mass-to-charge (m/z) ratio. This technique is used for the mass
determination of analytes and also for their structure determination. Qualitative and
quantitative infonnation can be obtained with this technique. The sensibility, accuracy,
low consumption and rapidity of analysis make MS a technique of choice for the
biomolecules analysis. Mass spectrometry is employed in different fields such as
proteomics,[77J glycomics,[78J metabo]omics,[79J lipidomics,[80J and in oligonucleotides
analysis.[81)
A mass spectrometer is essentially composed of three main parts: an ionization
source, a mass analyzer, and a detector.
1.2.1.100 sources
The function of the ionization source is to generate charged particles. Different
ionization sources have been developed, such as Fast Atom Bombardment (FAB),
Electron Ionization (El), Chemical Ionization (CI), ESI, Atmospheric Pressure
Photoionization (APPI), MALDI, and more recently, Desorption Electrospray Ionization
(DES I). A major consideration for the choice of an ionization source is the quantity of
internal energy that can be transferred to the molecule during the ionization process and
its physico-chemical properties.
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Electrospray ionization and MALDI ionization techniques are qualified as "soft"
because the analyte gains a minimum of internal energy during the ionization process,
which lowers the fragmentation. The most commonly used soft ionization methods are
Fast Atom Bombardment (FAB), Electrospray ionization (ESI) and Matrix Assisted
Laser Desorption Ionization (MALO I).
1.2.1.1. Electrospray Ionization (ESt)
The principle of ESI is very simple: a liquid composed of the analyte and a polar
solvent is passing through a capillary tube with a low flow rate (1-1 0 ~d min-I), and is
submitted to a strong electric field in atmospheric pressure to create the electrospray.[82]
A potential difference of 2-5 kY between the capillary and the counter electrode is
usually applied in order to create the electric field (Figure 1.4).[83] On the end of the
capillary tube, the liquid accumulates a charge at its surface, which breaks to produce
charged droplets. Lord Rayleigh was the first to deternline theoretically the maximum
quantity of charge that a liquid droplet can carry (known as the Rayleigh limit)J841When
the Coulomb forces reach the Rayleigh limit, the charged droplets break down to smaller
fine charged droplets. Moreover, the dispersion of the spray is also obtained by an inert
gas (usually nitrogen) which is injected coaxially to the capillary tube.
The fonned droplets thus experience a curtain of heated inert gas in order to
maximize the desolvatation process. The charged analyte molecules are then accelerated
toward the mass analyzer for detection.
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During the electrospray experiment, the analyte molecules acquire a charge
through proton transfer reactions between the electrospray solution and the analyte.
However, electrochemical and photoelectrochemical reactions which take place at the
electrode interfaces of the source have an influence on the ionization process.[85]
The importance of ESI is due to its ability to form multiply charged ions. In the
case of large biomolecules with a high molecular mass, such as proteins or
oligonucleotides, the formation of multiply charged ions allows to obtain analyte
molecules with a mass-to-charge ratio detectable with mass analyzers with a low nominal
mass limit. In addition, typical mass spectra obtained by ESI-MS of a biomolecule
correspond usually to a statistical distribution of multiply charged ions produced through
protonation [M + nH]"+, or deprotonation [M - nH]"-J86] The connection of the ESI to a
quadrupole mass analyzer allowed the development of the first mass spectrometer
capable of analyzing proteins with a molecular mass up to 40 kDa.[87,88] It has also to
been noted that during the ESI, low or none fragment ions are observed.
Figure 1.4. Schematic representation of the mechanism of electrospray ionization. l8JJ
[Reproduced with the permission of Ref. 83].
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Another advantage of E I is its ability to handle flow rates up to 1000 JlL min-I
which makes it connectable to high performance liquid chromatography (HPLC)
systems.[89]
1.2.1.2. Matrix Assisted Laser Desorption ionization (MALDI)
Matrix-assisted laser desorption/ionization is an extensively used ionization
source coupled with a TOF mass analyzer for the molecular mass detennination of
biomolecules and proteins identification.[90] For example, MALDl-TOF-MS was widely
used for the analysis of oligonuc!eotides,[91] oligosaccharides,[92] proteins,[90]
glycoproteins[92] and lipids[93]
Its high sensitivity, wide mass range, tolerance for salt and the fact that this method
produces a low amount of fragments, allowed the use of MALDI for the direct analysis of
biomolecules on tissue slices for MALDI imaging.[94]
The principle of the MALDI experiment consists on the ionization of the analyte
through a proton transfer reaction between a matrix and the analyte. First of all, the
matrix solution, composed of a compound which is able to absorb the laser energy, is
usually mixed with the analyte before spotting the mixture on a MALDI plate. However,
different spotting methods have been experienced, such as quick and dirty, dried droplet,
sandwich, seed-film layer and two-layer.[95] The mixture is then left to dry at room
temperature, resulting in a co-crystallization of the analyte with the matrix. Different
matrices have been tested for the analysis of analytes of different nature: 2,5-
dihydroxybenzoic acid for oligosaccharides, peptides and proteins,[96] sinapic acid for
proteins and a-cyano-4-hydroxycinnamic acid (a-CHCA) for a mixture of peptides.[97.98]
A laser beam (usually a nitrogen laser at 337 nm) is then applied on the spot of the
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MALDI plate and causes the desorption and the ionization of the matrix and the analyte
(Figure 1.5).[99J It has to be noticed that the ionization mechanism is still unclear.
However, most scientists believe that the ionization process results from three distinct
processes: the excitation of the matrix molecules by the laser photons, the desorption of
the analytes in the gas phase, and finally the ionization of the analyte in the gas
phase.[100,IOI] Moreover, the laser irradiation with a photon energy hv causes the
excitation of the matrix (MH), illustrated by the following equation: MH + hv -+ [MH]*.
A portion of the energy carried by the excited matrix molecule is then transferred to the
analyte. During the same time, the analyte and matrix molecules are desorbed to the gas
phase and get ionized by a proton transfer reaction which occurs either during the
collision of matrix molecules with the analyte molecule, or during an acid/base
reaction.[102]
Figure 1.5. Schematic representation of the ionization of the matrix and the analyte in a
MALDI source.[99] [Reproduced with the pennission of Ref. 99].
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The advantage of the MALDI source is that it mainly provides low charged ions
and thus facilitates the data interpretation. Recently, a major improvement of MALDI
sources was the ability to operate under atmospheric pressure.[I03) Different atmospheric
pressure sources, with the major advantage that they do not need a matrix, were then
developed, including laser-induced acoustic desorption (L1AD) MS and
desorption/ionization on silicon (AP_DIOS).[I04,I05]
1.2.2. Mass analyzers
The major role of a mass analyzer is to separate different species (molecules,
clusters or atoms) in their ionized form according to their m/z. Different mass analyzers
were developed, but the widely used are the scanning analyzers where the separation of
the ions is electronically-driven. This includes the quadrupole and the time-of-flight
(TOF). Moreover, hybrid mass spectrometers were also developed which consists on the
combination of different kind of mass analyzers. For example, the quadrupole-time-of-
flight (QTOF) mass spectrometer is widely used in proteomics. Another type of mass
analyzer was also developed: the trapping instruments. In these mass analyzers, the ions
are trapped and an ion with a specific m/z can be selected (the other ions are expelled
from the mass analyzer) in order to carry out different experiments, such as collision
induced dissociation (CID) by introducing a neutral gas in the mass analyzer. The mainly
used ion trap mass analyzers are the quadrupole ion trap, the orbitrap and the Fourier
transfonn ion cyclotron resonance (FTICR).
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The resolution, sensitivity, mass range and mass accuracy, which are the main
characteristics to consider during the analysis, differ from one analyzer to another.
1.2.2.1. Quadrupole mass filter
The quadrupole mass filter is an extensively used mass analyzer and it has also
been widely used for 30 years.(106) This analyzer is frequently associated with an on-line
separation technique, such as liquid chromatography (LC),[107) gas chromatography
(GC)[108) and capillary electrophoresis (CE).[109] However, its low resolution do not make
the quadrupole a mass analyzer of choice for molecules characterization.[lIO)
The principle of operation of this mass analyzer is based on the trajectory of the
ions inside the quadrupole chamber. Basically, the quadrupole is composed of four
parallel metal rods electronically connected (Figure 1.6).[106.111) A direct current (DC) and
a radiofrequency (RF) potential are simultaneously applied between one pair of rods and
the other, which cause the oscillation of the ions between the rods. By changing the
values of the DC and the RF, only one ion of a certain m/z value will have a stable
trajectory in the quadrupole and reach the detector (these are resonant ions), while the
ions with a different m/z value will collide with the cylinders and be lost (these are non
resonant ions). The electric field applied on the rods is described by the following
fomlula: (1)0 = ± (U ± Vcos wt), where ([>0 represents the voltage applied to the rods, U is
the DC voltage, V is the RF voltage amplitude and 00 is the frequency. Additionally,
inside the quadrupole mass analyzer, the trajectory of the ions will follow the equation of
Mathieu and will be separated according to their /11/Z. The quadrupole mass analyzer
presents several advantages: excellent transmission efficiency, suitability for GC, LC and
CE, low cost. robustness, easy to use. However, the mass range of the quadrupole (less
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than 4000 Da), its low resolution and the need to couple more than two quadrupoles to
achieve tandem mass spectrometry analysis are the major limitations of this analyzer.
~V
Figure 1.6. Schematic representation of a quadrupole mass filter[lll] [Reproduced with
the permission of Ref. III].
1.2.2.2. Time of flight (TOF) mass analyzer
In 1946, the TOF mass analyzer was introduced for the first time by Stephens['12]
and the first linear TOF commercial instrument was developed by Wiley and McLaren in
1955.[113] The TOF analyzer i well suited for pulsed ionization sources, such as the laser
desorption ionization. Figure 1.7 shows the scheme of a linear MALDI-TOF mass
spectrometer.[114] Its principle is very simple: it consists in measuring the time it takes for
an ion to traverse a field-free-time-of-flight tube. First of all, after the ionization process,
the ion leaves the ionization source with a charge q = Ze (Z = charge number, e =
elementary charge) and a mass m. The ion has a kinetic energy Eo = 1/2mv2 = qVs (v =
velocity of the ion). Thus, the time it takes for the ion to traverse the field-free region
with a length L is measured and directly related to the m/z value of the ion through the
kinetic energy equation previously mentioned.
24
An important parameter to be considered for a mass analyzer is its resolution. The
TOF analyzer has a resolution which is dependent on the mass of the analyte. It is well
known that the ions of the same m/z value have slightly different kinetic energies when
they enter the TOF mass analyzer.[1IS] This is the cause of a limitation of the resolution
for the TOF analyzers. At higher masses, the resolution of the TOF is limited. Moreover,
a reflectron was introduced in the TOF mass analyzer in order to improve the resolution.
The reflectron is composed of a series of charged ring electrodes, in which the first ring
has the lowest potential and the last ring the highest. Thus, the electrostatic field increases
from the first ring to the last one.[116] The reflectron is disposed at the end of the TOF
analyzer. After traversing the TOF, the ions experience the increasing electrostatic field
in the reflectron. They are then slowed down and stopped before being reflected and
accelerated in the opposite direction. Moreover, the faster ions of a given m/z value have
a higher kinetic energy and thus travel further into the reflectron before being reflected
than the slower ions. Then the path followed by the faster ions is longer than the one
followed by the slower ones. This phenomenon allows the slower ions to catch up with
the faster ones and these ions arrive to the detector at the same time.
Different applications of the MALDl-TOF mass spectrometer were reported, such
as for biomolecules and also for synthetic polymers and polymerlbiomolecule
conjugates.1117]
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Figure 1.7. Schematic representation ofa linear MALDI-TOF-MS instrument used in the
positive ion mode.[114] [Reproduced with the pennission of Ref. 114].
1.2.2.3. Hybrid quadrupole/time-of-tlight (QTOF) mass spectrometer
The hybrid mass spectrometers are composed of two or more mass analyzers of
different types. They are usually designed to perfonn tandem mass spectrometry
experiments. Figure 1.8 displays a schematic representation of a QTOF mass
spectrometer.II 18)
The QTOF mass spectrometer consists on a quadrupole mass analyzer (Q) used in
conjunction with an orthogonal TOF. In the QTOF mass spectrometer, the quadrupole is
usually used to select the ion of interest while the TOF analyzer acquires the mass
spectrum. However, when the quadrupole is operated with only the RF potentials applied
to the rods, all the ions emerge from the quadrupole and are separated in the TOF
analyzer,1118.119]
Different ionization sources can be used in conjunction with the hybrid QTOF
instruments, such as ESI,[I20J APPI[12IJ and MALDI.[I22)
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The QTOF mass spectrometer has different advantages. The ability to use an
electrospray ionization source with the mass spectrometer permits to lower the internal
energy transferred to the ion and thus minimizes the fragmentation of the molecular ions.
Consequently, the analysis of large biomolecules and their mass determination has been
achieved using ESI-QTOF MS.1118-120.123] The second main advantage of this hybrid
instrument is its high sensitivity and also its linear mass scale to 10,000.
The QTOF mass spectrometer is generally used with an electrospray inlet which allows
the coupling with a LC. One major application of LC-ESI-QTOF MS is the proteins
identification and sequencing.[I24-126]
Figure 1.8. Schematic representation of a QTOF.[118] [Reproduced with the pennission of
Ref. 118].
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1.2.2.4. Trapping mass analyzers
The trapping mass analyzers correspond to analyzers where the ions can be
retained (or trapped) for a certain period of time. Thus, ion/molecule reactions can be
studied with ion trap analyzers. The main advantage of these mass analyzers is also their
ability to perfonn consecutive tandem MS experiments.
1.2.2.4.1. Quadrupole Ion trap
The quadrupole ion trap (QIT) exists in two different fonns: a 3D configuration,
also known as a Paul trap, and a linear shape (linear QIT).
The Paul trap mass analyzer is composed of three hyperbolic electrodes, a central
electrode and also two endcap electrodes (Figure 1.9).[127.130J A DC current and a RF is
applied between the electrodes and the resulting forces allow to trap the ions between the
three hyperbolic electrodes. The ions are excited by the oscillation of the RF between the
two endcap electrodes, and are directed inside the ion trap by applying a driving voltage
to the ring electrode. Thus, by applying different voltages, the ions can be either trapped
or expelled from the ion trap.
The linear quadrupole ion trap (linear QIT) mass analyzer is composed of a set of
parallel rods built up in a square configuration. As for the quadrupole mass analyzer, a
DC CUITent and a RF is applied between two pairs of opposite rods and the ions are then
trapped inside the linear QIT. In addition, an electric potential on the end of the
electrodes allows the ions to be trapped axially in the ion trap.[131] The motion of the ions
between the parallel rods is described by the Mathieu Equations.
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In general, the quadrupole ion trap presents the advantages to have a high
sensitivity and a good resolution. However, its inconvenience resides in its low mass
accuracy. [I 30]
Endcap RIng En<lcap
Figure 1.9. Schematic representation of the ion trap.f I3O] [Reproduced with the
permission of Ref. 130].
1.2.2.4.2. Fourier Transform Ion Cyclotron Resonance (FTICR)
In the FTICR MS, the ions experience a magnetic field and their mass m/z is
determined based on their cyclotron frequencyY32] The ion cyclotron resonance (fCR)
cell is generally composed of a pair of trapping plates, a pair of excitation plates and a
pair of detection plates (Figure 1.10).[133] The ions can be trapped and stored under a
magnetic field with electric trapping plates, also called a Penning trap. The application of
an oscillating electric field perpendicular to the magnetic field effects excitation of the
ions to a higher cyclotron radius, and concentrates them in packets and making them
move in phase. When the ions pass close to the detection plates, they are detected as an
image CUlTent and the signal is named a free induction decay which is composed of a
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superposition of sine waves. The signal is thus recorded in a time domain and mass
spectrum is the result of the Fourier transform of this signal.
The main advantage of the FTICR is its high resolution and one application of this
technique is the molecule composition determination based on their accurate mass.[134]
However, FTICR-MS has also been applied for the analysis of proteins, glycoproteins
and oligonucleotides.[I35-137]
~
Figure 1.10. Schemaic representation of a cubic ICR cell.[133] [Reproduced with the
permission of Ref. 133].
1.2.2.4.3.0rbitrap
In 2000, Alexander Makarov introduced the Orbitrap.[138] This mass analyzer
(Figure 1.11) is composed of a spindle-like-shaped central electrode (a), an outer
electrode (b) and an insulating ceramic ring (C).[139] After ionization, the ions are injected
between the central and the outer electrodes and experience an electric field applied
tangentially to the electrodes. The ions undergo an electrostatic attraction to the central
electrode which is balanced by centrifugal forces, causing the ions to be trapped between
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the two electrodes. Thus, the ions have a cyclic motion around the central electrode and
also move on the axis of this electrode. The oscillations of an ion of a specific m/z along
the central spindle create a signal in a similar way to the FTICR-MS, which is then
converted through the Fourier transfonnation to a m/z value.[139. 1401
The resolving power (maximum of 200,000) and the mass accuracy (1-2 ppm)
confer to this trapping instrument a real advantage and several applications have been
reported such as the analysis of proteins,[141 1 glycoproteins,[142] metabolites,[143] and
0Iigonuc)eotides.[144] In addition, a hybrid instrument has been developed which consists
on the association of a linear quadrupole ion trap to the Orbitrap (LTQ-Orbitrap).[1451
Figure 1.11. Representation of the Themlo Fisher OrbitrapTM.[1391 [Reproduced with the
pennission of Ref. 133].
1.2.3. Ions in the gas phase
1.2.3.1. Gas phase ions formation and their fragmentation
The fonnation of gas phase ions is occulTing in the ionization source. It was
observed that during the ionization process, the energy gained by the ionized molecule
plays a role in the fomlation of in-source fragment ions.
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1.2.3.2. Tandem mass spectrometry
Tandem mass spectrometry (MS/MS) consists on multistage analyses.[I46] The
principle is based on the isolation of a precursor ion which is induced to fragment. The
resulting product ions are then detected.[I47] Tandem mass spectrometry has been
extensively used over the past 10 years for the structure characterization of
unknowns.[148] There are two different MS/MS: tandem in space and tandem in time
instruments.
In tandem in space, the mass spectrometer is composed of at least two analyzers
and a collision cell. After the ionization process, a precursor ion is selected in the first
analyzer and is introduced in the collision cell (Figure 1.12). The collisions of the
precursor ion with the neutral gas inside the collision cell allowed the f0n11ation of
product ions which are then separated in the second mass analyzer and detected.[I46.149.lsoJ
This procedure is also known as CID. Tandem in space MS i commonly used with the
triple quadrupole mass spectrometer and also with hybrid instruments, such as the QTOF.
Selection Collision Product ions
of the induced scan
precursor Ion dissociation
(CID)
Figure 1.12. Tandem mass spectrometry principle.[149l
For the tandem MS in time, the isolation of the precursor ion, its fragmentation
and the detection of the product ions take place in an ion trap mass analyzer where the
ions can be held (or trapped) for a specific time.[ISO] The QIT, the FTICR and the Orbitrap
can be used for this experiment.
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In addition, different activation methods which are not available for instruments
which perform tandem in space have been developed for the trapping instruments. For
example, the electron capture dissociation (ECD) has been introduced for FTICR-MS.(Isl]
It consists on introduction of low energy electrons in the [CR cell containing multiply
charged ions in the gas phase. The interaction between the charged ions and the electrons
produces odd-electron ions which undergo dissociation to fonn different type of
fragments. [n the case of proteins and peptides, the ECD produces mainly c- and z-
ions. lISI ] Electron capture dissociation has been proven to be well suited for the analysis
of glycopeptides because of its ability to foml exclusively c- an z-ions, while the
carbohydrate portion of the glycopeptide does not expelience fragmentations.(IS2] In the
Orbitrap instrument, radical anions (anthracene or azobenzene) are used to transfer
electrons to the charged molecules, and the following fragmentation process is similar to
the one observed when used ECD in a FTICR-MS. l1S3]
1.3. Mass spectrometry analysis of biomolecu[es
1.3.1. Mass spectrometry analysis of oligonucleotides
Deoxyribonucleic acid sequencing allows getting the sequence of nucleotides in a
particular gene. Different strategies have been developed for the MS analysis and
sequencing of oligonucleotides.
1.3.1.1. Sanger sequencing
In 1975, the group of Sanger introduced a new DNA sequencing method which is
also known as the dideoxy sequencing method. lIS4] Basically, a DNA portion is amplified
using the polymerase chain reaction (PCR). However, in addition to nucleotides
triphosphates ( TP), dideoxynucleotide triphosphates (dd TP) are also integrated in the
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o A sequence which stops further additions of nucleotides. This will result in the
production of 0 A sequences of different lengths. The MALOI-TOF-MS analysis of the
mixture of 0 A strands of different size allows the sequencing of the 0 A target
through the comparison of the molecular ion masses. Indeed, by calculating the mass
difference of two closest molecular ions, we can identify the nucleotide which correspond
to this difference.l 155j
1.3.1.2. Ladder sequencing
In the Ladder sequencing method, the target DNA sequence is first amplified
using PCR, and the resulting oligonucleotides are digested by means of an exonuclease
enzyme (snake venom phosphodiesterase for example).[156] After digestion, we generally
obtain oligonucleotides of different size. The MALDI-TOF-MS analysis of the mixture
allows detennining the sequence of the oligonucleotide by identifying the nucleotides
difference between two closest molecular ions.
1.3.1.3. Gas phase fragmentation of oligonucleotides
Several studies have been carried out on the gas phase fragmentation of
oligonucleotides.[157-159j McLuckey and coworkers proposed a nomenclature for the gas-
phase fragmentation of oligonucleotides (Figure 1.13), which is based on a previously
established nomenclature for the fragmentation ofpeptides.[157] The fragment ions which
include the 5' temlini of the oligonucleotide are designed as a, b, c and d, while those
including the 3' tennini are named w, x, y and z. The same group also observed that
during the CID-MS/MS analysis of oligonucleotides in the negative ion mode, the
following product ions are formed: (a -B), w, y and (d - H20).
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Figure 1.13. Oligonucleotides fragmentation nomenclature established by McLuckey and
coworkers (B 1, B2, B3 and B4 correspond to nucleic bases).[I57 j
In 1999, Rozenski introduced an online software called Mongo Oligo Mass
Calculator v2.06, which can predict the different possible product ions «a -B), w, y and
(d - H20)) of an oligonucleotide based on its sequenceJI60 j The software is also able to
predict the series of multi-charged molecular ions that we may observe for the ESI-MS
analysis of an oligonucleotide of known sequence.
Moreover, in an attempt to facilitate the oligonucleotide sequencing, Rozenski
developed an interactive program called Simple Oligonucleotide Sequencer (SOS), for ab
initio oligonucleotide sequencing by MS.[I61] The software uses the mass spectra and the
sequencing of the oligonucleotide is carried out residue by residue. The following
product ions can be identified in the negative ion mode: (a -B), w, y and (d - H20) which
allows the construction of oligonucleotide ladders in both the 3' -+ 5' directions and the
5' -+ 3' directions. The comparison of the ladders can then be carried out for homology
and overlap. The advantage of the software is the possibility to include modifications on
bases, sugars or backbones. However, the disadvantage of this program is that it cannot
be extend to oligonucleotides longer than mer-20 level.
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1.3.2. Mass spectrometry analysis of proteins and peptides
Different strategies have been developed for the MS analysis, identification and
sequencing of proteins.
"Shotgun proteomics" consists on the use of the "bottom-up approach" for the
identification of proteins.[162-164] First, the proteins are digested using a protease, such as
trypsin. The resulting complex mixture of peptides is then separated using LC-MS/MS.
The proteins are then identified by comparison of the MS data to theoretical peptide MS
data calculated from a genomic or proteomic database (example: National Center for
Biotechnology Infonnation, NCBI) using search engines such as Mascot and Sequest.[16S.
167] However, when the mixture of peptides is analyzed by MALDI-TOF-MS, the
identification of the protein is carried out using the same search engines and is called
peptidemassfingerplinting.[162]
Another strategy is successfully applied which is the "top-down approach". In this
technique, the entire protein is analyzed.[168] Molecular ions of the proteins are produced
by electrospray and one of them is selected and subjected to gas phase fragmentation. In
top-down proteomics it is necessary to work with high resolution mass analyzers. Indeed,
one challenge with this method is the generation of product ion masses from multiply
charged protein precursor ions. The interpretation of the tandem mass spectra allows the
sequencing of the protein. The data can also be uploaded in search engines such as
Mascot for the identification of the protein.
However, some proteins with unknown sequence or with post-translational
modifications are difficult to identify and to sequence. The protein sequence is then
detennined with minimal supp0l1 from genomic data, by de 1101'0 protein sequencing.
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Both of the previously mentioned methods were applied for the de novo sequencing of
proteins.[169 j Basically, the MS/MS spectra obtained by the "bottom-up" or "top-down"
approaches are used for the detennination of the protein sequence.
A gas-phase peptide fragmentation nomenclature was introduced by Roepstorff
and Fohlman and lately modified by Johnson and coworkers (Figure I.l4)JI7O·171] The
fragment ions including the N-tenninus of the peptide are called a, band c, while the x, y
and z fragment ions include the C-tenninus.
Figure 1.14. Gas phase fragmentation nomenclature of a peptideJI70.171] [Reproduced
with the pennission of Ref. 170].
1.3.3. Mass spectrometry analysis of glycoconjugates
Glycoconjugates cOITespond to biomolecules such as proteins, peptides or lipid
aglycones which are covalently linked to glycosyl chains of olygosaccharides or
polysaccharides. Several MS methods have been applied for the structure detennination
of carbohydrates and glycoconjugates.[172-174]
Domon and Costello were the first to report the CID-MS/MS analysis of
protonated complex glycoconjugate 1l10Iecules.[172.174j They also introduced a universal
nomenclature for the fragmentation of glycoconjugates.[ 172] Figure 1.\5 illustrates the
possible product ions which can be obtained during the CID-MS/MS analysis of a
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ganglioside, according to the nomenclature established by Domon and Costello. The A, B
and C product ions correspond to ions that include the non-reducing end of the
oligosaccharide, while the X, Y and Z product ions incorporate the aglycon (reducing end
of the oligosaccharide). It has to be noted that X and A product ions are produced by the
fragmentation of the glycosidic ring, and the ring bond which is broken to produce the
ions is noted on A and X symbols.
i OH i H
/ / / /
2,5A1 8 1 c1 2,4~ 8:i C2 0,2A3 SJ
Figure 1.15. Carbohydrate fragmentation nomenclature developed by Domon and
Costello.(I72] [Reproduced with the permission of Ref. 172].
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Abstract
In this manuscript we present the differentiation and sequencing of three
constitutional isobaric 18-mer D A oligomers, namely: GATTCATAGCTACGAATC
1, AATTCGTAGCTACGAATC 2, and AATTCGTACCTACGAATG 3 using
electrospray ionization-mass spectrometry with a hybrid QqTOF-MS/MS instrument.
The conventional single scan ESI-QqTOF-MS analyses of the DNA oligomers
afforded the same series of deprotonated molecular ions. CID-MS/MS analyses were
used to differentiate and to sequence the three DNA oligomers. Different CID-MS/MS
an\llyses of the various deprotonated molecules: [M - 8Ht at m/z 683.9881 and [M-
9Ht at m/z 607.8775 were acquired for each 18-mer DNA oligomer. It was established
that we could distinguish two different types of diagnostic product ions: a) the product
ions formed by identical cleavage sites within each precursor anion, having the same
isobaric masses and b) the product ions formed by identical cleavage sites, but having
different masses. These specific diagnostic product ions facilitated the characterization of
each isobaric 18-mer D A oligomer. In addition, we also indicate that a series of product
ions were common for at least two constitutional isobaric 18-mer oligomers. The Mongo
Oligo Software was used exclusively to perform the characterization and the correct
sequencing of each isobaric DNA oligomer.
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2.1. Introduction
In modem molecular biotechnology, the analysis of DNA oligomers has become a
topic of primary importance, since establishing the size, purity, and sequence of nucleic
acids is a prerequisite to their use as molecular probes in medicinal science. The sequence
of D A encodes the necessary infonnation for all living organisms to survive and
reproduce. Therefore, knowledge of the DNA sequences is useful in biological
research.(I·3] In medicine, for example, DNA sequencing can be used to identify, diagnose
and, potentially, to develop treatments for genetic diseases. Similarly, research into
pathogens may lead to treatments for contagious diseases. Biotechnology is a burgeoning
discipline, with the potential for many useful products and services.[4]
Significant progress in the area of accurate mass detennination, sequencing, and
study of D A oIigomers and non-covalent interactions has been made possible by the use
of novel mass spectrometric techniques.l4.6] MALDI-TOF-MS has been explored widely
for DNA sequencing.p· ll ] The Sanger dideoxy-procedure has been generally used for the
sequencing of DNA-fragments. When compared to gel electrophoresis-based sequencing
systems, mass spectrometry enables high resolution of the D A-sequenced fragments,
fast separation (on a microsecond time scale), and completely eliminates compressions
that are associated with gel electrophoresis.[8.9] In addition, the use of mass spectrometry
for the analysis of the monomeric constituents of nucleic acids (nucleobases, nucleosides,
nucleotides and derivatives) has been widely established in the literature for the last four
decades.(lO.12] Before tandem mass spectrometry was used in conjunction with MALDI-
MS, the gas phase fragmentation of the DNA anions were carried out with a TOF
reflectron mass spectrometer using post-source decay.[13. IS l
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Another successful method used for the sequencing of DNA is the ladder
sequencing method'p 6J It consists of the chemical cleavage of the oligonucleotide with an
exonuclease (phosphodiesterase for single strands of DNA and exonuclease III for double
strands) digestion that sequentially removes nucleotides from the 3 - or the 5 - terminus of
the 0Iigomer.[17-2I J The exonuclease digestion was found to be both time and pH-
dependent. Mass spectrometric analysis of the digestion products of the oligomer and the
sequence of the unmodified or modified oligomer is resolved by the mass change after
the loss of each nucleotide.[17-21j
The ability of ESI-MS to fonn multiply charged ions in combination with
improved mass range in novel state-of-the-art MS instruments has made possible the
detection of increasingly larger oligonucleotide fragment ions. In reality, because DNA
has an acidic phosphodiester backbone, oligonucleotides are usually analyzed by ESI-MS
in the negative ion mode. Elucidation of the sequence of oligonucleotides by MS/MS of
multiply charged D A ions has been studied intensively over the past decade[22j and ESI-
MS and CID-MS/MS protocols have been established for the characterization of intact
DNA oligomers that vary in size up to 70 residues.[11.23-28j
Although CID-MS/MS analyses provide an excellent basis for detecting both the
length and sequence variations of oligonucleotides,PI] the presence of multiply charged
ions can make interpretation of the spectra complicated. McLuckey et at. were the first to
produce a nomenclature for the product ions obtained during the dissociation of multi-
charged oligonucleotides (Figure 2.1 (a»Y9.30J It was discerned, that under moderate CID-
MS/MS and MS" conditions, further consecutive fragmentations occurred from previous
charge-separation reactions. Thus, the presence of the complementary ions arising from
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these decompositions greatly facilitated spectral interpretation.[30,31] Furthermore, during
the CID-MS/MS analysis of the studied oligonucleotides, the formation of internal
product ions was also observed and these afforded valuable composition information on
the sequence stretches. eedless to say, that the manual interpretation of the MS/MS
analysis of oligonucleotides can be difficult, time-consuming, and prone to error because
of the large number of product ions present. Consequently, efforts were made to simplify
the process by relating the product ions obtained with the particular structure of a
precursor oligonucleotide anion. A computer-based algorithm, to automatically derive
sequence infonnation from the MS/MS spectra for oligonucleotides of a completely
unknown sequence, was developed by McCloskey and coworkers.[32]
Rozenski and McCloskey developed a novel approach for the nearest-neighbor
determination, based on the analysis of fragment ions of the nucleic acid formed in the
ionization region of the mass spectrometer, along with the product ions obtained from
MS/MS of the precursor oligonucleotide anion.[33] The same authors wrote software for
the ab initio determination of unknown oligon!1cleotide sequences up to the 20-mer level
and was termed Simple Oligonucleotide SequencerY4] However, this method cannot be
extended to longer oligonucleotide sequences because missing fragments in the series of
[a-B) or w ions would prevent the successful passage through the whole sequence.
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(a)
[a2- 8 1- W2
(b)
5
0 Ls
[-1= 'HO-U-OH OO-;p
'? l"'-r"l 60 ~-~ -nH-H,O
-+- ~ h 6Hy" [a-S]"- [d-H,O]"-
[pd(A)f
f=furanyl
p=phosphate
Figure 2.1. (a) Nomenclature for different oligonucleotide fragment types which
includes the 3' or 5' terminus and (b) complementary fragment ions
formation.(example: [a2 - 8 2t and W2 X-), example of internal fragment ion [pd(A)pfl
and [pd(A»)".
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The Mongo Oligo Mass Calculator v2.06 software was developed by Rozenski and
collaborators and is available online.[3S] This software is used to determine the sequence
of oligonucleotides provided by ESI-ClD-MS/MS analysis of multi-charged ions and/or
enzymatic digests. It is also capable of providing the molecular mass calculation of
oligonucleotides and to predict the possible ClD product ions [a - B], [d - H20], Yand w.
In addition, this software permits the determination of internal product ions (information
about sequence stretches) that may be obtained for the analysis of a known
oligonucleotide. Please note that the formation of internal product ions [pd(A)pfT
predicted by this program correspond to the following product ions represented as
[A2:A2r, [A6:A6r, [Ag:Agr, [AI2:AI2r, [A1s:A1Sr and [A I6 :A I6r for the oligonucleotide J
(Figure 2.1 (b)). The Mongo Oligo Program also calculates the possible mass of exo- and
endonuclease digests ions.[3S]
The purpose of this work was to try to sequence, with a QqTOF-MS/MS hybrid
instrument, an isobaric series of three self complementary 18-mer DNA oligomers which
have the same base composition but different orders. The Mongo Oligo Program was
used to obtain the ClD-MS/MS correct sequencing. These 18-mer DNA oligomers are
being used in our laboratory for the synthesis of model retrorsine derived-DNA adducts
compounds used for the study. The retrorsine is a pro-carcinogen pyrrolizidine alkaloid,
and its metabolites formed during liver microsomal activation are toxics and can bind
DNA, causing cancerY6.37]
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2.2. Material and methods
2.2.1. Sample preparation
The three constitutional isobaric 18-mer D A oligomers used in our experiments
were purchased from Oswel D A Service Laboratory (Southampton, UK). These three
self complementary 18-mer DNA oligomers were made up of 18 residues with the
following sequences: GATTCATAGCTACGAATC 1, AATTCGTAGCTACGAATC 2,
and AATTCGTACCTACGAATG 3, having the same base composition but different
sequences.
2.2.2. Electrospray quadrupole orthogonal time-of-flight mass spectrometry
Conventional electrospray ionization-mass spectrometry for all the oligomers was
acquired in the negative ion mode using an Applied Biosystems API-QSTAR XL
quadrupole orthogonal time of-flight (QqTOF)-MS/MS hybrid tandem mass spectrometer
(Applied Biosystems International-MDS Sciex, Foster City, California, USA). This
instrument is capable of analyzing a mass range of m/z 50 to 10,000, with a resolution of
10,000 in the negative ion mode. ESI was performed with the turbo ionspray source
operated at -4.2 kY. The ESI-MS were recorded with a cone voltage setting (declustering
potential I, DPI) of -50 Y, a declustering potential 2 (DP2) of -10 Y, a focusing potential
(FP) of -255 Y, a curtain gas of20 Pascal (Pa), an ion source gas I (GSI) of30 Pa, and
an ion source gas 2 (GS2) ono Pa, which were generally kept constant for the analyses.
A solution of each oligonucleotide at a concentration of I mg mL'\ was prepared
by dissolving I mg of each sample in I mL of a mixture of acetonitrile/water (80/20)
(v/v). Sample solution was then directly infused, with an integrated Harvard syringe
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pump (Harvard Apparatus, Hollister, MA) at a rate of 5 ilL min-I. One drop of diluted
triethylamine was added to 500 ilL of the oligonucleotide solutions with a concentration
of I mg mL- 1, to increase the formation of the deprotonated molecular anions in the ion
source of the mass spectrometer.
The TOF analyzer was calibrated for the mass range of the measured analytes
using the following oligomer: TGATCA which was dissolved in a I: I mixture of
acetonitrile (ACN or CH)CN)-water (H20) to a final concentration of I mg mL- 1 and
checking for the exact masses of the [M - Hr at m/z 1789.3431 and [M - 2Ht at m/z
894.1679, and using the TCA oligomer and checking for the exact mass of the [M - Hr at
m/z 843.1870 and [M - 2Ht at m/z 421.0899.
2.2.3. Low-energy collision CID-MS/MS analyses
Product ion scan experiments were recorded with the same instrument. The
product ion spectra were obtained from fragmentation in the QqTOF-MS/MS hybrid
instrument. In the product ion scan mode, the first quadrupole (Q I) selected the
corresponding precursor ion. The precursor ion was fragmented into product ions by
collision with nitrogen in the radio-frequency (RF), linear acceleration pulsar high
pressure (L1NAC) equipped, quadrupole collision cell. Nitrogen collision gas was added
to the enclosed chamber of the quadrupole (Q2) to give an indicated pressure of I x 10-5
torr for collisional activation of the sample ions. The collision energy (CE) and the CID
gas conditions ensured that the precursor ion remained abundant. The product ions were
scanned and sorted in the orthogonal mass resolving time-of-flight analyzer which
measured the occurrence of particular product ions, previously fomled in the Q2. We
have found the collision energies for the CID-MS/MS ofdeprotonated molecules of these
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oligomers did not exceed 40 eV while the declustering potential was kept at the same
value (DPI = -50 V) as that of the electrospray full scan ESI-MS experiments.
2.3. Results and discussion
i, Chang and Oberacher et al. have studied the sequence verification of different
length oligonucleotides using ESI_QTOF_MS.[38,39] The results were also compared to
those obtained with an ESI triple quadrupole MS and an ESI Ion Trap MS. They found
that the resolving power of the QTOF and its sensitivity allowed better interpretation of
the spectra and also easier sequencing of the oligonucleotides. It is important to mention
that the resolving power of the QqTOF-MS instrument can only reach 20,000 full width
at half maximum (FWHM)[39,40] which is a moderate resolution of lower orders of
magnitude when compared to high resolution-mass spectrometry such as Fourier
transform ion cyclotron resonance mass spectrometry (FTICR-MS or FT-MS) or the
recent LTQ Orbitrap XL Hybrid FT which can reach up to 1,000,000 FWHM.[41,42j
In this rationale, the ESI-QqTOF-MS and CID-MS/MS analyses of this series of isobaric
18-mer oligonucleotides were perfonned using a QqTOF-MS/MS hybrid instrument. Thi
latter instrument allowed us to identify and separate the isotopic deprotonated molecules
without ambiguity.
In addition, we have opted to use reliable software (Mongo Oligo Mass
Calculator) for the identification and characterization of the ClD-product ions obtained
from the product ion scan analyses of the well resolved, diagnostic isotopic deprotonated
molecules, selected of our isobaric 18-mer oligomers. The Mongo Oligo Mass Calculator
uses the sequence of a know oligonucleotide as input for the calculations. It can be used
for calculating masses of oligonucleotides, electrospray series, fragment product ions
69
obtained by collision-induced dissociation (CID), and fragments of enzymatic digests by
endonuclease and exonucleaseYS] The method consists on comparing the product ion
spectra masses generated by CID of multiply charged oligonucleotide ions to the
predicted m/z values, employing established fragmentation pathways obtained from a
known reference sequence. The program can also calculate the masses of modified
residues. An accompanying tool is Oligo Composition Calculator which finds
oligonucleotide composition when the user inputs a mass. Mongo Oligo Mass Calculator
is by far the most comprehensive program for the analysis of genetic mass spectrometric
data with multiple functionalities.[3S.43]
2.3.1. ESI-QqTOF-MS analyses
The ESI-QqTOF-MS (negative ionization mode) of the three isobaric IS-mer
DNA oligomers showed identical series of multi-charged deprotonated molecular anions
(Table 2.1, Figure A. I). Seeing that the identical molecular weight of the isobaric IS-mer
D A oligomers is high, the intensity of the monoisotopic mass of the deprotonated
molecules tends to be lower than the nominal and average masses. As expected, ESI-
QqTOF-MS analysis of the three constitutional isobaric IS-mer D A oligomers gave the
equivalent series of highly charged deprotonated molecular anions with the same m/z
values. It is also well known that the DNA molecular anions, when highly charged, are
extremely easy to fragment.[30JI.33-3S.43] In addition, the three analyzed isobaric IS-mer
oligomers, formed in the gas phase the same series of sodiated adduct anions. The
theoretical monoisotopic m/z values of the deprotonated molecules and their D. deviations
(in ppm) are presented in Table 2.1.
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Table 2.1. Molecular and fragment ions obtained during the conventional ESl-QqTOF-
MS analysis of the oligomers 1- 3.
Ion
Calculated Deviation Deviation Deviation
m/z for 1 (ppm) for 2 (ppm) for 3 (ppm)
[M-IIH]II. 497.1712 14 15 17
[M+Na-12H]II. 499.1695 9 II -18
[M_IOH]lo. 546.9890 II -13 18
[M+Na-IIH]lo. 549.1860 2 0 -4
[M + K - II H] 10- 550.7830 -I 4
[M+2Na-12H]'0- 551.3840 I 8 -34
[M-9Ht 607.8775 -3 -4 29
[M+Na-IOHt 610.3200 -10 -5 39
[M+K-IOHt 612.0948 -16 -II
[M + 2Na - II Ht 612.7624 -18 -18 13
[M-8Ht 683.9881 -7 -3 I
[M +Na -9Ht 686.7340 -6 -8 -3
[M+K-9Ht 688.731 -13 -13
[M + 2Na - 10Ht 689.4836 -15 -7 2
[M-7H( 781.8446 -7 -9 -25
[M +Na-8H( 784.9849 -9 -9 -44
[M+K-8H( 787.2669 -12 -6
[M +2Na-9H( 788.1252 -12 -3 -48
[M-6Ht" 912.3199 0 0 -8
[M + Na -7Ht" 915.9836 2 -I -59
[M +K-7Ht" 918.6459 -6 -4
[M+2Na- 8Ht" 919.6472 -5 -2 -24
[M +3Na-9Ht" 923.3109 -22 -15 -51
[M-5Hf 1094.9853 -5 -I -9
[M +Na-6Hf 1099.3817 -7 7 -38
[M +2Na -7Hf 1103.7781 -3 7 -55
[M +3Na- 8Hf 1108.1745 -32 -10 -2
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2.3.2. Low-energy collision CID-MS/MS analyses
In general, during all the tandem analyses presented herein, we performed on the
extracted isotopic precursor ions. The CID-MS/MS experiments of the deprotonated
molecules [M - 8H]8- at m/z 683.9881 and [M - 9Ht at m/z 607.8775, were acquired for
each isobaric 18-mer DNA oligomer. Initial attempts to generate product-ion scans from
the multi-charged oligonucleotide anion precursors relied on maximizing the abundances
of the product ions of high masses to obtain as much infonnation as possible on each
different sequence. Thus, the best CE was chosen for each molecular anion, which was
about 30 eV. As already reported in the literature, we have found that when the analyzed
anion was highly charged, it needed less CE to fragment.[44]
2.3.3. CID-MS/MS analysis of the 1M - 8H18- deprotonated molecules at mlz 683.9881
extracted from the isobaric I8-mer DNA oligomers 1-3
We have noticed that each individual product ion scan created a series of different
diagnostic ions (observed only in one oligonucleotide), as well as common product ions
(Figure 2.2 for oligomer I). The specific product ions obtained by CID-MS/MS analysis
of the [M - 8Ht ion at m/z 683.9881 of the 18-mer D A oligomers 1-3 are shown in
Figure 2.3 and Tables A.I-A.3. It is important to point out that the examination of each
diagnostic product ion indicated that their formations were not localized within the same
sequential region of the constitutional 18-mer oligomers. Therefore, the fonnations of
these diagnostic product ions are unique and constitute a fingerprint of the analyzed
isobaric 18-mer oligomers. On the other hand, the CID-MS/MS fragmentations of the
deprotonated molecules, yielded identical mini-sequences, occurring at the same cleavage
positions; however, the product ions formed had different charged states. This latter
72
observation may be due to the existence of different deprotonation sites of the respective
analyzed oligomers. In addition, it is well known that the final CID-MS/MS
fragmentation pattern obtained can be influenced by the nucleobases present in each of
the analyzed IS-mer DNA 0Iigomers.[I2] It is logical to expect that isobaric
oligonucleotides with different sequences basically have different physical-chemical
properties, which can be the reason for the differences observed during their gas-phase
fragmentations.
Additionally, we observed the formation complementary product ions, which
helped in the product ion identification. McLuckey el al. found that when a base is
eliminated from the deprotonated molecule [M - nH]n- (n >1), it produces the anion [M -
nH - 8](n-I>- (8 = lost base), which fragments further to afford the complementary pair of
product ions w:- and [am - 8t in which x, k > I and (x + k) = (n - I) (Figure
2.1 (a».[30.31] Another fragmentation pathway leading to the formation of complementary
product ions involves the loss of a neutral base (A, T, C or G) to produce the following
anion: [M - nH - 8H)"- (8H = neutral base loss) which also fragments, leading to the
fonnation of the following complementary product ions: w:- and [am - 8t (x, k > I
and (x + k) = n).
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w}
rnlz
Figure 2.2. Low-energy elD tandem mass spectra of the [M - 8H]8- anion at mlz
683.9881 of the oligomer 1.
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Thus, in the CID-MS/MS analysis of the multi-charged precursor [M - 8H]s- ion,
the loss of a single base (A, T, C or G) can produce the hepta-charged product anion: [M
- 8H - B( which probably fragments spontaneously and therefore is not detected.
However, this [M - 8H _B]7- product ion is able to afford the following complementary
product ions. For the oligomer I (Figure 2.6(a», we identified complementary product
ions: [a16 - B(A)]6- at m/z 787.9272 and W2- at m/z 610.0910, and [a12 - B(A)t at m/z
871.3856 and w/ at m/z 617.4181. However, no complementary product ions were
observed for the constitutional isobaric DNA oligomer 2 (Figures 2.3(b) and 2.6(b)). For
the DNA oligomer 3, we identified the complementary product ions [as - B(A)]3- at m/z
750.4395 and WI04- at m/z 771.6299; [a12 - B(A)t at m/z 861.3868 and w/ at /11/z
630.7709 and [a16 - B(A)t at m/z 781.2867 and W2- at /11/z 650.0968 (Figures 2.3(c) and
2.6(c». Furthermore, a neutral base loss during the CID-MS/MS analysis of the precursor
ion [M - 8Ht is able to form the octa-charged product ion [M - 8H - Bt (not detected in
the spectra), which is an intennediate ion for the production of the following
complementary product ions: [a16 - B(A)]6- at /11/z 787.9272 and w{ at /11/z 304.5429 and
[al2 - B(A)tat m/z 696.9452 and w/ at /11/z 617.4181 for the oligonucleotide I (Figures
2.3(a) and 2.6(a)). Also, we were not able to identify any complementary product ions for
the oligonucleotide 2 (Figures 2.3(b) and 2.6(b)). Finally, the complementary product
ions [a16 - B(A)]6- at /11/z 781.2867 and w{ at m/z 324.5523; [a15 - B(A)t at m/z
729.0918 and wt at m/z 481.0689; [a12 - B(A)t at /11/z 861.3868 and w/ at m/z
472.8377 and [as - B(A)]4- at /11/z 562.5952 and W1Q4- at /11/z 771.6299 were detected for the
oligonucleotide 3 (Figures 2.3(c) and 2.6(c».
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The CID-MS/MS analyses confinn without doubt, the known fact, that these three
18-mer DNA oligomers, while being isobaric, have indeed different sequences_
:~ G-1-A---Tj-T__-cj_jA-Tj-A-tG__C(_Aj-C---GtA-~-At T---C 3'
)' [Gg:ClOfj-- [A15.A1SJ
[d1 - H20J-
[d3 - H20J- [d5- H20f [a7 - Bf- [a12 - BJ5-
[as- Bf"
Y7:_ _
~ n n
S' A---A-tT1.-TJ_CtG_;j-A_~_T_(A~_-C--G---A.---.A/T--C 3'
[a3 - BI- [Gs T71 [G9.C13J [G I4:A1SJJ-l
[T3'T4f [CIO:c1d- [G I4.A1Sf
[d4 - H20J2-
(c) wll W12S- WI04- w/ ws4-
S' AtA---TIT---C+G-C.---A- -C---C.---T-(A-(C---G---A1A---T---G 3'L[G6~f J-t r )
[Ai~J3- [C9.T11 r [a15 _ BJ6-
[as- BJ4-
Figure 2.3. Different specific product ions obtained during the CID-MS/MS analysis of
the [M - 8H]8- ion at mlz 683_9881, for the following (a) oligomer J, (b) oligomer 2 and
(c) oligomer 3.
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2.3.4. CID-MS/MS analysis of the 1M - 9H( deprotonated molecules at m/z
607.8775 extracted from the isobaric 18-mer DNA oligomers 1-3
The CID-MS/MS analysis of the [M - 9Ht ion at mlz 607.8775 for the
oligonucleotide 1 (Figure 2.4), afforded different diagnostic product ions (Tables A 1-
A3). The cleavage sites within each analyzed respective precursor ion are shown in
Figure 2.5. As expected, we have identified a series of diagnostic complementary product
ions that were tentatively assigned as being created from the non-detected [M - 9H - B]8'
intennediate product ion. Accordingly, we have identified for oligomer J the following
complementary product ions: [al2 - B(A)]s, at mlz 696.8982 and W6J · at mlz 617.4415; [al2
- B(A)t at mlz 871.3750 and W64• at mlz 462.8181; and [al6 - B(A)]6. at mlz 787.9570
and w/· at mlz 304.5428 (Figures 2.5(a) and 2.7(a». It is interesting to note that for the
CID-MS/MS analyses of the [M - 9Ht ion at mlz 607.8775 extracted fonn the 18-mer
oligomers 2 and 3 we did not observe the fonnation of any complementary product ions
(Figures 2.5(b) and 2.7(b), and 2.5(c) and 2.7(c». Unfortunately, we were not able to
identity the pairs of complementary product ions arising from the fragmentation of the
intennediary nona-charged product ion [M - 9H - Bt (not detected), which should be
produced during the CID-MS/MS analysis of the precursor ion [M - 9Ht via the loss of
a neutral base. It is evident that the CID-MS/MS of the precursor [M - 9Ht ion at ml=
607.8775 affords less complementary product ions than the analysis of the [M - 8H]8.
precursor ion.
77
w,·
100% ~06.0502
['I;.BI'·
w,'
700 750 800 850
rnlz
Figure 2.4. Low-energy em tandem mass spectra of the [M - 9Ht anion at /11/z
607.8775 of the oligomer J.
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(: G--AtTtT ~--A- -T-J-A_I":C~j_T- -Af~::-:: _~~__A__-T--C 3'
~_ H20] [a7 - Bf [Gg ClO]
[T3 c5f [a7 - BJ3 [Gg Tll ]2 \:~: ~ ~\;
[a5- B]2 [as- BJ: [Gg C13l3
[d5 - H20]2 [~:~ -H~bf [Gg G14f
[as-Bf
[as- Bf
(b) "
5' A-j-A---T---T-l-C-l-G--T-A-G-I-C--T--A--C-l-G--A--:A- (T-C 3'
L[A2T4]2:.-J L-[GsGgf~ L[G14A1S]~-l
(c) W105• yl
5' A--A-~T-- j-C--.~---T -A-fc-rc---T-t-A---C~j-G---A---A---T---G· 3'
[T3.T4] [A12: C13J
[T3:T7]4-
Figure 2.5. Different specific product ions obtained during the CID-MS/MS analysis of
the [M - 9Ht ion at m/z 607.8775, for the following (a) oligomer 1, (b) oligomer 2 and
(c) oligomer 3.
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2.3.5. Common product ions present in the product ion scans of the oligomers 1-3
During each single CID-MS/MS analysis conducted with the different series of
precursor ions selected from the oligomers 1-3, we have observed a common series of
either identical or similar product ions shown in Tables A.4 and A.5. We have tried to
classify them into two types: a) the product ions formed by identical cleavage sites within
each precursor anion, having the same masses which corresponded to product ions with
the same bases composition and b) the product ions formed by identical cleavage sites,
however having different masses, corresponding to product ions with a different bases
composition. Accordingly, depending on the cleavage site, some product ions may have
identical masses.
Thus, the CID-MS/MS of the precursor ions [M - 8Ht at m/z 683.9881 and [M -
9H( at m/z 607.8775 extracted from GATTCATAGCTACGAATC 1 (Figures 2.6(a)
and 2.7(a), Tables A.2 and A.3) and AATTCGTAGCTACGAATC 2 (Figures 2.6(b) and
2.7(b), Tables A.2 and A.3) have the following common product ions with the same
masses (the common sequence from each termini of the two oligonucleotides is displayed
in bold): Wn and Yn (n :::: 12), [am - B) (m ~ 7) and [dp - H20] (p ~ 6). Indeed, during the
CID-MS/MS analysis of the [M - 8H]s- at m/z 683.9881 the common product ions, with
the same masses of these two oligomers, are: W22- at m/z 304.5429, WI- at m/z 306.0488,
w/ at m/z 461.0687, w/ at I11Iz 521.0813, yl- at l11/z 577.6099, W2- at l11/z 610.0910, w/
at I11/Z 617.4181, y/ at m/z 742.1333, [as - B]3- at m/z 750.4478, w/ at l11/z 782.1231, Y3-
at I11/Z 843.1699, Y62- at I11/Z 886.6554, W3- at m/z 923.1469, wt at I11/Z 926.6393 and [a7-
Bfat I11Iz 974.1417.
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[a3- B)-
[T3 T7f
[a2-B]' la7- Bf"
[d2- H20 j'
(c) W 7 Y\ 2
5' _ALG~h~~~r1~~:j:~'_T-_Aj[~~~L§'~~.J:§:[:: J~f-::C 3I-A IT,c.l t":.BI::l;~"G"1 t' 1-'
2 [as B]3 [Til G141
2
[a16 B)6
[a5 B] [ClD G14)3
[T3 Td
[a2- B]-
Figure 2.6. Common product ions (isobarics and non isobarics) to at least two
oligonucleotides obtained during the CID-MS/MS analysis of the [M - 8H( ion at
m/z 683.9881, for the following (a) oligomer J, (b) oligomer 2 and (c) oligomer 3.
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[a2- B]-
[d2- H20]"
[a2 - BJ-
[d2- H20]-
Y3- wl-
S' IC~'._Ai-;J::~:k} ,G---Tj-A---c-f-C~f-l~~~:~. -c-f~:p~{:f-:~( 3'
-!-ctG,T,1 L'T1c,,"':J j-'
[a3- Bj- [Tll G14f [a16- 8]6-
[d2- H20]-
Figure 2.7. Common product ions (isobarics and non isobarics) to at least two
oligonucleotides obtained during the CID-MS/MS analysis of the [M - 9Ht ion at m/z
607_8775, for the following (a) oligomer 1, (b) oligomer 2 and (c) oligomer 3_
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The product ion scan of the [M - 9Ht at m/z 607.8775 gives us the following common
product ions having the same masses of the two oligonucleotides: wl at m/z 304.5428,
WI' at m/z 306.0502, w{ at m/z 461.0683, W2' at m/z 610.0859, ws4. at m/z 617.0860, y{
at m/z 742.1295, w{ at m/z 782.1193, Y3' at m/z 843.1642, y/ at m/z 886.6485, W3' at
m/z 923.1414 and Y4' at m/z 1156.2161.
The comparison of the CID-MS/MS of the precursor ion [M - 8H]s. at m/z
683.9881 extracted from the GATTCATAGCTACGAATC 1 and the
AATTCGTACCTACGAATG 3. (differences in the bases location between the two
oligomers are displayed in bold) (Figures 2.6(a) and 2.6(c» revealed the fonnation of one
common product ion [as - 8]3' at m/z 750.4478 having the same mass (Table A.4)
However, it is worth noting that this product ion has the same base composition, but with
a different sequence for the two oligonucleotides. This is not surprising, as in the CID-
MS/MS analyses of the deprotonated molecules [M - 8Ht at m/z 683.9881 and also [M-
9H]9. at m/z 607.8775 obtained from oligomers 1 and 3, the extracted precursor ions have
different tennini and therefore cannot fonn the common product ions wn, Yn, [am - 8] and
[dp- H20] with the same sequence. Please note that, in the CID-MS/MS of the precursor
ion [M - 9Ht extracted from GATTCATAGCTACGAATC 1 and the
AATTCGTACCTACGAATG 3 no common product ion having the same mass were
observed.
Finally, the comparison between the CID-MS/MS of the precursor ions [M - 8H]s.
at m/z 683.9881 (Figure 2.6, Table A.4) and [M - 9Ht at m/z 607.8775 (Figure 2.7,
Table A.5) extracted from AATTCGTAGCTACGAATC and
AATTCGTACCTACGAATG 3 produced the following common product ions having
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the same masses: W n and Yn (n ~ 10), [am - 8] (m :s 9) and [dp - H20] (p :s 8). Indeed,
during the CID-MS/MS of the precursor ions [M - 8Ht at m/z 683.9881 we observed the
following common product ions having the same mass: [a2 - 8r at m/z 410.0818, [as-
8]20 at m/z 665.1079, W1770 at m/z 748.5498 and [as - 8]30 at m/z 750.4530. From these
observations, it was construed that, although these common product ions contain the
same bases, they do not necessarily have the same sequence.
We also observed the formation of common internal product ions with the same
masses which correspond to the same sequence. For example, the internal product ion
[Til :G ,4f at m/z 705.5935 of the CID-MS/MS analysis of the [M - 8H]sO molecular ion at
m/z 683.9881 (and [M - 9Ht at m/z 607.8775) correspond to the following sequence
[pd(TACG)pfiOfor the oligomers 1-3 (Figures 2.6 and 2.7, Tables A.4 and A.5). We can
also say that the product ions W n and Yn (n :s 12) correspond to part of a same sequence
for the GATTCATAGCTACGAATC 1 and AATTCGTAGCTACGAATC 20ligomers
(the common sequence from each termini of the two oligonucleotides is displayed in
bold), as well as the product ions [am - 8] (m:S 9) and [dp - H20] (p:S 8) which have the
sequence for the AATTCGTAGCTACGAATC and
AATTCGTACCTACGAATG 3. However in the case of the CID-MS/MS of [M - 8H]sO
at m/z 683.9881 and [M - 9Ht at m/z 607.8775 extracted from
GATTCATAGCTACGAATC 1 and AATTCGTACCTACGAATG 3 oligomers do not
have common product ions. This is explained by the fact that these two oligonucleotides
1 and 3 have different bases at their 3-' and 5-' termini. In addition, these constitutional
isobaric 18-mer DNA oligomers can break down from both their 3-' and 5-' tennini.
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Furthennore, we also have observed the fonnation of internal product ions,
having the same masses, but different sequences. For example, the internal product ion
[Cs:T7f at m/z 541.0725 correspond to the ion [pd(CAT)pff for the oligonucleotide 1.
Unfortunately, this product ion at m/z 541.0725, can also correspond to the following
ions: [pd(TAC)pff, [pd(ATC)pfJ2- and [pd(CAT)pfJ2- for the oligonucleotide 1;
[pd(TAC)pfJ2- and [pd(ATC)pfJ2- for the oligonucleotide 2 and [pd(TAC)pfJ2- and
[pd(CTA)pfJ2- for the oligonucleotide 3 (Tables A.4 and A.5). In addition, the internal
product ion [Cs:T7f represents the sequence [pd(CGT)pfJ2- at m/z 549.0629 for the
oligomers 2 and 3. We can conclude from this example, that the internal product ions can
give limited infonnation about the sequence stretches of the oligonucleotides.
In the CID-MS/MS analyses of the precursor ions [M - 8H]s- at m/z 683.9881 and
[M - 9Ht at m/z 607.8775 extracted fonn the 18-mer DNA oligomers 1-3, we noticed
the presence of the product ions arising from the same specific site cleavages but which
have different masses. Thus, the GATTCATAGCTACGAATC 1 and
AATTCGTAGCTACGAATC 2 give the following common product ions with different
masses: Wn and Yn (n ~ 13), [am - B) (2 :s m :s 6) and [dp - H20] (p :s 5). The
GATTCATAGCTACGAATC 1 and AATTCGTACCTACGAATG 3 have the following
common product ions which differ in their masses: W nand Yn (n:S 9 and 13:S n:S 17), [am
- B) (2 :s m :s 6 and m ~ 10) and [dp - H20] (p :s 5 and 9 :s p :s 17).
Finally, for the pair AATTCGTAGCTACGAATC and
AATTCGTACCTACGAATG 3, we identified the common product ions, which have not
the same masses: W nand Yn (n:S 9), [am- B) (m ~ 10) and [dp - H20] (9:S p:S 17).
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2.4. Conclusion
The constitutional isobaric 18-mer DNA oligomers
GATTCATAGCTACGAATC, AATTCGTAGCTACGAATC and
AATTCGTACCTACGAATG 1-3 (Molecular Mass = 5479.9560 Da) were analyzed by
negative electrospray mass spectrometry. The resolution of the QqTOF mass
spectrometer allowed us to observe the isotopic distribution of each ion, which is helpful
for the identification of the molecular ions and the fragments ions.
The conventional ESI-QqTOF-MS of these 18-mer DNA oligomers exhibited
identical series of multi-charged deprotonated molecular ions. Low-energy collision-
induced dissociation tandem mass spectrometric analysis of the multi-charged
oligonucleotide anions [M - 8H]8. at m/z 683.9881 and [M - 9Ht- at m/z 607.8775
provided characteristic and distinct fingerprint patterns which permitted discrimination
amongst the individual oligomers and allowed complete bi-directional sequence
verification. On the other hand, the ab initio sequencing was not possible for the 18-mer
oligonucleotides because complicated CID-MS/MS spectra derived from highly charged
precursor ions were obtained.
Finally, we would like to indicate that the Mongo Oligo Mass Calculator v2.06
software, developed by Rozenski, is an excellent program which facilitates the
charactelization and sequencing of DNA oligomers and helped to decipher the complex
CID-MS/MS analyses obtained in this work.
Appendix A. Supplementary data
Supplementary are data associated \\'ith this chapter (page 23/)
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Abstract
We present the MALDI-TOFrrOF-MS analyses of various hapten-BSA
neoglycoconjugates obtained by squaric acid chemistry coupling of the spacer-equiped,
terminal monosaccharide of the O-specific polysaccharide (O-PS) of Vibrio cholerae 01,
serotype Ogawa, to BSA. These analyses allowed not only to calculate the molecular
masses of the hapten-BSA neoglycoconjugates with different hapten:BSA ratios (4.3: I,
6.6: I and 13.2: I) but, more importantly, also to localize the covalent linkages
(conjugation sites) between the hapten and the carrier protein. Detennination of the site
of glycation was based on comparison of the MALDI-TOFrrOF-MS analysis of the
peptides resulting from the digestion of BSA with similar data resulting from the
digestion of BSA-glycoconjugates, followed by sequencing by MALDI-TOF/TOF-
MS/MS of the glycated peptides. The product ion scans of the protonated molecules were
carried out with a MALDI-TOFrrOF-MS/MS tandem mass spectrometer equipped with a
high CE cell. The high-energy cm spectra afforded product-ions fonned by
fragmentation of the carbohydrate hapten and amino acid sequences conjugated with
fragments of the carbohydrate hapten. We were able to identify three conjugation sites on
lysine residues (Lys 235, Lys 437 and Lys 455). It was shown that these lysine residues
are very reactive and bind lysine specific reagents. We presume that these Lys residues
belong to those which are considered to be sterically more accessible on the surface of
the 3-dimensional structure. The identification of the y-series product ions was very
useful for the sequencing of various peptides. The series of a- and b-product-ions
confinned the sequence of the conjugated peptides.
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3.1. Introduction
During the last century, LPS have been extensively studied because of their
importance as essential components of outer membranes in gram-negative bacteria.l l ] The
LPS macromolecule consists of an internal core oligosaccharide attached to the lipid A,
and an external core oligosaccharide which is glycosylated by a polysaccharide, also
called the O-specific polysaccharide (O-PS). The latter is composed of oligosaccharide
repeating units whose structure and composition differ for various genera and bacterial
serotypesY.3] Although, the LPSs are known to activate the complement and
macrophages, they can also induce endotoxic shock. The toxic properties of the LPSs
reside largely in the lipid A, whereas the characteristic immunological properties reside
in theO-PS.
It has been established that O-specific polysaccharides are the essential virulence
factors and protective antigens of pathogenic gram-negative bacteria.[4] Many LPS-
derived neoglycoconjugates, which included O-specific antigens, synthetic
oligosaccharide antigens and delipidated LPS, have been used as protective vaccines in
numerous therapeutic studies.[1.9j It has been demonstrated that protein conjugates of 0-
PS of several enteropathogenic bacteria are safe and immunogenic in humans. They can
elicit high titers of serum antibodies, which can be boosted by subsequent vaccinations,
and offer protection against the homologous bacteria. In addition, it has been established
that the efficacy of the neoglycoconjugate vaccines depend mainly on the structural
(architectonic) variables. These include, but are not limited to, the size of the antigenic
sacchalide, the average number of saccharide chains per conjugate molecule, the distance
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between the saccharide and the protein, the site of attachment to the protein, and the
nature of the carrierprotein.[IO-12]
Cholera is a disease caused by the gram-negative bacteria Vibrio cholerae, which
causes severe bacterial infection of the intestine. The infection occurs in endemic areas or
anywhere by ingesting contaminated food or liquids.(13) The Vibrio cholerae strain
belongs to the Vibrionaceae family of bacteria which is divided into some 200
serogroups.[14j KovaC's group, has been involved in developing a conjugate vaccine for
cholera from synthetic fragments of the OopS of Vibrio cholerae 0: I conjugated by
single point attachment to protein carriers. They have prepared well-defined
neoglycoconjugates using spacer-equipped synthetic oligosaccharides attached to squaric
acid monoesters. The oligosaccharides used mimick fragments of the O-specific
polysaccharide of the two main strains of Vibrio cholerae serogroup 0 I, serotypes
Ogawa (Figure 3.1 (a» and Inaba. The OopS of both strains is composed of a chain of
about 15-20 u-( I~2)-linked monomers of 4-amino-4,6-dideoxY-D-mannopyranosyl
residues (D-perosamine) in which the amino group is acetylated with 3-deoxY-L-glycero-
tetronic acid.[15.16) The O-PSs of the two strains differ in that only in the Ogawa strain is
the 0-2 of the upstream[17] terminal perosamine residue methylated.[18-20]
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Figure 3.1. (a) Schematic representation of the general structure of carbohydrate-spacer-
squaric acid-protein constructs from oligosaccharide fragments of the O-polysaccharide
of the Vibrio cholerae 01, serotype Ogawa and (b) MALDI-TOFrrOF-MS analysis of
native BSA, and (c) hapten-BSA neoglycoconjugates with a hapten:protein ratio of 4.3: I.
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It is well known that the f;-amino groups of lysine residues in proteins are very
reactive and, therefore, amenable to covalent attachments of haptens. The effect of
attaching a hydrophilic carbohydrate hapten to such amino groups substantially alters the
physicochemical and functional immunological properties of the carrier protein. There
are 60 lysine residues in the BSA which are distributed in three homologous a-helical
domains (I, II and III), and theoretically, all can be derivatizedyl.22] Unfortunately,
methods suitable for detennination of the composition ofneoglycoconjugates reveal only
the carbohydrate:protein ratios but cannot localize the exact lysine residues where the
haptens are attached. In addition, the carbohydrate:protein ratios in neoglycoconjugates
are usually detennined by colorimetric methods and not by MS. Regrettably, the
reliability of calibration curves required by colorimetry have always been questionable,
especially when they are to be used to analyze mixtures where oligosaccharides that
mimic the structure of rare or unstable sugar-containing bacterial polysaccharides are in
mixture with variable amounts of protein carriers.
Currently, several methods have been developed for the MS analysis of N-
glycoproteins.123-25] ESI and MALOI techniques have been used to evaluate the
distribution of glycation within the glycated hemoglobin molecule and for the
detennination of advanced glycation end-products on proteins associated with aging and
various diseases.[26-28] Recently, the characterization of the glycation sites of bovine
insulin was detennined by MALOI-MS/MS[29] However, reports on detailed structural
elucidation of the synthesized neoglycoconjugate vaccines by mass spectrometry has
been quite meager. Little work has been done with regard to localizing the lysine residues
where the carbohydrate haptens are attached in protein carriers. Recently, the
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carbohydrate:protein ratio (loading) in synthetic neoglycoconjugates has been measured
objectively by MALDI-TOFrrOF-MS and SELDl-TOF-MSyo-34j However, neither these
sophisticated techniques can locate the carbohydrate-bearing lysine residues.
With the task outlined above in mind, we have used a conventional approach
whereby the digestion of glycoprotein with a protease was followed by mass spectral
analysis of the resulting glycopeptides. Accordingly, we have compared the MALDl-
TOF/TOF-MS analysis of the intact glycoconjugates composed of the simple antigenic
glycosyl hapten the 1-[(2-aminoethylamido)carbonylpentyl-4-N-methylamino-4,6-
dideoxy-a-o-mannopyranosyl]-2-methoxycyclobutene-3,4-dione conjugated to BSA to
that of the BSA alone. In addition, we also compared the MALDI-TOF/TOF-MS of the
peptides resulting from the digestion of the BSA to those resulting from the digestion of
the hapten-BSA neoglycoconjugates. The sequencing of the resulting peptides was
performed by high-energy collision dissociation CID-TOFrrOF-MS/MS using the
selected protonated molecules formed from the released glycated peptides.
3.2. Materials and Methods
3.2.1. Preparation of the hapten-BSA neoglycoconjugates
The hapten-BSA conjugates were synthesized as described previously.[34 j Briefly,
the 4-(3-deoxy-L-g/ycero)-2-0-methyl-a-o-perosamine, which corresponds to the
upstream tenninal moiety of the O-PS of Vibrio cho/erae serogroup 0 I serotype Ogawa
antigen, was first prepared in the fonn of methyl 6-hydroxyhexanoyl a-glycoside, whose
aglycone fonned a spacer. The reaction of the spacer-equipped sugar with 1,2-
diaminoethane converted the methyl ester group in the spacer into the corresponding
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amino amide, and the subsequent reaction with diethyl squarate resulted in formation of
squarate monoester. Finally, the conjugation with the BSA was canied out in commercial
borate buffer (pH 9.0) at the initial molar carbohydrate:protein ratio of 100: I. The
process of conjugation was monitored by SELDl-TOF-MS, and portions of the
conjugation mixtures were withdrawn at various reaction times'p41 to give the
corresponding BSA conjugates. Isolation and purification of the hapten-BSA
neoglycoconjugates was achieved by ultrafiltration, using centrifugal devices, to remove
low molecular mass materials present (buffer salts and the unchanged carbohydrate
derivative). According to the SELDI-TOF-MS analysis perfonned by Kovac's group, the
carbohydrate:protein ratios were found to be 4.4: I, 7.1: 1 and 13.4: 1.[34] When re-
measured during this work the carbohydrate:protein ratios found were 4.3: I, 6.6: 1 and
13.2:1.
3.2.2. Digestion
The hapten-BSA conjugate was reduced with 10 mM dithiothreitol (DTT) and
alkylated with 100 mM iodoacetamide, followed by tryptic digestion using a solution of
20 nglmL trypsin in NH4HC03 (50 mM) and keeping the samples at 37°C (water bath)
overnight. The sample was then dried under vacuum and reconstituted in 20 ~lL of 1%
acetic acid. Before mass spectral analysis, an aliquot of each sample (I 0 ~lL) was purified
using ZipTip C 18 (Millipore, Bedford, MA).
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3.2.3 MALDI-TOF-MS and MALDI-TOFrrOF-MS/MS analyses
Mass spectral analysis were carried out with a 4700 Proteomics analyzer with
TOF-TOF optics (Applied Biosystems Foster City, CA) and a 200-Hz frequency-tripled
d:YAG laser. CHCA was used as matrix for the analysis of BSA, hapten-BSA
conjugate, and the peptides resulting from their digestions, with an average of 5000 to
8000 laser shots per spectra. The MS/MS analyses were achieved with air as collision gas
at collision energy of I kY, which corresponded to the difference between the
accelerating potential (8 kY) and the floating cell (7 kY). The internal calibration of the
digested glycoproteins and BSA was perfonned in the range 600-3200 using as standards
peptides known to be present in the BSA.
3.3. Results
3.3.1. MALDI-TOF/TOF-MS analysis of BSA and the hapten-BSA
neoglycoconjugates
To detennine the number of haptens conjugated to the BSA, the BSA used as the
starting carrier and the carbohydrate hapten-BSA neoglycoconjugates were analysed by
single stage MS using MALDI-TOFITOF-MS. Figure 3.1 shows the spectra of the
starting BSA (b) and the synthetic neoglycoconjugate with 4.3: 1 hapten:BSA ratio (c).
We also recorded the MALDI-TOF/TOF-MS of the synthetic neoglycoconjugate with
6.6: I and 13.2: I hapten:BSA ratios, which gave the expected spectra (Figure B.I,
Appendix B). The molecular masses of these synthetic neoglycoconjugates are listed in
Table 3.1. The squaric acid chemistry of conjugation covalently links the carbohydrate
squaric acid ethyl ester to the E-amino function of the lysine residues in BSA with the
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concomitant loss of EtOH. Consequently, knowing that the molecular mass of the
monosaccharide-squaric acid portion was 513.23 Da, it became possible to calculate and
verify the hapten:BSA ratio in the formed neoglycoconjugates. As expected,
neoglycoconjugates resulting from longer reaction time[341 showed higher ratio of
conjugated haptens to the BSA carrier. Accordingly, the conjugate formed after the
reaction time of 45 min, 1.5 h and 6 h showed carbohydrate:protein ratios of 4.3: I, 6.6: I
and 13.2:1, respectively.
Table 3.1. Molecular masses and calculated hapten:BSA ratios ofBSA and hapten-BSA
conjugates.
IM+2HI2+ IM+HI+ 12M+HI+ RemeasuredHaoten:BSA ratio
StandardBSA 33,115 66,310 133,019
Ha ten:BSA4:1 34,410 68,586 136,501 4.3:1
Ha ten:BSA 7:1 34,659 70,125 139,462 6.6:1
Ha ten:BSA 13:1 36,498 73,413 145,870 13.2:1
To identify the specific glycation sites in the formed neoglycoconjugates, the
samples were enzymatically digested with trypsin, as described in the Materials and
Methods section. Figure 3.2 displays the MALDI-TOFrrOF-MS analysis of peptides
resulting from the digestion of the BSA (a) and of those from the hapten-BSA
neoglycoconjugate with an initial ratio of 4.3: I (b), 6.6: I (c) and 13.2: 1 (d). Identities of
the diagnostically significant peptides and glycated peptides are shown in Tables 3.2 and
3.3. We have assigned only the peaks which appeared in the MALOl spectra of the
digested hapten-BSA neoglycoconjugates (circled in the MALOI spectra, Figure 3.2).
Accordingly, the following peaks corresponded to the glycated peptides at mlz 830.41,
mlz 912.48, mlz 1069.60, mlz 1330.72, mlz 1405.73, mlz 1514.82, mlz 1662.70, mlz
1691.79, mlz 2153.16 and mlz 3025.37 (Figure 3.2). Unquestionably, these peaks were
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assigned to the glycated peptides, in which the resulting molecular masses corresponded
to the exact addition of the glycan mass increment of 513.23 Da for the targeted digested
tryptic peptides. It is interesting to note that for the glycated peptide ions at m/z 1330.72
and 1514.82, the peptide portions were different from any peptides formed during the
conventional digestion of the BSA carrier protein. However, the unique peak at m/z
2153.16 appears to be associated to an observed ung1ycated peptide at m/z 1639.94
formed during the conventional enzymatic digestion of BSA. The formation of peptides
with m/z 1330.72, 1514.82 and 2153. I6 is listed in the Table 3.3. These glycated peptides
had a mass shift of 513.23 Da (characteristic of the glycation with one hapten residue)
when compared with the m/z values of peptides (theoretical values). Note that the starting
BSA is a commercial product, which has already gone through some
purification/precipitation process. Therefore the glycated peptides were assigned as
SLGK*VGTR (T63-T64, 452-459) at m/z 817.49, ALK*AWSVAR (T34-T35, 233-241)
at m/z 1001.59 and K*VPQVSTPTLVEVSR (T61-T62, 437-451) at m/z 1639.94. The
conjugation/glycation site that points to the lysine residue in the carrier protein is denoted
by an asterisk. We were able to detect some other unidentified peptides (not formed
during the conventional BSA digestion) and these were suspected to be glycated.
However, their CID-MS/MS analyses did not give any useful infonnation pennitting their
sequencing.
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(a)
(b)
Figure 3.2. MALDI-TOF/TOF-MS spect~ of the digested (a) BSA, and hapten-BSA
conjugates with hapten:protein ratios of (b) 4.3: I, (c) 6.6: 1 and (d) 13.2: 1.
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(c)
Figure 3.2. (continued)
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Table 3.2. MALDI-TOF/TOF-MS peptide mapping of the digested BSA (after recalibration).
Peptide Location Observed Calculated Accuracy Missed Peptide sequence
# m/z m/z ppm cleavage
T46-T48 310-340 3511.6710 3511.6725 0 2 SHClAEVEKDAIPENLPPLT ADFAEDKDVCK
T40-T42 264-285 2612.1848 2612.1655 -7 2 VHKECCHGDLLECADDRADLAK
T47-T48 319-340 2458.1887 2458.1812 -3 1 DAIPENLPPLTADFAEDKDVCK
T41-T42 267-285 2247.9478 2247.9433 -2 1 ECCHGDLLECADDRADLAK
T40-T41 264-280 2113.8802 2113.8853 2 1 VHKECCHGDLLECADDR
T23-T24 168-183 2045.0297 2045.0285 -1 0 RHPYFYAPELLYYANK
T73 529-544 1907.9257 1907.9213 -2 0 LFTFHADICTLPDTEK
T24 169-183 1888.9312 1888.9265 -2 0 HPYFYAPELLYYANK
T71 508-523 1880.9254 1880.9216 -2 0 RPCFSALTPDETYVPK
T66 469-482 1724.8388 1724.8351 -2 0 MPCTEDYLSLILNR
T61-T62 437-451 1639.9433 1639.9383 -3 0 KVPQVSTPTLVEVSR
T50 347-359 1567.7488 1567.7433 -4 0 DAFLGSFLYEYSR
T59 421-433 1479.8008 1479.7960 -3 0 LGEYGFQNALIVR
T51-T52 360-371 1439.8178 1439.8123 -4 1 RHPEYAVSVLLR
T12 89-100 1419.7009 1419.6942 -5 0 SLHTLFGDELCK
T79 569-580 1399.6932 1399.6931 0 0 TVMENFVAFVDK
T57 402-412 1305.7236 1305.7167 -5 0 HLVDEPQNLIK
T52 361-371 1283.7186 1283.7112 -6 0 HPEYAVSVLLR
T7-T8 35-44 1249.6273 1249.6217 -4 1 FKDLGEEHFK
T10 66-75 1163.6400 1163.6312 -8 0 LVNELTEFAK
T22 161-167 927.4996 927.4940 -6 0 YLYEIAR
T35 236-241 689.3793 689.3735 -8 0 AWSVAR
T27 205-209 649.3320 649.3343 4 0 IETMR
T13 101-105 545.3421 545.3411 -2 0 VASLR
§Table 3.3. MALDI-TOF/TOF-MS peptide mapping of the digested neoglycoconjugate with a hapten:protein ratio of 4.3:1, after
recalibration (glycated peptides bolted).
Peptide Location Observed Calculated Accuracy Missed Sequence
# mlz mlz ppm cleavage
T46-T48 310-340 3511.6660 3511.6725 2 2 SHClAEVEKDAIPENLPPLTADFAEDKDVCK
T47-T48 319-340 2458.1830 2458.1812 -I I DAIPENLPPLTADFAEDKDVCK
T41-T42 267-285 2247.9370 2247.9433 3 2 ECCHGDLLECADDRADLAK
T78-T79 569-587 2220.0518 2219.9775 -33 I TVMENFVAFVDKCCAADDK
T61-T62 437-451 2153.1589 2153.1700 5 0 K*VPQVSTPTLVEVSR
T23-T24 168-183 2045.0183 2045.0285 5 0 RHPYFYAPELLYYANK
T16-T17 123-138 1901.9634 1901.8703 -49 2 NECFLSHKDDSPDLPK
T71 508-523 1880.9166 1880.9216 3 0 RPCFSALTPDETYVPK
T66 469-482 1724.8308 1724.8351 2 0 MPCTEDYLSLILNR
T61-T62 437-451 1639.9406 1639.9383 -1 1 KVPQVSTPTLVEVSR
T50 347-359 1567.7419 1567.7433 I 0 DAFLGSFLYEYSR
T34-T35 233-241 1514.8213 1514.8213 0 1 ALK*AWSVAR
T59 421-433 1479.7950 1479.7960 I 0 LGEYGFQNALIVR
T51-T52 360-371 1439.8118 1439.8123 0 I RHPEYAVSVLLR
T12 89-100 1419.7020 1419.6942 -5 0 SLHTLFGDELCK
T63-T64 452-459 1330.7236 1330.7213 -2 1 SLGK*VGTR
T57 402-412 1305.7179 1305.7167 -I 0 HLVDEPQNLIK
T52 361-371 1283.7125 1283.7112 -I 0 HPEYAVSVLLR
T7-T8 35-44 1249.6237 1249.6217 -2 I FKDLGEEHFK
T10 66-75 1163.6368 1163.6312 -5 0 LVNELTEFAK
T22 161-167 927.4966 927.4940 -3 0 YLYEIAR
T35 236-241 689.3730 689.3735 1 0 AWSVAR
T20-T21 156-160 665.3673 665.3775 15 I KFWGK
TI3 101-105 545.3493 545.3411 -15 0 VASLR
3.3.2. High-energy CID-MS/MS analyses of the digested BSA and hapten-BSA
conjugates
To locate the glycation sites, the peptides were analysed by CID-TOF/TOF-MS/MS
(Figure 3.3, Tables B.I-B.3). Analysis of the CID-MS/MS spectrum of the glycated
peptide with m/z 1330.72 (Figure 3.3(a), Table B.I) allowed us to confirm the sequence
of the peptide and to localize the carbohydrate hapten adduct, which resulted to the
attachment to the Lys 455 residue. The sequencing of this glycated peptide was
determined by identifying the y-series of product-ions: SLGK*YGTR (452-459). We also
noted that the carbohydrate hapten undergoes fragmentation during the MS/MS analysis.
Accordingly, simple sugar fragments were also present in the CID spectra (Figure 3.4), as
evidenced by the presence of the following product-ions: [C6HsN03t at m/z 142.07,
[C11H1s ost at m/z 244.13, [C11HZO 06t at m/z 262.14 and [CIsH30N07t at m/z
336.21. In addition, we noted the presence of the precursor molecular ion that lost a
hapten fragment and the following product-ions: [M + H - C 11 HI9 06t at m/z 1069.59
and [M + H - C 11 H I9 0 6 - NH3t at m/z 1052.57, where C 11 HI9 0 6 represents a product
ion fragment of the carbohydrate-spacer moiety. The CID spectrum also contained
fragments of the a-, b- and z-series formed from product ions representing portions of the
carbohydrate-spacer peptide fragments: [34 - C 1sHzsN07Y· at m/z 537.33, [b4 -
C"H I9N06t at m/z 638.39, [bs - CIIHI9N06t at m/z 737.46 and [Z6 - C I,H I9N06t at m/z
852.48. The secondary cleavage of the carbohydrate-spacer portion gives rise to
additional specific product ions of the carbohydrate-spacer moiety. These also include the
presence of a radical product ion, as for example the [a4 - ClsH28N07Y· ion at 111/:::
537.33, which allowed the unambiguous characterization of the carbohydrate moiety as
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the radical product ion obtained contains the carbohydrate unit, in addition to a small part
of the spacer. Therefore, the presence of this radical product ion and the other product
ions with carbohydrate-spacer moieties represents diagnostic product ion signatures.
Their formation is the result of the labile fragmentation of the carbohydrate-spacer
portion due to its instability to the high-energy collision, which takes place during the
MS/MS experiment. The presence of these product ions complicates the em spectra,
making them more difficult to interpret. It is important to note that the peptide
sequencing described here was performed without the help of a data sequencing based
program.
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[M+H-CllH,,NO.J'
(b)
Figure 3.3. MALDI-CID-TOF/TOF-MS/MS spectra of the glycated peptide (a)
SLGK*VGTR at m/z 1330.72, (b) ALK*AWSVAR at m/z 1514.82 and (c)
K*VPQVSTPTLVEVSR at m/z 2153.16.
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Figure 3.3. (continued)
Figure 3.4. Hapten fragments observed during the the MALDI-TOF/TOF-MS/MS
analysis of the SLGK*YGTR hapten-peptide conjugate at m/z 1330.72.
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The MALDl-TOF/TOF-MS/MS analysis of the conjugated peptide with m/z
1514.82 (Figure 3.3(b), Table B.2) allowed us to confirm the glycated peptide sequence
and the localization of the glycosyl hapten attached to the Lys 235 residue. The direct
sequencing of this glycated peptide assigned as ALK*AWSVAR (233-241) was afforded
by using the diagnostic CID y-product ions. Note that the CID-MS/MS analysis of the
ALK*AWSVAR (233-241) gave a series of similar (not identical) product ions derived
from glycated peptide SLGK*VGTR. These were identified as follows: [CIIHISNOst at
m/z 244.13, [CIIH20N06t at m/z 262.14 and [ClsH30N07t at m/z 336.20, as well as the
product-ion formed by the loss of glycosyl hapten (as above) fragments: [M + H -
C3H602t at m/z 1440.10, [M + H - CIIHI9N06t at m/z 1253.69, [M + H - CIIH20N07Y'
at m/z 1236.64 and [M + H - CI9H36N20St at m/z 1092.56. Finally, the presence of
product ions of the a-, b- and c- series, produced by the specific cleavage of the
conjugated carbohydrate-spacer peptide is, respectively, assigned as: [b3 - CIIHI9N06t at
m/z 565.37, [as - CI9H3SN20St at m/z 636.42, [a6 - CI9H3SN20Sr' at m/z 723.44, [as -
CIIHI9N06t at m/z 794.49, [bs - CIIHI9N06t at m/z 822.51 and [C7 - CJ7H3INOst at m/z
909.53. This result allowed us to confinn the sequence of this glycated peptide.
The localisation and the sequence of the glycated peptide at m/z 2153.16 were
determined by MALDl-TOF/TOF-MS/MS analysis (Figure 3.3(c), Table B.3). It was
found that the sequence of this peptide is K*VPQVSTPTLVEVSR (437-451) and that the
carbohydrate hapten was conjugated to the Lys 437 residue. As for the previously
analyzed glycated peptides, we observed product-ions for the glycosyl hapten (as
discussed above): [CIIHISNOst at m/z 244.13, [ClsH26N304t at m/z 312.21,
[ClsH30N07t at /11/Z 336.21, [C19H30N307t at m/z 412.25, [C23H33N309t· at m/z 495.26
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and [C23H3S 3010( at m/z 513.31. The fragmentation of the glycosyl hapten (as
described above) induces also the fonnation of product ions assigned as follows: [M + H
- C2HsOt at m/z 2108.15 and [M + H - CIIHI9N06t at m/z 1892.01. In addition, we also
noted the expected,series of a- and b-product ions [b2 - C23H37 30lOt at m/z 226.15, [a3
- C23H3S 30lOt at m/z 297.21, [b3 - C23H3S 30lOt at m/z 325.23, [b4 - C23 H36 301OY· at
m/z 452.31, [b2 - CIIHI9N06t at m/z 480.33, [b4 - CIIHI9N06t at m/z 705.45 and [bs -
C7HI3N03t at m/z 804.51.
In the MALDI-TOF/TOF mass spectra of the BSA neoglycoconjugate with
carbohydrate:protein ratio of 4.3: I, we have identified the major glycated peptides at m/z
1330.72, 1514.82 and 2153.16, which had higher intensities than the other non-identified
peptides (Figure 3.2). We can, thus, conclude that the synthetic hapten-BSA
neoglycoconjugate (4.3:1) carries the carbohydrate hapten preferentially at Lys 455 (RA
= 72.6%), Lys 235 (RA = 46.1 %) and Lys437 (RA = 35.9%). It allowed us to conclude
that the conjugate consisted of a mixture of isofonns derivatized mainly on the Lys 455,
Lys 437 and Lys 235 residues.
For the digested hapten-BSA neoglycoconjugate with a carbohydrate:BSA ratio
of 6.6: I, we found that the glycated peptides at the Lys 455, Lys 235 and Lys 437
positions had relative abundances of 29.5%, 13.0% and 11.0%, respectively. Similarly,
the digest from the neoglycoconjugate with a carbohydrate:protein ratio of 13.2: I
afforded the same series of glycated peptides as the latter one, with the respective relative
abundances of 12.7%,10.45% and 4.5%.
The purpose of this work was to identify all the glycated peptides present in the
digests of the studied neoglycoconjugates (having chemically attached 4 to 13 haptens).
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Unfortunately, we were only able to characterize three of these. It is also interesting to
note that the carbohydrate conjugation was observed in two different domains of the
BSA, that is, in the domain IIA through the binding to the Lys 235 and in the domain
111A via the conjugation to the Lys 437 and Lys 455.[22J We presume that these Lys
residues belong to those that are considered to be sterically more accessible on the
surface of the tridimensional structure. During the MALDI-TOF-MS analysis of the
digested BSA neoglycoconjugate, we observed some protonated molecules that did not
correspond to any peptides of the digested native BSA. Unfortunatly, we were not able to
identify them.
Before summarizing conclusions of this investigation, we may pose a simple and
obvious question: Since, according to the MALDI-TOF-MS analysis, the BSA-
neoglycoconjugate with the highest degree of substitution should carry, on average, -13
sugars, and each Lys residue carries, presumably, only one sugar-spacer moiety, what
happened to the other glycated peptides? It is tempting to answer this question with the
following rationale. We propose that the carbohydrate-spacer attached to lysine residues
alters their chemical properties, and makes the resulting glycated peptides less reactive
during the enzymatic digestion. This may affect the outcome of the digestion. We,
therefore, propose that in order to produce a larger number of diagnostically significant
glycated peptides, the digestion of BSA-neoglycoconjugate should be carried out with a
different peptidase. In addition, these "missing", non-identified protonated molecules
may also correspond to glycated peptides which are unstable in the gas-phase, and
therefore, disintegrate during MALDI-TOF-MS analysis by either in-source or post-
source decay. To prevent such phenomena from occurring in our subsequent studies,
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electrospray ionization low-energy tandem mass spectrometry is the analytical tool of
choice.
Finally, we would like to mention a unique phenomenon that occurred while
analyzing this series of neoglycoconjugates by MALDl-TOFrrOF-MS. The single stage
MALDI-TOFrrOF-MS of the hapten-BSA conjugate measured with the collision
induced dissociation gas in the collision cell turned on resulted in cleavage of some of the
covalently attached carbohydrate haptens, with the concomitant release of the BSA ions.
This manifested itself by alteration of the average hapten:BSA ratios from 4.3: I, 6.6: I
and 13.2:1, originally found for the glycoconjugates, to 2.0:1, 4.5:1 and 11.5:1,
respectively. This appears to indicate that the carbohydrate-carrier bonds are slightly
labile to high collision energy, which they are subjected to during the studies by mass
spectrometry (Figure 3.5, Table 3.4).
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Figure 3.5. MALDI-TOF/TOF-MS analysis of the neoglycoconjugates with hapten:BSA
ratios 4: I (a), 7: 1 (b) and 13: 1 (c), with the collision cell switched on.
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Table 3.4. Molecular masses of BSA and hapten-BSA conjugates and their calculated
hapten:BSA ratios, obtained during the MALDI-TOF-MS analysis of the glycoconjugate
with the collision cell switched on.
IM+2H)H IM+H( 12M+H( RecalculatedHanten:BSA ratio
I BSAstandard 33,115 66,310 133,019
I Hapten:BSA4.3:1 33,610 67,435 134,987 2.0:1
I Hapten:BSA6.6:1 34,098 68,879 137,795 4.5:1
I Hapten:BSA 13.2:1 36,147 72,273 144,317 11.5:1
3.4. Conclusion
The detailed structural analysis of neoglycoconjugates is an important step in the
verification of the structure of conjugate vaccines before their use as pharmaceuticals. In
this study, a carbohydrate hapten-BSA neoglycoconjugate was analyzed by MALDI-
TOFrrOF-MS in order to confirm its structure and to localize the sites of the chemical
attachment of the carbohydrate hapten onto the carrier protein. To explore the feasibility
of the aforementioned task, three different carbohydrate-BSA neoglycoconjugates were
subjected to MALDI-TOFrrOF-MS analysis of their proteolytic digests. The conjugates,
which were obtained with different carbohydrate:protein ratios (4.3: 1,6.6: I and 13.2: I),
were prepared by chemical attachment of the carbohydrate hapten to the protein carrier.
We know that the product-ion scans, measured with the MALDI-TOFrrOF-MS/MS,
occur with high energy collision induced dissociation. This high-energy precursor
fragmentation promotes the primary fragmentations of the carbohydrate hapten, resulting
in CID spectra containing amino acid sequences attached to fragments of the
carbohydrate. As a result, we were able to identify the conjugation sites involving three
different lysine residues (Lys 235, Lys 437 and Lys 455). Although only few points of
glycation could be detennined, the identification of the y-series ions was very useful for
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the peptide sequencing. The series of a- and b-ions confinned the sequence of the
conjugated peptides, although they included product ions containing fragments of the
hapten. Identification of the other unknown peptides will be carried out in the future,
using a MALDI-QqTOF-MSIMS hybrid instrument using lower-energy collision
dissociation and FTICResonance mass spectrometer with an electron capture dissociation
cell, which is known to produce mainly c- and z-ions during the MS/MS analysis of
peptides.
Appendix B. Supplementary data
Supplementary data are associated with this chapter (page 243)
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Abstract
We present herein an efficient mass spectrometric method for the localization of
the glycation sites of a model neoglycoconjugate vaccine model formed by a construct of
the tetrasaccharide side chain of the Bacillus anthracis exosporium and the protein carrier
BSA. The glycoconjugate was digested with both trypsin and GluC V8 endoproteinase
and the digests were then analyzed by MALDl-TOF/TOF-CID-MS/MS and nano-LC-
ESl-QqTOF-CID-MS/MS. The sequences of the unknown peptides analyzed by MALDl-
TOF/TOF-CID-MS/MS, following digestion with the GluC V8 endoproteinase, allowed
us to recognize five glycopeptides whose glycation occupancies were respectively on Lys
235, Lys 420 and Lys 498. Similarly, the same analysis was performed on the tryptic
digests which permitted us to recognize the glycation sites on Lys 100 and Lys 374. In
addition, we have also used LC-ESl-QqTOF-CID-MS/MS analysis for the identification
of the tryptic digests. However, this analysis identified a higher number of glycopeptides
than would be expected from a glycoconjugate composed from carbohydrate:protein ratio
of 5.4: I, which would have resulted in a glycation occupancy of 18 specific sites. This
discrepancy was due to the large number of glycoforms formed during the synthetic
carbohydrate-spacer-carrier protein conjugation. Likewise, the LC-ESl-QqTOF-MS/MS
analysis of the GluC V8 digest also identified 17 different glycation sites on the
glycoconjugate.
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4.1. Introduction
Bacterial LPS have been extensively studied during the last decades and their use
in the synthesis of neoglycoconjugates as potential vaccines has been successful.[J-7]
Different parameters have been found to influence the efficacy of a glycoconjugate
vaccine, such as the saccharide size, the average number of saccharide chains per
conjugate molecule, nature of the carrier and the distance between the saccharide and the
protein in the fonned glycoconjugate.[8-11] Until very recently, the covalent attachment
sites of the antigenic saccharide to the protein in all neoglycoconjugates have not been
detennined. We were the first to attempt such an investigation and have unraveled some
of the glycation sites in the neoglycoconjugates made from BSA and the O-PS of Vibrio
cholerae 01, serotype Ogawa.112]
Bacillus anlhracis belongs to the Gram-positive bacterium family and is the cause
of anthrax, a disease which can affect animals and humans.113] The bacterium is known to
fonn endosporesl1 4] which, when mature, are resistant to extreme conditions
(temperature, radiations, desiccation, physical damage, harsh chemicals).115] The
currently increased interest in anthrax is because some fonns of Bacillus anlhracis, which
are the etiologic agent of anthrax,[J6] including anthrax spores, can be used as biological
weapons. Several studies have been carried out on the B. anthracis to understand its
pathogenesis, to discover new markers for its detection, and also to identify constituents
of its spore that could be targeted for its inactivation. [I7J
Different synthetic vaccines have been developed against anthrax; these were
based on the immunogenic conjugates of the capsular polypeptide (polyglutamic acid) of
B. anlhracis, and an anthrax capsular vaccine has also been developed.[J81
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A better understanding of the anthrax spores composition and structure was
necessary before a vaccine for anthrax could be developed based on a component of
anthrax spores. Recently, the structure of the tetrasaccharide side chain of the collagen
like region of the major glycoprotein of the B. anthracis exosporium was determined by
Daubenspeck et al.[19] The upstream terminal of the tetrasaccharide was found to be the
new sugar anthrose [4,6-dideoxy-4-(3-hydroxy-3-methylbutyramido)-2-0-methyl-D-
glucopyranose]. By comparing the NMR data of the synthetic tetrasaccharide[ZOj with
those recorded[I9j for the tetrasaccharide isolated from B. anthracis exosporium, it was
confinned that the structure of the tetrasaccharide was correct as proposed.[19j Kovac et
al. synthesized the tetrasaccharide side chain and linked it to the BSA using squaric acid
chemistry.[ZI] They obtained synthetic glycoconjugates having an average
carbohydrate:protein ratio of 3.5: I and 5.7: 1. Figure 4.1 displays a schematic
representation of the general structure of the carbohydrate-protein neoglycoconjugate
construct from the tetrasaccharide side chain of the B. anthracis exosporium.
The analysis and the localization of the glycation sites in carbohydrate-protein
neoglycoconjugates is a very important feature for the quality control of the conjugate
vaccines. Different strategies have been developed for the analysis of glycoproteins,
mainly based on the MS analysis of enzymatic digests.[Zz.z3] In a previous study on the
detennination of the glycation sites in synthetic neoglycoconjugate models of Vibrio
cholerae 0 I, we have shown that out of the 59 possible glycation sites on BSA, we were
only able to characterize three, when using a standard method which consists on the
trypsin digestion of the glycoconjugate. We hypothesized that this protease may not be
the best to release all the glycated peptides from this neoglycoconjugate. IJZ] In addition,
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the unraveling of some of the glycation sites in this neoglycoconjugate was achieved by
performing MSIMS analysis using a MALDI-TOFfTOF-MSIMS instrument, with the
benefit of high-energy collision dissociation.[ 12l
In this manuscript, we present an efficient method for the localization of the
glycation sites of the neoglycoconjugate formed by the antigenic tetrasaccharide side
chain of the B. an/hracis exosporium covalently attached to the BSA protein carrier. The
digestion of the glycoconjugate was carried out with two different proteases: trypsin and
Glue V8. The analysis and sequencing of the resulting peptides and glycopeptides was
performed separately by using two different state-of-the art mass spectrometric and
tandem mass spectrometric methods.
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Figure 4.1. Schematic representation of the general structure of carbohydrate-protein
constructs from oligosaccharide fragments of the antigenic tetrasaccharide side chain of
the B. an/hracis exosporium.
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4.2. Materials and Methods
4.2.1. Preparation of the hapten-BSA neoglycoconjugate
The synthesis of the hapten-BSA glycoconjugate has been described previously.(21)
Thus, the synthetic 2-0-methyl-~-D-glucopyranosyl-(1-+3)-a-L-rhamnopyranosyl-
(1-+3)-a-L-rhamnopyranosyl-( 1-+2)-a-L-rhamnopyranoside corresponding to the B.
anthracis exosporium tetrasaccharide was first treated with ethylenediamine to give the
2-aminoethyl amide, which, when treated with diethyl squarate afforded the squaric acid
monoethylester. The conjugation of this hapten to BSA (Sigma Aldrich, Saint Louis, MO,
USA) in 0.5 M borate buffer (pH 9.0) was followed by SELDI-TOF-MS,[27] which made
it possible to obtain the hapten-BSA glycoconjugates, with a predetennined
carbohydrate:protein ratio of -5: I. Isolation of the neoglycoconjugate was carried out by
ultrafiltration with the aid ofa centrifugal device with a cut-off 30,000 Da.
4.2.2. Digestion
The digestions of the hapten-BSA glycoconjugates were carried out with trypsin and
Glu-C V8 protease (Sigma Aldrich, Saint Louis, MO, USA). Thus, I00 ~lg of the
glycoconjugate (1.4 nmol) was dissolved in a mixture of 0.1 % RapiGest SF Surfactant (I
J..lg, Waters, USA) in 50 mM of H4HC03 (I 00 ~lL) at a pH of 8.0 and reduced by
treatment with 2 J..lL of 10 mM dithiothreitol (Sigma Aldrich, Saint Louis, MO, USA) for
30 min at room temperature, followed by alkylation with 2 ~lL of a 50 mM iodoacetamide
(Sigma Aldrich, Saint Louis, MO, USA) for 1 h at room temperature. A portion (50 ~lg,
0.7 nmol) of the BSA glycoconjugate was digested with trypsin using a 20 nglmL of
trypsin dissolved in H4HC03 (50 mM, 1 mL) at a tlypsin:glycoprotein ratio of 1:25
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(w/w) and incubated at 37°C overnight with shaking. The other 50 ~lg (0.7 nmol) of the
BSA glycoconjugate was digested using the GluC Y8 endoprotease protease:glycoprotein
ratio of 1:25 (w/w) and incubated at 37°C overnight with shaking. The sample was then
dried under vacuum and the residue was dissolved in 20 ~lL of 1% acetic acid (Sigma-
Aldrich, Oakville, 0 , Canada). An aliquot of each sample (10 ~L) was then cleaned up
using ZipTip C 18 (Millipore, Bedford, MA, USA) before mass spectral analysis.
4.2.3. MALDI-TOF/TOF-MS and MALDI-TOF/TOF-CID-MS/MS analyses
Mass spectral analyses were c3lTied out with an ABI 4800 equipped with TOF-TOF
optics (Applied Biosystems Foster City, CA) and a 200-Hz frequency Nd:YAG laser. a-
Cyano-4-hydroxycinnamic acid was used as matrix for the analysis of BSA, hapten-BSA
conjugate, and the peptides resulting from their digestions, with an average of 5000 to
8000 laser shots per spectra. Basically, I ~L of a 20 mglmL solution of a-CHCA
(dissolved in acetone, 0.1% TFA) was spotted on the MALDI plate and dried at room
temperature. Then, an aliquot of I ~L of sample was spotted on the top of the dried
matrix and let to dry before the MALDI-MS experiments.
The tandem mass spectrometric analyses were achieved with air as collision gas and at
collision energy of I kY, which correspond to the difference between the accelerating
potential (8 kY) and the floating cell (7 ky).[28] The internal calibration of the digested
glycoproteins and BSA was perfonned in the range m/z 600-3200 using known peptides
of the BSA.
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4.2.4. LC-ESI-QqTOF-CID-MS/MS analysis
The peptides were separated on a DIONEX UltiMate3000 Nano LC System
(Germering, Germany). 250 finol of digested glycoprotein was dissolved in 0.1 % TFA
and loaded onto a precolumn (300 ~lIn i.d. x 5 mm, CI8 PepMaplOO, 5 llm (LC Packing,
Sunnyvale, CA)) in order to desalt and concentrate the sample. After their elution from
the precolumn, the mixture of peptides and glycopeptides was separated on a nanoflow
analytical column (75 llm i.d. x 15 em. C 18 PepMap 100, 3 llm, 100 A, (LC Packing,
Sunnyvale, CA)) at a flow rate of 180 nL/min. The mobile phase eluents used were
composed of 0.1% FA/O.OI% TFA/2% ACN (A) and 0.08% FA/0.008% TFA/98% ACN
(B). The elution started with 0% B for 10 min, followed by a gradient of 0-60% B in 55
min and 60-90% B in 3 min and was kept at 90% B for 3 min. The tandem mass
spectrometry analysis of the eluted peptides and glycopeptides was accomplished using
an Applied Biosystems API-QSTAR XL quadrupole orthogonal time-of-flight (QqTOF)-
MS/MS hybrid tandem mass spectrometer (Applied Biosystems Intemational-MDS
Sciex, Foster City, CA, USA) equipped with a nano-electrospray source (Protana XYZ
manipulator) which produces the electrospray through a PicoTip needle (10 ~lm i.d., New
Objectives, Woburn, MA, USA) carrying a voltage of 2400 V. The TOF analyzer was
calibrated using a renin solution (1 pmol/llL) and looking for the ions at mlz 586.9815
and mlz 879.9723. The collision energies used during the CID-MS/MS analyses were
determined automatically using the Information Dependent Acquisition method
integrated in the Analyst software.
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4.3. Results
As mentioned earlier, the aim of this study was to localize the glycation sites for
the neoglycoconjugate composed of the antigenic tetrasaccharide side chain of B.
anthracis exosporium covalently attached to the BSA protein carrier. In this rationale, we
have aimed to search the best method for the characterization of the glycopeptides. The
digestion of the glycoconjugate was carried out with two different proteases: trypsin and
GluC V8. Although trypsin cleaves proteins at the carboxyl side of lysine and/or arginine
residues,124 1 GluC V8 endoproteinase is known to cleave protein at the C-tenninus of the
peptide bond on glutamic acid residues at pH 4.0 and on both glutamic acid and aspartic
acid residues atpH 7.8.[25,26]
Furthennore, for the analysis and sequencing of the resulting peptides and
glycopeptides, we have used two different mass spectrometric approaches. The first one
involved the analysis of the digests by MALDI-TOF/TOF-MS (MALDI-MS), followed
by peptides sequencing using high collision energy MALDI-TOF/TOF-CID-MS/MS
(MALDI-MS/MS). The second approach involved analysis of the mixed peptide digests
by LC-ESI-QqTOF-MS (LC-MS) followed by peptide sequencing using low-energy
collision induced dissociation CID-QqTOF-MS/MS analysis (LC-MS/MS). A scheme,
indicating the general strategy used in this manuscript, is illustrated in Figure 4,2,
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4.3.1. MALDI-TOF/TOF-MS analysis of BSA and the hapten-BSA
neoglycoconjugates
Single stage MALDI-MS analysis of the BSA and the carbohydrate hapten-BSA
glycoconjugate allowed us to determine the average number of carbohydrate-spacer
covalently attached to the BSA by comparison of the observed molecular weight of the
glycoconjugate to the molecular weight of the native BSA. Thus, the MALDl-MS
analysis of the hapten-BSA glycoconjugate allowed us to identify the protonated
molecule [M + Ht at m/z 71,448.36 and [M + 2H]2+ at m/z 35,730.08 (Figure C.I,
Appendix C). Using these data, we calculated the molecular mass of the hapten-BSA
glycoconjugate which was 71,448.36 Da. Finally, the comparison of the observed
molecular weight of the BSA and the hapten-BSA enabled us to calculate the average
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hapten:BSA ratio on the glycoconjugate. As previously reported, during the conjugation,
the squaric acid is covalently linked to the E-amino groups of the lysine residues in BSA
with loss of a molecule of ethano1.[9.12,2Ij Knowing the molecular mass of the
tetrasaccharide-squaric acid unit (950.43 Oa), we were able to calculate the carbohydrate
hapten:BSA ratio which was found to be 5.4: I. The glycated peptides on the BSA were
identified by the peptide mass fingerprinting (PMF) experiment on the hapten-BSA
conjugate digests and the CID-MS/MS analysis of the glycated peptides permitted to
localize the glycation site.
4.3.2. PMF analysis using MALDI-TOFrrOF-MS of the digested hapten-BSA
neoglycoconjugates
MALDI-MS analysis was carried out on the digested (trypsin and GluC V8)
hapten-BSA glycoconjugate and the obtained MS spectra were submitted to the Mascot
library to identify by PMF the peptides matching to the BSA (Figure 4.3, Tables C.l and
C.2). The following parameters were applied for the Mascot library searching:
carbamidomethyl (C) as fixed modifications, oxidation (M) as variable modifications, a
peptide mass tolerance of ± 0.2 Oa and a maximum of missed cleavages of I.
The Mascot report of the tryptic and GluC V8 digests spectra gave a match to two
isoforms of the Serum Albumin protein fTom the Bos taurus species, namely, the serum
albumin precursor (giI1351907) and the serum albumin (giI74267962). Thus, we
postulated that the obtained peptides that were not a match with the peptides of the BSA
had to be conjugated with the hapten carbohydrate. Consequently, these were analyzed by
MALOI-MS/MS analy is.
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The MALDI-MS analysis of the carbohydrate hapten-BSA glycoconjugate digested
with trypsin (Figure 4.3(a) Table C.I) afforded only three identifiable glycopeptides
having different glycation sites. These diagnostic three glycopeptides corresponded to the
BSA peptides whose molecular masses have increased by 950.43 Da. These were verified
identified to have the following structures: ALK*AWSVAR at m/z 1951.0130,
VTK*CCTESLVNR at m/z 2416.1372, and QNCDQFEK*LGEYGFQNALlVR at m/z
3478.6429 (glycation represented with an asterisk on the lysine residue).
The MALDI-MS analysis of the glycopeptides resulting from the digestion of the
hapten-BSA glycoconjugate with the GluC V8 protease (Figure 4.3(b), Table C.2)
afforded only three glycopeptides: LCK*VASLRE at m/z 2025.0186,
YAVSVLLRLAK*E at m/z 2311.2476 and YAVSVLLRLAK*EYE at m/z 2603.3484.
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Figure 4.3. MALDI-MS analysis of the glycoconjugate trypsin digests (a) and Glue V8
endoproteinase digests (b).
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4.3.3. High-energy MALDI-TOFrrOF-CID-MS/MS analyses of the glycated
peptides
4.3.3.1. MALDI-TOF/TOF-CID-MS/MS analyses of the glycated peptides obtained
after trypsin digestion of the carbohydrate hapten-BSA glycoconjugate
The sequence and the detennination of the glycation sites of the trypsin obtained
glycopeptides were verified by MS/MS. Thus, we carefully analyzed by MALDI-MS/MS
analyses the precursor protonated molecules [M + Hf extracted from the following
glycoeptides: ALK*AWSVAR (Lys 235) at m/z 1951.0130 presented in Figure 4.4(a)
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(Table C.3); VTK*CCTESLVNR at m/z 2416.1372 (Figure C.2), and
QNCDQFEK*LGEYGFQ ALIVR at mlz 3478.6429 (Figure C.3).
During the high-energy CID-MS/MS analysis of the glycopeptide ALK*AWSVAR
(Lys 235) at mlz 1951.0130 (Figure 4.4(a), Table C.3), we observed a series of
consecutive losses due to the various carbohydrate tragments. These losses seem to
indicate that during CID-MS/MS analyses, the glycosyl hapten fragmented in the gas-
phase, and this permits the unambiguous identification and localization of the glycation
site.
For the nomenclature of the glycopeptide product ions obtained, we have used the
nomenclature established by Domon and Costello for the carbohydrate portion as: A, 8,
C, X, Y and 2.[29] Thus, we observed that the product ions generated by the
tragmentation of the carbohydrate hapten, occurred by the successive losses of either
each of the monosaccharide 8 1 (-259 Da), disaccharide 82 (-405 Da), trisaccharide 8) (-
551 Da) and/or the tetrasaccharide 8 4 (-697 Da), leading respectively to the formation of
the following product ions: Y/ at mlz 1691.8829, Y/ at mlz 1545.8376, Y2+ at mlz
1399.7768 and Y 1+ at mlz 1253.7010. We also noted that the difference between Y/ and
Y/, Y2+ and Y 1+, Y 1+ and Yo+ was 146 Da (Figure 4.4(a), Table C.3), and this difference
corresponded to one a-L-rhamnopyranosyl unit. We therefore propose in this study, that
the loss of a glycosyl unit represents a diagnostic tragmentation signature of the synthetic
tetrasaccharide. This attribute is extremely important for the confinnation of the identity
of the carbohydrate hapten covalently linked to the peptide. In addition, different
carbohydrate product ions resulting trom other tragmentation routes were also identified
and these were assigned as follows: CI7H26N)O/ at mlz 336.1242,8 1+ at I11lz 260.0739,
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[8 1 - H20t at m/z 242.0709, 2,sAI+ at m/z 230.0719, C II H I6 302+ at m/z 222.0670 and
[C 1 - CSHIIN02t at m/z 159.0486 [Figure 4.4(b)].
To minimize the ambiguity in the nomenclature used in this study, we have also
used the pre-existing peptides nomenclature involving the detection of the X-, y-, z-ions
and the a-, b-, c-ions for the individual peptide sequence.130.31] In consequence, it is
important to point out that the b- and y-product ions obtained, included the glycated
lysine, which have lost part of the carbohydrate moiety. However, it is important to
comprehend that these peptides still preserved the portion of the attached spacer-squaric
acid chain. The following are examples of the b- and y-product ions that we have
observed: [b3 - 84t at m/z 565.2661, [b4 - 84t at m/z 636.2715 and [Y7 - 82t at m/z
1361.7265.
High-energy CID-MS/MS analysis of the [M + Ht precursor ion at m/z
2416.1372 of the glycopeptide VTK*CCTESLV R (Figure C.2) permitted us to pinpoint
the tetrasaccharide hapten location site on the Lys 498. This CID-MS/MS analysis also
showed the consecutive losses of the glycosyl portions of the tetrasaccharide 8 1-4 to
afford the product ions YO.3 and other oligosaccharide product ions (Figure C.2). Finally,
able to identify the following glycopeptide
QNCDQFEK*LGEYGFQNALlVR at m/z 3478.6429 (Figure C.3) which contained the
carbohydrate hapten covalently attached to the Lys 420 residue.
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Figure 4.4, (a) MALDI-TOF/TOF-MS/MS spectra of the glycated peptide
ALK*AWSVAR (Lys 235) at m/z 1951.0130. (b) Different product ions involving the
fragmentation of the carbohydrate hapten observed during the MALDI-TOF/TOF-
MS/MS analysis of the glycated peptide ALK*AWSVAR (Lys 235) at m/z 1951.0130.
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Figure 4.4. (continued)
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It is noteworthy to mention that during high-energy CID-MS/MS analysis, we
were subjected to a small amount oftlawed results. For instance, what we presumed to be
a glycated peptide at m/z 2338.1690, turned unfortunately to be the intact entire non-
glycated peptide [MPCTEOYLSLlLNR). This discrepancy was most probably due to the
fact that during MALOI-MS/MS analysis the instrument ion gate selection of the
precursor ion allowed also the transmission of non-glycated peptide which was isobaric
to the selected precursor ion at m/z 2338.1690. In addition, it has been recently reported
that the ions produced in the MALOI source cause post source decay[32.33] and that they
may overlap the product ions resulting from the high energy CID analysis of selected
precursor ions, which complicate the product ions spectra.[34j
4.3.3.1. MALDI-TOF/TOF-CID-MS/MS analyses of the glycated peptides obtained
after the GluC Y8 digestion of the carbohydrate hapten-BSA conjugate
The digested GluC V8 endoproteinase glycated peptides were detected by single
stage MALDl-MS analysis and analyzed by MALDl-MS/MS. The high energy CID-
MS/MS analysis of the precursor ion [M + Ht at m/z 2025.0186 extracted from the
glycopeptide LCK*YASLRE (Figure CA, Table CA) allowed us to confirm the sequence
of the uncleaved complete glycopeptide ion and to localize the carbohydrate occupancy
on the covalently attached Lys 100 residue. Once more, the protonated glycopeptide
precursor ion at I11/Z 2025.0186 afforded various peptide product ions containing the full
intact peptide portion, which have lost sections of the intact tetrasaccharide hapten. These
product ions were identified as: Y/ at m/z 1765.8924, Y/ at I11/Z 1619.8220, Y 1+ at I11/Z
1473.7520, Yo+ at m/z 1327.7091 and [Yo - NH3t at m/z 1310.6732. The sequence
coverage of this glycopeptide is shown in Figure CA and, as expected, some peptide
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product ions were observed with the loss of the entire tetrasaccharide B4 moiety: [b6 -
B4t at m/z 911.4274, [bs - B4t at m/z 824.3805, [b4 - B4t at m/z 753.3832, [b3 - B4t at
m/z 654.3269 and [K*V - B4t at m/z 452.3055. In addition, the following diagnostic
carbohydrate-spacer product ions created by fragmentation of the tetrasaccharide spacer
portion were also detected: C17H26N30/ at m/z 336.2023, BI+ at m/z 260.1505, [B I -
H20t at m/z 242.1599, CIIHI6N30/ at m/z 222.1627, [C I - C3H70t at m/z 202.1093 and
C7H130/ at m/z 129.1094.
High-energy CID-MS/MS analysis of the precursor ions [M + Ht at m/z
2311.2476 extracted from the glycopeptide YAVSVLLRLAK*E (Figure C.5) and at m/z
2603.3484 for the glycopeptide YAVSVLLRLAK*EYE (Figure C.6) revealed that the
second glycation site was located on the Lys 374 residue. To sum up, the MALDI-
MS/MS analysis of the digested carbohydrate-BSA conjugate with trypsin and GluC V8
allowed us to identifY five glycation sites: Lys 100, Lys 235, Lys 374, Lys 420 and Lys
498. It is crucial to point out that the detection of carbohydrate product ions are
diagnostic of the presence of the glycated peptide and also allow the validation of the
location of the covalently attached carbohydrate hapten sites. However, we report herein
a conjecture on the uses of the single stage MALDl-MS analyses, which in our opinion
can be attributed to the low sensitivity of detection of the mixture of glycopeptides and
accordingly, some glycated peptides were not detected at all. Moreover, the low
precursor ion selectivity of the linear TOF in addition to the overlapping of the PSD and
CID fragment ions can complicate the interpretation of the product ions spectrum.[34.3S]
143
4.3.4. LC-ESI-QqTOF-CID-MS/MS analysis of the digested carbohydrate-BSA
conjugate
In this rationale, as mentioned before, we have used a second approach, involving
the analysis of the peptide digests by LC-ESI-QqTOF-MS (LC-MS) followed by peptide
sequencing using low-energy CID-QqTOF-MS/MS analysis (LC-MS/MS). Therefore, as
expected, we have found that the Nano-LC-MSIMS analysis of the digested hapten-BSA
glycoconjugate presented several advantages compared to the MALDI-MS/MS analysis
of the glycated peptides. This was mainly due to the chromatographic separation, which
restrains the ionization suppression effect present during the MALDI-MS analysisY6.37]
Moreover, the CID-MS/MS analyses are low-energy compared with the high-energy
CID-MS/MS experiments realized with the TOFITOF-MS/MS instrument. For that
reason, it is well known that the low energy CID-MS/MS analysis of peptides generally
produces unique peptide diagnostic b- and y-ions, which provide a bidirectional analysis
oftheirsequenceYS]
Nano LC-MS/MS was carried out on both tryptic digests and GluC V8 digests.
The results were submitted to the Mascot library, in order to identify the peptides
belonging to the BSA. For the analysis of the tryptic digests, the Mascot library gave a
match with two serum albumin protein isofonns from the B. taurus species:
albumin precursor (giI1351907) and serum albumin (giI74267962).
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4.3.4.1. ClD-MS/MS of the tryptic digested peptides
The detected peptides that matched to these two isoforms are reported in Table
C.5. The detected peptides covered 58% of the sequence of the serum albumin protein
from B. taurus (giI74267962) and in addition, four unique peptides for this protein were
identified [Table C.5]: TVME FVAFVGK at m/z 671.3491 (+2), ETYGDMADCCAK
at m/z 710.7665 (+2), LGEYGFQNELlVR at m/z 769.4033 (+2) and
MPCAEDYLSLlLNR at m/z 847.9184 (+2) (charge of the molecular ions are shown in
brackets). Similarly, the digested peptides covered 57% of the sequence of the serum
albumin precursor from B. taurus (giI1351907) and one unique peptide was detected for
this protein: ETYGDMADCCEKQEPER at m/z 706.6155 (+3). All the peptides that
could not be assigned to any protein hits were presumed to be potentially glycated
peptides.
The low-energy CID-MS/MS analysis of the extracted precursor ions extracted
from the tetrasaccharide-spacer-BSA neoglycoconjugate and the corresponding
glycopeptide product ions identified are shown in Table 4.1. Thus, the LC-MS/MS
analyses permitted us to identify the carbohydrate occupancy located on the following 18
lysine glycation sites indicated as follows: Lys 140, Lys 155, Lys 156, Lys 204, Lys 211,
Lys 228, Lys 235, Lys 304, Lys 374, Lys 401, Lys 420, Lys 437, Lys 455, Lys 463, Lys
495, Lys 498, Lys 547 and Lys 559. In this justification and for simplification purposes,
we only decided to describe two examples of the low energy CID-MS/MS analyses of the
glycopeptides. Figures 4.5(a) (Table C.6) and 4.5(b) exhibit two examples of the gas-
phase fragmentation resulting from the CID-MS/MS analysis of the glycopeptides, as
well as the product ion calculated masses and the mass deviation of the experimental
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masses compared to the calculated ones. In these low-energy cm analyses, we observed
the consecutive losses of carbohydrate moieties from the intact glycopeptides, as well as
the formation of peptide product ions characterized by either the loss of the entire
carbohydrate moiety and/or the partially fragmented carbohydrate product ions.
Table 4.1. Tryptic glycopeptides identified of the bovine serum albumin protein by LC-
ESI-QqTOF-MS/MS analysis of the hapten-BSA glycoconjugate.
Precursor ion Deviation Missed
m/z Mr(expt) Mr(calc) Peptide
(charge) Da cleavage
729.8826(+2) 1457.7506 1457.7389 0.0117 1 Kl-IK*P(Lys559)
733.3170(+2) 1464.6194 1464.7698 -0.1504 1 QIK*K (Lys 547)
770.3757(+2) 1538.7369 1538.7338 0.0031 1 ADEK*K (Lys 155)
807.9138(+2) 1613.8129 1613.7964 0.0165 0 K*FWGK (Lys 156)
828.0811 (+3) 2481.2213 2481.2005 0.0208 2 LKECCDK*PLLEK (L s 304)
832.7770(+3) 2495.3092 2495.3146 -0.0054 1 LK*HLYDEPQNLlK (L s 401)
863.7965 (+3) 2588.3677 2588.3572 0.0105 0 K*YPQYSTPTLYEYSR (Lys 437)
883.9655(+2) 1765.9164 1765.9085 0.0079 1 SLGK*YGTR (Lys 455)
922.0941 (+3) 2763.2605 2763.2493 0.0112 1 LAK*EYEATLEECCAK (Lys374)
969.5086(+2) 1937.0026 1936.9868 0.0158 1 TPYSEK*YTK (Lys 495)
970.4900(+2) 1938.9738 1938.9772 -0.0034 1 EK*YLTSSAR (Lys 211)
976.0173 (+2) 1950.0201 1950.0085 0.0116 1 ALK*AWSYAR (Lys 235)
990.4710(+3) 2968.3911 2968.3886 0.0025 2 LK*PDPNTLCDEFKADEK (Lys140)
1073.0144(+2) 2144.0143 2144.0082 0.0061 1 CASIQK*FGER (Lys 228)
1058.4652(+2) 2114.9159 2114.9123 0.0036 1 CCTK*PESER (L s 463)
1208.5857(+2) 2415.1569 2415.1284 0.0285 1 YTK*CCTESLVNR (Lys 498)
1160.2172(+3) 3477.6297 3477.6385 -0.0088 1 QNCDQFEK*LGEYGFQNALlYR(Lys420)
1169.5978 (+2) 2337.1810 2337.1583 0.0227 1 GACLLPK*IETMR (Lys 204)
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Figure 4.5. LC-QqTOF-MS/MS spectra of the tryptic glycated peptides (a)
CCTK*PESER (Lys 463) at m/z 1058.4652 (+2), (b) CASIQK*FGER (Lys 228) at m/z
1073.0144 (+2) and GluC Y8 digests (c) K*YTKCCTE (Lys 495) at /11/z 987.9658 (+2)
and (d) K*QEPERNE (Lys 117) at /11/z 989.9697 (+2).
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For example, the CID-MS/MS analysis of the glycopeptide precursor ion [M +
2H]2+ at m/z 1058.4652 extracted from CCTK*PESER (Lys 463) [Figure 4.5(a), Table
C.6], showed the following peptide ions which were assigned to be formed by the loss of
the carbohydrate moieties: Y/ at m/z 1856.7628, Yz+ at m/z 1710.7332, Y I+ at m/z
1564.6742 and Yo+ at m/z 1418.6321. As observed for the previous MALDI-MSIMS
analysis of the glycated peptides, we were able to identify peptide fragment ions
presenting a loss of a carbohydrate moiety: [Y7 - 8 4t at m/z 1098.5412, [Y6 - 8 4t at m/z
997.4909 and [b4 - 8 4t at m/z 802.3246. The following carbohydrate-spacer product ions
were also detected: 8z+ at m/z 406.2071, C17H26N30/ at m/z 336.1908, C I+ at /11/z
276.1435,8 1+ at m/z 260.1460, [8 1 - Hzt at m/z 258.1313, [8 1 - HzOt at /11/z 242.1354,
CIIHI6N30Z+ at m/z 222.1184, [C I - C3H70t at /11/z 202.1034, Z.4AI+ at /11/z 184.0928 and
[8 1- CsHgOzt at /11/z 160.0945. The further continuous coverage of the peptide sequence
was also achieved by detection of the y- and b-ions.
The CID-MS/MS analysis of the precursor ion [M + 2H]z+ at /11/z 1073.0144
isolated from the glycopeptide CASIQK*FGER (Lys 228), followed the same gas-phase
fragmentation pathway as that of [M + 2Hf+ precursor ion at /11/z 1058.4652, described
above [Figure 4.5(b)].
4.3.4.2. CID-MS/MS of the GluC V8 digested peptides
The Mascot library search of the product ions obtained by the LC-MS/MS
analysis of the GluC V8 digests matches the same serum albumin proteins as observed
for the analysis of the tryptic digests, namely, serum albumin precursor (B. taurus)
(giI1351907) and serum albumin (B. taurus) (giI74267962). The sequences of the
peptides which matched these two isofonns are displayed in Table C.7. The protein
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sequence coverage was 42% for the serum albumin (giI74267962) and 45% for the
precursor serum albumin (giI1351907), which is consistently lower than the coverage
obtained with the tryptic digests.
The following 17 glycation sites were also confirmed by low-energy CID-MS/MS
analyses: Lys 65, Lys 75, Lys 88, Lys 100, Lys 117, Lys 151, Lys 183, Lys 197, Lys 256,
Lys 266, Lys 304, Lys 309, Lys 336, Lys 374, Lys 420, Lys 455 and Lys 495 (Table 4.2).
To illustrate the fragmentation of the glycated peptides identified after the digetion of the
hapten-BSA glycoconjugate with the endoproteinase GluC Y8, two CID- spectra [Figures
4.5(c) and 4.5(d)] are displayed.
The LC-MS/MS analysis of the glycopeptide precursor ion [M + 2H]2+ at /11/Z
987.9658 isolated from the glycopeptide K*YTKCCTE (Lys 495) [Figure 4.5(c), Table
C.8], enabled us to observe peptide product ions obtained by loss of the fragmented
tetrasaccharide portion of the glycoconjugate: Y2+ at /11/z 1569.6618, Y I+ at /11/z
1423.6440, Yo+ at /11/z 1277.5919 and [Yo - H20t at /11/z 1259.5710. The y- and b-
product ions permitted us to cover the peptide sequence, and the detection of fragmented
peptide formed by loss of the tetrasaccharide moiety helped for the localization of the
carbohydrate hapten on the Lys 495 residue: [b7 - B4t at m/z 1130.5222, [bs - B4t at m/z
869.4469, [b4 - B4t at m/z 709.4351, [b3 - B4t at m/z 581.3174 and [b2 - B4t at m/z
480.2884. In addition, we noted that the same fragmented carbohydrate product ions,
which were detected for the trypsin digestion of the hapten-BSA glycoconjugate, were
also present: B2+ at /11/z 406.2084, C17H26N30/ at /11/z 336.1892, C I+ at /11/z 276.1415, B I+
at m/z 260.1460, [B I - H2t at m/z 258.1307, [B I - H20t at m/z 242.1380, [C I - C3H70t
at /11/z 202.1047, 2.4A I+at /11/z 184.0948 and [B I - CSHg02t at m/z 160.0912.
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Table 4.2. Glycopeptides identified in the bovine serum albumin protein by LC-ESl-
QqTOF-MS/MS analysis of the hapten-BSA glycoconjugate digested with the
endoproteinase GluC V8.
Precursor ion Deviation Missed
mlz Mr(expt) Mr(calc) Peptide
(charj~e) Da cleavage
698.3598(+2) 1394.7051 1394.6803 0.0248 0 K*LGE (Lys 420)
790.3774(+2) 1578.7403 1578.7288 0.0115 I K*QEPE (Lys 117)
844.3721 (+2) 1686.7297 1686.7499 -0.0202 I EFK*ADE (Lys 151)
894.4637(+2) 1786.9128 1786.8976 0.0152 0 HVK*LVNE (Lys 65)
862.9539(+2) 1723.8933 1723.8754 0.01179 1 YTK*LYTD (L s 256)
897.4200(+2) 1792.8255 1792.8176 0.0079 0 K*SHClAE (Lys 309)
902.4801 (+2) 1802.9456 1802.9289 0.0167 0 LTKYHK*E (L s 266)
2883.4439 2883.4093 0.0346 0 YSRSLGK*YGTRCCTKPE (Lys962.1552(+2) 455)
987.9658(+2) 1973.9171 1973.8949 0.0222 0 K*YTKCCTE (Lys 495)
989.9697(+2) 1977.9248 1977.9154 0.0094 2 K*QEPERNE (Lys 117)
992.4568 (+2) 1982.8989 1982.884 0.0149 I CCDK*PLLE (Lys 304)
995.4702(+2) 1988.9258 1988.8912 0.0346 I FAK*TCYADE (Lys 75)
1013.0142 2024.0138 2024.0123 0.0015 0 LCK*yASLRE (Lys 100)(+2)
1048.5225 2095.0305 2094.9984 0.0321 1 K*SLHTLFGDE (Lys 88)(+2)
1097.0595 2192.1045 2192.0909 0.0136 0 DK*GACLLPKIE (Lys 197)(+2)
1124.5018 2246.9890 2246.9876 0.0014 I DK*DYCKNYQE(Lys 336)(+2)
1336.1446 2670.2746 2670.2728 0.0018 0 LLYYANK*YNGYFQE (Lys 183)(+2)
1156.132(+2) 2310.2495 2310.2345 0.0150 0 YAYSYLLRLAK*E (Lys 374)
The other example that we selected to discuss was the glycopeptide K*QEPERNE
(Lys 117) [Figure 4.5(d)]. The low-energy CID-MS/MS analysis of this glycopeptide
precursor ion [M + H]2+ at m/z 989.9697 extracted from K*QEPERNE (Lys 117) also
exhibited the expected y- and b- product ions, which cover the peptide sequence, the
carbohydrate product ions and also the diagnostic peptide product ions, which have lost
the tetrasaccharide B4 portion.
During the LC-MS/MS analysis of the digested hapten-BSA glycoconjugate with
both trypsin and GluC V8, we were able to identify more glycation sites than we did
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during the MALDI-TOF/TOF-MS/MS analysis of the digested glycoprotein. LC-MS/MS
analysis allowed us to confidently identify 30 glycation sites on the lysine residues with
total sequence coverage of92%, whereas only 5 glycation sites were identified during the
MALDI-MSIMS analysis of the digested glycoconjugate. The reason for this discrepancy
seems to lie entirely on the formation of various glycoforms, as a result of the protocol
for the carbohydrate conjugation which involves, intentionally, an insufficient amount of
glycation agent to affect a complete derivatization of the protein carrier. Moreover,
during the study we also observed identically located lysine residues in their derivatized
and underivatized fonn. For example, the Lys 183 was detected through the underivatized
doubly charged peptide ion LLYYANKYNGVFQE at m/z 861.4378 and also through its
derivatized fonn on the doubly charged peptide ion LLYYANK*YNGVFQE at m/z
1336.1446 obtained from the GluC V8 digestion of the neoglycoconjugate. These
observations support the fact that the sample is composed of a mixture of glycoforms.
The total glycation sites identified during the study are summarized on Figure
4.6(a). In addition, Figure 4.6(b) displays the 3D representation of the BSA obtained by
homology modeling using the Swiss-Pdb Viewer software, where the glycated lysine
residues are highlighted in red. IJ9.40J We can observe that most of the glycated Iysines are
located on the outer-surface region of the protein. Thus, we can presume that the
carbohydrate hapten functionalization and occupancy on the outer surface of the BSA
will depend entirely on its tertiary structure.
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(a)
1 MKWVTFISLL LLFSSAYSRG VFRRDTHKSE IAHRFKDLGE EHFKGLVLIA
51 FSQYLQQCPF DEHVK*LVNEL TEFAK*TCVAD ESHAGCEK*SL HTLFGDELCK*
101 VASLRETYGD MADCCAK*QEP ERNECFLSHK DDSPDLPKLK* PDPNTLCDEF
151 K*ADEK*K*FWGK YLYEIARRHP YFYAPELLYY ANK*YNGVFQE CCQAEDK*GAC
201 LLPK* IETMRE K*VLTSSARQR LRCASIQK* FG ERALK*AWSVA RLSQKFPKAE
251 FVEVTK*LVTD LTKVHK*ECCH GDLLECADDR ADLAKYICDN QDTISSKLKE
301 CCDK*PLLEK*S HCIAEVEKDA IPENLPPLTA DFAEDK'DVCK NYQEAKDAFL
351 GSFLYEYSRR HPEYAVSVLL EECCAKDDPH ACYSTVFDKL
401 K*HLVDEPQNL IKQNCDQFEK* IVRYTRK*VPQ VSTPTLVEVS
451 RSLGK*VGTRC CTK*PESERMP NRLCVLHEKT PVSEK*VTK*CC
501 TESLVNRRPC FSALTPDETY VPKAFDEKLF TFHADICTLP DTEKQIK*KQT
551 ALVELLKHK*P KATEEQLKTV MENFVAFVGK CCAADDKEAC FAVEGPKLVV
601 STQTALA
(b)
Figure 4.6. (a) BSA sequence where the glycation sites are indicated by an asterisk (red
= identified on tryptic digests, blue = identified on GluC V8 digests and red and
underlined = identified on both tryptic and GluC V8 digests) and (b) 3D structure of the
BSA. The glycated lysine residues are highlighted in red (Swiss-Pdb Viewer software).
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4.4. Conclusion
We have analyzed a B. anlhracis neoglycoconjugate vaccine using the MALDI-
and LC-ESI-tandem mass spectrometry. This was achieved to localize the carbohydrate
hapten occupancies and their conjugation sites in the synthetic tetrasaccharide B.
anlhracis exosporium-squaric acid linker-BSA protein carrier neoglycoconjugate. The
single stage MALDI-MS analysis of the glycoconjugate was carried out to verify the
average hapten:BSA ratio, which was found to be 5.4: I.
The high-energy MALDI-MS/MS analyses were carried out on tryptic and GluC
V8 digests of the conjugate, and these allowed us to sequence and reveal only five
glycation sites of the identified glycopeptides. It is noteworthy that the MALDI-MS/MS
experiments of the digested GluC V8 endoproteinase enabled the identification of three
new glycation sites, which were not revealed during the analysis of the tryptic digests.
The nano-LC-MS/MS analysis of the tryptic and GluC V8 digests pennitted us to identify
many more glycation sites (30 were identified). Fewer carbohydrate-spacer fragment ions
were observed during the LC-MS/MS analysis when compared with the MALDI-MS/MS
analyses, which are done with higher collision energies that enhance carbohydrate
cleavages.
The use of GluC V8 endoproteinase for the neoglycoconjugate digestion enabled
us to identify more carbohydrate hapten occupancies and their respective glycation sites
than when only trypsin was used. Thus, a total of 18 glycation sites were identified in the
CID-MS/MS analysis of the tryptic digest, and 12 novel glycation sites were observed
through the LC-MS/MS analysis of the GluC V8 digest of the carbohydrate-BSA
conjugate.
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Finally, the central conclusion drawn from this work, as expected, is the nano-LC-
MS/MS analysis of tryptic and GluC V8 digests is a reliable tool for the determination of
carbohydrate occupancy and glycation sites of carbohydrate-protein conjugate vaccines.
Furthermore, as presented in this manuscript, we were able to use successfully
ESI-CID-MS/MS to circumvent the complicated interpretation of the MALDI-CID
fragmentation of the product ions containing the carbohydrate moieties. We are
proposing to use in our future work, some more advanced activation methods for ESI-
MS/MS analysis, such as electron transfer dissociation and electron capture dissociation
measured by, FTICR-MS and Orbitrap mass spectrometers.[42-44] These non-ergodic
activation methods are known specifically to lead dissociation of the peptide backbone
solely and to leave intact any further chemical modifications in the selected precursor
ion.[41.42]
Appendix C. Supplementary data
Supplementwy data are associated with this chapter (page 248)
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CHAPTER 5: Revealing the glycation sites in neoglycoconjugate models formed by
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Ogawa with the BSA protein carrier using LC-ESI-QqTOF-MS/MS
This chapter has been submitted: Farid Jahouh,1 Rina Saksena,2 Pavol Kovac2 and Joseph
H. Banoub l ,3* 2011,1. Mass Spectrom., submitted.
I Department of Chemistry, Memorial University ofNewfoundland, Saint John's,
NL, AlB 3V6, Canada
2NIDDK, LBC, National Institutes of Health, Bethesda, MD 20892-0815, USA
3Department of Fisheries and Oceans Canada, Science Branch, Special Projects,
Saint John's, NL, Canada, AIC 5XI
161
Abstract
We present the determination of glycation sites in synthetic neoglycoconjugate
vaccine models fonned by conjugation of the antigenic monosaccharide hapten of Vibrio
cholerae 01 serotype Ogawa to BSA carrier using nano-LC-ESI-QqTOF-MS/MS.
MALDI-TOF/TOF-MS/MS analyses of tryptic digests of the glycoconjugates having
hapten:BSA ratio of 4.3:1,6.6:1 and 13.2:1 revealed only three glycation sites (lysine
residues: Lys 235, Lys 437 and Lys 455). Trypsin and GluC V8 proteases were used for
the digestion of the neoglycoconjugates. The digests gave complementary structural
information and maximized the number of recognized glycation sites. We report
identification of 20, 27 and 33 glycation sites using LC-ESI-QqTOF-MS/MS analysis of
a series of digested synthetic neoglycoconjugate vaccines with a hapten:BSA ratio of
respectively 4.3:1, 6.6:1 and 13.2:1. We also propose that all the glycated lysine residues
are located mainly on the outer surface of the protein.
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5.1 Introduction
Different studies have been carried out on the analysis of glycoproteins using
mass spectrometry.lI-3] Novel soft ionization techniques such as ESI and MALDI were
applied successfully for the determination of the glycation sites of N- and 0-
glycoproteins, as well as for the general carbohydrate structure detennination.13 .4]
Generally, two methods have been applied. The first involves cleavage of the glycans
from the protein by hydrolysis, followed by a purification step and MS analysis of the
intact carbohydrate portions.[s.6] It has been described that sometimes it is necessary to
derivatize the released polysaccharides in order to obtain a sufficiently high m/z signal of
the released carbohydrate.(7] The second approach is based on the digestion of the entire
glycoprotein with endoproteases, followed by MS and MS/MS analyses of the digests
obtained.l8•9] The main advantage of this method is that the product ions fonned
correspond to the glycopeptide fragments, which contain information about the exact
glycation site. IIO]
In our previous work, we have reported the determination of the glycation sites of
a series of neoglycoconjugate models by MALDI-TOF-MS/MS. These glycoconjugates
were composed of the spacer-equipped terminal monosaccharide antigen of the O-PS of
V. cho/erae 01, serotype Ogawa covalently attached to the protein carrier BSA.!II] We
were able to detemline the hapten:BSA ratios for the different synthetic glycoconjugate
preparations as being 4.3: I, 6.6: 1 and 13.2: 1. The obtained glycoconjugates were
digested with trypsin and the resulting digests were analyzed by MALDI-TOF/TOF-
MS/MS in order to detennine the conjugation sites between the spacer-equipped
carbohydrate and the carrier protein. In that study, we reported that three glycation sites
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on the Lys 235, Lys 437 and Lys 455 residues were identified on the three analyzed
glycoconjugates. We observed that digestion of our hapten-BSA glycoconjugates with
the protease trypsin may have not been best choice. Additionally, it is well known that
ion suppression effects can occur during the MALDI-TOF-MS experiments, resulting in a
curtailed MALDI-MS spectrum.[12.13] This suppression phenomenon may be explained by
competition in the ionization of the different analytes and by presence of contaminants in
the sample.
We recently reported the determination of the glycation sites in an experimental
Bacillus anthracis neoglycoconjugate vaccine by MALDI-TOF/TOF-CID-MS/MS and
LC-ESI-QqTOF-MS/MS.(I4] The MALDI-TOF-MS analysis of the intact glycoconjugate
pennitted us to detennine the hapten-to-BSA ratio which was found to be 5.4: I. The
carbohydrate-protein vaccine was digested using two different proteases: trypsin and the
GluC V8 endoproteinase. The different digests were subsequently subjected to MALDI-
TOF/TOF-MS/MS and LC-ESI-QqTOF-MSIMS analysis. The study revealed that the
LC-ESI-QqTOF-MS/MS analysis of the different digests allowed identification of 30
glycation sites, than 5 shown by the MALDI-TOF/TOF-MS/MS analysis of the same
digests. We thus concluded that the LC-ESI-QqTOF-MS/MS analysis of both tryptic and
GluC V8 digests was the more efficient method for the investigation of the glycation sites
in synthetic carbohydrate-protein glycoconjugates.
In the present work, we applied the same strategy to test V. cholerae 01 serotype
Ogawa neoglycoconjugate vaccines.[14] We digested the synthetic glycoconjugate V.
cholerae 01 serotype Ogawa, fonned by the conjugation of the monosaccharide antigen
to the BSA with different hapten-to-BSA ratios (4.3:1, 6.6:1 and 13.2:1), separately with
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trypsin and the GluC V8 endoproteinase. The different digests were then analyzed by LC-
ESI-QqTOF-MS/MS and the glycopeptides were sequenced manually in order to
determine the glycation sites.
5.2. Material and Methods
5.2.1. Preparation ofthe hapten-BSA neoglycoconjugate
The synthesis of the hapten-BSA glycoconjugates has been described
previously.(ISl The synthesis started with preparation of the methyl 6-hydroxyhexanoyl a-
glycoside of the upstream telminal moiety of the O-PS of V cholerae serogroup 01
serotype Ogawa antigen [4-(3-deoxY-L-glycero)-2-0-methyl-a-D-perosamine]. The
spacer-equipped sugar was then treated with 1,2-diaminoethane which converted the
methyl ester into the corresponding amino amide. Reaction of the latter with diethyl
squarate produced a squarate monoester. The hapten thus obtained was conjugated with
BSA (Sigma Aldrich, Saint Louis, MO, USA) as described. IIS] Isolation of the
neoglycoconjugates was carried out by ultrafiltration using centrifugal filters with a
molecular weight cut-off of 30,000 Da.
5.2.2. eoglycoconjugates digestion with different proteases
The digestions of the hapten-BSA glycoconjugates were carried out with trypsin
and Glu-C V8 protease (Sigma Aldrich, Saint Louis, MO, USA). Thus, I00 ~lg of the
glycoconjugate was dissolved in a mixture of 0.1 % RapiGest SF Surfactant (I ~lg,
Waters, USA) in 50 mM ofNH4HC03 (100 ~lL) at a pH of8.0 and reduced by treatment
with 2 ~lL of 10 mM of DTT (Sigma Aldrich, Saint Louis, MO, USA) for 30 min at room
temperature, followed by alkylation with 2 ~IL of a 50 mM iodoacetamide (Sigma
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Aldrich, Saint Louis, MO, USA) for I h at room temperature. A portion (50 ~lg) of the
BSA glycoconjugate was digested with trypsin using 20 nglmL of trypsin dissolved in
NH4HC03 (50 mM, I mL, pH 7.8) at a trypsin:glycoprotein ratio of 1:25 (w/w) and
incubated at 37°C overnight with shaking. The other 50 ~lg of the BSA glycoconjugate
was digested using the GluC V8 endoprotease dissolved in NH4HC03 (50 mM, I mL, pH
7.8) at a protease:glycoprotein ratio of 1:25 (w/w) and incubated at 37°C overnight with
shaking. The sample was then dried under vacuum and the residue was dissolved in 20
ilL of I% acetic acid (Sigma-Aldrich, Oakville, ON, Canada). An aliquot of each sample
(10 JlL) was then cleaned up using ZipTip CI8 (Millipore, Bedford, MA, USA) before
mass spectral analysis.
5.2.3. LC-ESI-QqTOF-CID-MS/MS analysis
The peptides were separated on a DlONEX UltiMate3000 Nano LC System
(Gennering, Gennany). 250 fino I of digested glycoprotein was dissolved in 0.1 % TFA
and loaded onto a precolumn (300 ~lm i.d. x 5 mm, CI8 PepMaplOO, 5 Jlm (LC Packing,
Sunnyvale, CA» in order to desalt and concentrate the sample. After their elution from
the precolumn, the mixture of peptides and glycopeptides was separated on a nanoflow
analytical column (75 Jlm i.d. xl5 cm, CI8 PepMap 100,3 Jlm, 100 A, (LC Packing,
Sunnyvale, CA» at a flow rate of 180 nL/min. The mobile phase eluents used were
composed of 0.1 % FA/O.O I% TFA/2% ACN (A) and 0.08% FA/0.008% TFA/98% ACN
(B). The elution started with 0% B for 10 min, followed by a gradient of 0-60% B in 55
min and 60-90% B in 3 min and was kept at 90% B for 3 min. The MS/MS analysis of
the eluted peptides and glycopeptides was accomplished using an Applied Biosystems
API-QSTAR XL quadrupole orthogonal time-of-flight (QqTOF)-MS/MS hybrid tandem
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mass spectrometer (Applied Biosystems Intemational-MDS Sciex, Foster City, CA,
USA) equipped with a nano-electrospray source (Protana XYZ manipulator) which
produces the e1ectrospray through a PicoTip needle (10 )..1m i.d., ew Objectives,
Woburn, MA, USA) carrying a voltage of 2400 V. The TOF analyzer was calibrated
using a renin solution (I pmol/)..lL) and looking for the ions at mlz 586.9815 and 111/;:.
879.9723. The collision energies used during the CID-MS/MS analyses were determined
automatically using the Information Dependent Acquisition method integrated in the
Analyst software.
5.3. Results
The intent of this study was to determine the glycation sites in synthetic hapten-
BSA glycoconjugates prepared by conjugation of the antigenic monosaccharide hapten of
V. cholerae 01 serotype Ogawa to BSA having hapten-to-BSA ratios of4.3:1, 6.6:1 and
13.2:1.
The nomenclature of carbohydrate fragments which will be used to identify the
various glycopeptides was described by Domon and Costello[3], whereas the
nomenclature used to identify the true peptide fragments is the one described by
Roepstorff el 01. [16] and recently modified by Johnson and coworkers.[I7]
The Nano-LC-ESI-QqTOF-MS/MS analysis of the tryptic digests of the
neoglycoconjugates with a hapten:BSA ratio of 4.3: I, 6.6: I and 13.2: I allowed the
identification of two serum albumin protein isofonns from the Bos taurus species on the
Mascot library: serum albumin precursor (giI1351907) with the following sequence
coverage: 61 % for the neoglycoconjugate possessing a hapten:BSA ratio of 4.3: 1,61 %
for the neoglycoconjugate with a hapten:BSA ratio of 6.6: I and 47 % for the
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neoglycoconjugate with a hapten:BSA ratio of 13.2: I. In addition, during the Mascot
library search, we also identified the serum albumin protein (giI74267962) for the
analysis of all the neoglycoconjugates.
The submission of the LC-ESI-QqTOF-MS/MS data of the GluC Y8 digests to
the Mascot library allowed identification of two serum albumin protein isoforms from the
B. taurus species: serum albumin precursor (giI1351907, sequence coverage of 55 % for
the neoglycoconjugate with a hapten:BSA ratio 4.3:1, 45 % for the neoglycoconjugate
with a hapten:BSA ratio 6.6: I and 40 % for the neoglycoconjugate with a hapten:BSA
ratio 13.2: I) and serum albumin (giI74267962).
We have identified molecular masses of glycopeptides produced from the
digested glycoconjugates by comparison of the m/z values of the obtained molecular ions
which did not correspond to BSA digests in the Mascot report, with the calculated /11/z
values of all the possible glycopeptides. Thus, the masses of the glycopeptides were
identified by the addition of either one or two carbohydrate-hapten residues (513.23 Da),
corresponding to the m/z values of the formed glycopeptides. In other words, the m/z
values of the peptides which matched to the theoretical mass of a "peptide +
carbohydrate-linker" were identified, extracted and subjected to low-energy CID-MS/MS
for sequencing to identify the glycation sites.
5.3.1. Mass spectrometry determination of the glycation sites on the
neoglycoconjugate possessing a hapten:BSA ratio of 4.3: 1
The previously described strategy allowed us to identify II glycation sites
through the sequencing of the following glycopeptides obtained from the tryptic digests
of the neoglycoconjugate with a hapten:BSA ratio of 4.3:1 (Table 5.1): SLGK*YGTR
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(Lys 455) at m/z 665.8810 (+2), EK*VLTSSAR (Lys 21 J) at m/z 752.4233 (+2),
ALK*AWSVAR (Lys 235) at m/z 757.9261 (+2), K*QTALVELLK (Lys 548) at m/z
828.4992 (+2), CCTK*PESER (Lys 463) at m/z 840.3949 (+2),
LK*PDPNTLCDEFKADEK (Lys 140) at m/z 845.0908 (+3), DTHK*SEIAHR (Lys 28)
at m/z 853.9445 (+2), GACLLPK*IETMR (Lys 204) at m/z 951.5091 (+2),
K*VPQVSTPTLVEVSR (Lys 437) at m/z 1077.1129 (+2), LAK*EYEATLEECCAK
(Lys 374) at m/z 1164.5375 (+2) and QNCDQFEK*LGEYGFQNALlVR (Lys 420) at
m/z 1014.8462 (+3).
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~Table 5.1. Tryptic glycopeptides identified during LC-ESI-QqTOF-MS/MS analysis of the hapten-BSA glycoconjugate with a
hapten:BSA ratio of4.3:1, 6.6:1 and 13.2:1.
Peptide Hapten:BSA ratio Hapten:BSA ratio Hapten:BSA ratioMissed 4.3:1 6.6:1 13.2:1
Sequence (asterisk = glycation Calculated Observed Deviation Observed Deviation Observed Deviation
mlz mlz mlz mlz
site) (charge) cleavage (charge) (Da) (charge) (Da) (charge) (Da)
SLGK*YGTR (Lys 455) 665.8643 1 665.8810 0.0168 665.8694 0.0052 665.8699 0.0057(+2) (+2) (+2) (+2)
EK*YLTSSAR (Lys 211) 752.3987 1 752.4233 0.0246 752.4114 0.0127 752.3971 -0.0016(+2) (+2) (+2) (+2)
ALK*AWSYAR (Lys 235) 757.9143 1 757.9261 0.0118 757.9189 0.0046 757.9248 0.0105(+2) (+2) (+2) (+2)
K*QTALYELLK (Lys 548) 828.4770 1 828.4992 0.0222 828.4872 0.0103 828.4857 0.0087(+2) (+2) (+2) (+2)
CCTK*PESER (Lys 463) 840.3662 I 840.3949 0.0287 840.3788 0.0126 840.3769 0.0107(+2) (+2) (+2) (+2)
LK*PDPNTLCDEFKADEK (Lys 845.0720 3 845.0908 0.0188 845.0839 0.0119 845.0911 0.0191140) (+3) (+3) (+3) (+3)
DTHK*SEIAHR (Lys 28) 853.9209 1 853.9445 0.0236 853.9366 0.0158(+2) (+2) (+2)
GACLLPK*IETMR (Lys 204) 951.4892 1 951.5091 0.0199 951.5014 0.0122 951.5006 0.0114(+2) (+2) (+2) (+2)
K*YPQYSTPTLYEYSR (Lys 437) 1077.0887 0 1077.1129 0.0243 1077.0985 0.0099 1077.0975 0.0089(+2) (+2) (+2) (+2)
LAK*EYEATLEECCAK (Lys 1164.5347 2 1164.5375 0.0028 1164.5613 0.0266 1164.5540 0.0193374) (+2) (+2) (+2) (+2)
QNCDQFEK*LGEYGFQNALIYR 1014.8220 1 1014.8462 0.0242 1014.8390 0.0170 1014.8534 0.0314(Lys420) (+3) (+3) (+3) (+3)
HKPK*ATEEQLK (Lys 561) 607.9779 3 607.9966 0.0187 608.0033 0.0254(+3) (+3) (+3)
;;
ei ei ei ei
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Figure 5.1 (a) displays the mass spectra obtained from the extraction of the
precursor ion at m/z 752.4233 (+2) corresponding to the glycated peptide EK*YLTSSAR
(Lys 211). The CID-MS/MS analysis of this glycated peptide reveals a signature of the
carbohydrate moiety through the following product ions: 8+ at m/z 262.1265, [8 - HzOt
at 111/z 244.1142, [8 - 2H zOt at I11/Z 226.1047, [Z.5A - 2HzOt at m/z 152.0663, [8-
C4H603t at m/z 142.0815 and (SA - CH40 3t at m/z 124.0708 (Figure 5.2). Moreover,
we were also able to detect the entire peptide attached to the linker portion: y+ at m/z
1242.6794 and Z+ at I11/Z 1224.6785. Also, we noticed that the product ion at m/z
336.1918 could be assigned to two different structures: [8 + C4HIOOt (CISH30NO/) and
C17Hz6N30/ (Figure 5.2). However, since the product at m/z 336.1918 was also detected
in our previous work on Bacillus anthracis neoglycoconjugate vaccine model, it was
assigned to the structure: [C17Hz6N304t corresponding to a linker portion attached to a
lysine residue (Figure 5.2).[14] Similarly, the product ion [CIIHI6N30Zt at I11/Z 222.1187
was produced from a different linker portion attached to a lysine residue. This latter
product ion was also detected in our previous work on the glycation sites detennination
of Bacillus anthracis neoglycoconjugate vaccine model.[I4]
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Figure 5.1. LC-ESI-QqTOF-MS/MS spectra of the tryptic glycopeptides (a)
EK*YLTSSAR (Lys 211) at mlz 752.4233 (+2), (b) GACLLPK*IETMR (Lys 204) at mlz
951.5091 (+2), (c) YTK*CCTESLVNR (Lys 498) at mlz 990.4813 (+2) and
FK*DLGEEHFK (Lys 36) at mlz 881.9491 (+2).
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Figure 5.2. Different product ions involving the fragmentation of the carbohydrate
hapten observed during the LC-ESI-QqTOF-MS/MS analysis of the tryptic glycopeptide
EK*YLTSSAR (Lys 211) at m/z 752.4233 (+2).
The CID-MS/MS analysis of this glycated peptide EK*YLTSSAR (Lys 211) at
m/z 752.4233 (+2), allowed us to observe the formation of product ions cOlTesponding to
glycopeptide fragments obtained by the loss of their carbohydrate portion: [Ys - Br at m/z
1113.6384, [bs - Br at /11/z 1068.5932, [b7 - Br at /11/z 997.5436, [b6 - Br at m/z
910.5089, [bs - Br at m/z 823.4703, [b s - B - H20r at /11/z 805.4549, [b4 - Br at /11/z
722.4164, [b4 - B - H20r at /11/z 704.4081, [b3 - Br at /11/z 609.3292, [b3 - B - H20r at
/11/z 591.3171, [b2 - Br at /11/z 510.2563 and [b2 - B - H20r at /11/z 492.2474. The series
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of detected y- and b-ions which represented the sequence of the glycopeptides are listed
in Table 5.2.
Table 5.2. LC-ESI-QqTOF-MS/MS analysis of the glycated peptide EK*YLTSSAR (Lys
21 I) at m/z 752.4233 (+2).
Molecular ion
Calculated Experimental Deviation
III/Z III/Z Da
y. 1242.6683 1242.6794 0.0111
z+ 1224.6577 1224.6785 0.0208
[Ys- sf 1113.6252 1113.6384 0.0132
[bs - sf 1068.5572 1068.5932 0.0360
[b)-Sf 997.5201 997.5436 0.0235
[b6-S]' 910.4880 910.5089 0.0209
[bs - Sf 823.4560 823.4703 0.0143
[bs-S-H1of 805.4454 805.4549 0.0095
Y) 733.4197 733.4340 0.0143
[b~ - sf 722.4083 722.4164 0.0081
[b4-S-H1of 704.3977 704.4081 0.0104
Y6 634.3513 634.3576 0.0063
[b)-sf 609.3243 609.3292 0.0049
[b)-S-H1Of 591.3137 591.3171 0.0034
Ys 521.2673 521.2713 0.0040
[bz - sf 510.2558 510.2563 0.0005
[b1-S-H1Or 492.2452 492.2474 0.0022
Y4 420.2196 420.2190 -0.0006
C 17HZ6 N.10 4+ 336.1918 336.1918 0.0000
Y) 333.1875 333.1851 -0.0024
S· 262.1290 262.1265 -0.0025
[S-HzOr 244.1179 244.1142 -0.0037
[S-2HzOr 226.1079 226.1047 -0.0032
C 11 HI6N)Ol' 222.1237 222.1187 -0.0050
YI 175.1184 175.1162 -0.0022
(SA-2H1Or 152.0706 152.0663 -0.0043
[S - C~H60)]' 142.0863 142.0815 -0.0048
[15A - CH4O,r 124.0757 124.0708 -0.0049
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Figure 5. I(b) shows another example CID-MS/MS analysis of a glycated peptide
detected during the analysis of the tryptic digests of the hapten-BSA neoglycoconjuagte
with a hapten:BSA ratio of 4.3: I: GACLLPK*IETMR (Lys 204) at m/z 95 I .5091 (+2).
The LC-ESI-QqTOF-MS/MS analysis of the GluC V8 digests of the
neoglycoconjugate with a hapten: BSA ratio of 4.3: I pennitted the localization of 10
glycation sites through the sequencing of the following glycopeptides (Table 5.3):
K*SHCIAE (Lys 309) at m/z 679.3320 (+2), LTKVHK*E (Lys 266) at m/z 684.3867
(+2), K*VTKCCTE (Lys 495) at m/z 769.8677 (+2), K*QEPERNE (Lys 117) at m/z
771.8852 (+2), K*SLHTLFGDE (Lys 88) at m/z 830.4932 (+2), DKGACLLPK*IE (Lys
204) at m/z 878.9783 (+2), AK*DAFLGSFLYE (Lys 346) at I11/Z 937.4871 (+2),
KK*FWGKYLYE (Lys 156) at I11/Z 937.9877 (+2), LLYYANK*YNGVFQE (Lys 183)
at I11/Z I I 18.071 1 (+2) and VSRSLGK*VGTRCCTKPE (Lys 455) at I11/Z 816.7646 (+3).
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Table 5.3. GluC V8 glycopeptide digests identified during LC-ESl-QqTOF-MS/MS analysis of the hapten-BSA
glycoconjugate with a hapten:BSA ratio of 4.3: 1,6.6: 1 and 13.2: 1.
Peptide Hapten:BSA ratio Hapten:BSA ratio Hapten:BSA ratioMissed 4.3:1 6.6:1 13.2:1
Sequence (asterisk = glycation Calculated Observed Deviation Observed Deviation Observed Deviation
m/z m/z m/z m/z
site) (char e) cleavage (chan!:e) (Da) (chan!:e) (Da) (chan!:e) (Da)
K*SHCIAE (Lys 309) 679.3189 0 679.3320 0.0131 679.3343 0.0154 679.3284 0.0095(+2) (+2) (+2) (+2)
LTKYHK*E (Lys 266) 684.3745 0 684.3867 0.0122 684.3851 0.0106 684.3795 0.0050(+2) (+2) (+2) (+2)
K*YTKCCTE (Lys 495) 769.8575 0 769.8677 0.0102 769.8720 0.0145 769.8668 0.0093(+2) (+2) (+2) (+2)
K*QEPERNE (Lys 117) 771.8678 2 771.8852 0.0174 771.8795 0.0117 771.8883 0.0205(+2) (+2) (+2) (+2)
K*SLHTLFGDE (Lys 88) 830.4093 I 830.4932 0.0839 830.4246 0.0153 830.4196 0.0103(+2) (+2) (+2) (+2)
DKGACLLPK*IE (Lys 204) 878.9556 0 878.9783 0.0227 878.9669 0.0113 878.9643 0.0087(+2) (+2) (+2) (+2)
AK*DAFLGSFLYE (Lys 346) 937.4590 1 937.4871 0.0281 937.4759 0.0169 937.4798 0.0208(+2) (+2) (+2) (+2)
KK*FWGKYLYE (Lys 156) 937.9824 0 937.9877 0.0053 937.9862 0.0038 937.9648 -0.0176(+2) (+2) (+2) (+2)
LLYYANK*YNGYFQE (Lys 1118.0465 0 1118.0711 0.0246 1118.0587 0.0122 1118.0511 0.0046183) (+2) (+2) (+2) (+2)
YSRSLGK*YGTRCCTKPE 816.7456 0 816.7646 0.0190 816.7583 0.0127 816.7483 0.0027(Lys455) (+3) (+3) (+3) (+3)
K*TPYSE (Lys 489) 587.2979 0 587.3103 0.0124 587.3041 0.0062(+2) (+2) (+2)
GPK*LYYSTQTALA (Lys 899.4959 0 899.5080 0.0121 899.5092 0.0133597) (+2) (+2) (+2)
LLKHKPK*ATEE (Lys 561) 903.9960 1 904.0190 0.0230 903.9916 -0.0044(+2) (+2) (+2)
K*QIKKQTALYE (Lys 544) 900.0117 0 900.0234 0.0117 900.0165 0.0048(+2) (+2) (+2)
YTK*LYTD (Lys 256) 644.8478 0 644.8498 0.0020(+2) (+2)
HYK*LYNE (Lys 65) 676.3588 0 676.3647 0.0059(+2) (+2)
YEK*DAIPE (Lys 318) 707.3534 2 707.3578 0.0044(+2) (+2)
CCDK*PLLE (Lys 304) 774.3520 774.3662 0.0142(+2) (+2)
LCK*YASLRE (Lys 100) 794.9162 0 794.9163 0.0001(+2) (+2)
YSRSLG K*YGTRCCTK*PE 987.8230 0 987.8313 0.0083(Lys455, Lys463) (+3) (+3)
00
KK*FWGK*YLYE (Lys 156, 1194.5985 0 1194.5626 -0.0359
1 160) (+2) (+2)
NFYAFYDK*CCAADDKE 1201.5300 3 1201.5350 0.0050(Lys580) (+2) (+2)
Figure 5.3 displays two examples of glycopeptides identified during the LC-ESI-
Qq-TOF-MS/MS analysis of the GluC Y8 digests of the neoglycoconjugate with a
hapten:BSA ratio of 4.3:1: (a) K*SHCIAE (Lys 309) at m/z 679.3320 (+2) and (b)
YSRSLGK*YGTRCCTKPE (Lys 455) at m/z 816.7646 (+3). The fragmentation pathway
followed by the glycopeptide YSRSLGK*YGTRCCTKPE (Lys 455) at m/z 816.7646
(+3) allowed us to identify the glycation site exclusively on the Lys 455 residue (Figure
5.3(b), Table 5.4). The precursor ion YSRSLGK*YGTRCCTKPE (Lys 455) at m/z
816.7646 (+3) produced characteristic carbohydrate moiety product ions, identified as
follows: B+ at m/z 262.1247, [B - H20t at m/z 244.1136, [B - 2H20t at m/z 226.1042,
[2.5A _ 2H20t at m/z 152.0669, [B - C4H603t at /11/z 142.0824 and [2.5A1 - CH40 3t at
/11/z 124.0714. Furthermore, we detected the following product ion y2+ at /11/z 1094.0368
corresponding to the entire glycopeptide minus the loss of the entire carbohydrate
portion. In addition we also observed product ions corresponding to distinct
fragmentation of the peptide backbone minus the loss of the entire carbohydrate moiety;
needless to say that these product ions included the previously derivatized lysine: [Y12 -
Bt at m/z 1644.7886, [YII - Bt at m/z 1587.7061, [bg - Bt at m/z 1136.5123, [bg - Bt at
/11/z 1079.5651, [b 16 - Bf+ at m/z 1020.5277, [b7 - Bt at /11/Z 980.5699, [b 15 - Bf+ at /11/z
972.0032, [b 14 - Bf+ at /11/z 907.9123 and [GK* - Bt at m/z 438.2288. Therefore, these
product ions allowed us to sequence and characterize this glycopeptide correctly.
Finally, the following product ions, characteristic of a spacer portion attached to a
lysine residue were also identified as follows: [C17H26N304t at m/z 336.1787 and
[CIIHI6N302t at /11/z 222.1242. The bidirectional sequence of the glycated peptide was
also detennined through the identification of the y- and b-ions (Figure 5.3(b), Table 5.4).
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Figure 5.3. LC-ESI-QqTOF-MS/MS spectra of the glycopeptides obtained during the
digestion of the neoglycoconjugates with the GluC Y8 endoproteinase: (a) K*SHCIAE
(Lys 309) at m/z 679.3320 (+2), (b) YSRSLGK*YGTRCCTKPE (Lys 455) at m/z
816.7646 (+3), (c) GPK*LYYSTQTALA (Lys 597) at m/z 899.5080 (+2) and
YSRSLGK*YGTRCCTK*PE (Lys 455, Lys 463) at m/z 987.8313 (+3).
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Table 5.4. LC-ES1-QqTOF-MS/MS analysis of the glycated peptide
YSRSLGK*YGTRCCTKPE (Lys 455) at m/z 816.7646 (+3).
Mo1ecularion
Calculated Experimental Deviation
m/z m/z Da
[YI2- Bf 1644.7821 1644.7886 -0.0065
[YII-Bf 1587.7607 1587.7061 0.0546
[b9 -Bf 1136.5422 1136.5123 0.0299
Y9 1108.4868 1108.4700 0.0168
y2+ 1094.0541 1094.0368 0.0172
[bs-Bf 1079.6208 1079.5651 0.0557
Ys 1051.4654 1051.4701 -0.0047
[b I6 - B]2+ 1020.5278 1020.5277 0.0001
[b7-Bf 980.5524 980.5699 -0.0175
[b ls - B]2+ 972.0014 972.0032 -0.0018
Y7 950.4177 950.4802 -0.0625
[b I4 -Bt 907.9539 907.9123 0.0416
Y6 794.3166 794.3096 0.0070
Ys 634.2859 634.2643 0.0216
b6' 600.3469 600.3362 0.0107
bs+ 543.3255 543.3074 0.0181
Y4 474.2553 474.2656 -0.0103
[GK*-Bf 438.2342 438.2288 0.0054
b/ 430.2414 430.2307 0.0107
Y, 373.2076 373.2188 -0.0112
b/ 343.2094 343.2028 0.0066
C I7 H26N,O/ 336.1918 336.1787 0.0131
B+ 262.1290 262.1247 0.0043
Y2 245.1126 245.1127 -0.0001
[B-H20r 244.1179 244.1136 0.0043
[B-2H20f 226.1079 226.1042 0.0037
C II H I6N,02+ 222.1237 222.1242 -0.0005
b2' 187.1083 187.1204 -0.0121
eSA- 2H2Oj' 152.0706 152.0669 0.0037
[YI-H2r 146.0453 146.0706 -0.0253
[B -C4H60,j" 142.0863 142.0824 0.0039
e
sAl - CH4O,r 124.0757 124.0714 0.0043
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To sum it up, a total of 20 glycation sites were identified during the LC-ESI-
QqTOF-MS/MS analysis of the tryptic and GluC V8 digests of the neoglycoconjugate
with a hapten:BSA ratio of 4.3: I [Figure 5.4(a)] for total sequence coverage of 89%.
Figure 5.5(a) displays the 3-D structure of the BSA represented using the Swiss-Pdb
Viewer software, where the glycated lysine residues are highlighted in red.[18.19j A quick
glance at Figure 5.5(a) allowed us to observe that the glycated lysine residues are located
on the outer surface of the protein.
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(a)
(b)
(c)
1 MKWVTFISLL LLFSSAYSRG VFRRDTHK* SE IAHRFKDLGE EHFKGLVLIA
51 FSQYLQQCPF DEHVKLVNEL TEFAKTCVAD ESHAGCEK'SL HTLFGDELCK
101 VASLRETYGD MADCCAK*QEP ERNECFLSHK DDSPDLPKLK* PDPNTLCDEF
151 KADEKK*FWGK YLYEIARRHP YFYAPELLYY ANK'YNGVFQE CCQAEDKGAC
201 LLPK*IETMRE K*VLTSSARQR LRCASIQKFG ERALK*AWSVA RLSQKFPKAE
251 FVEVTKLVTD LTKVHK*ECCH GDLLECADDR ADLAKYICDN QDTISSKLKE
301 CCDKPLLEK* S HCIAEVEKDA IPENLPPLTA DFAEDKDVCK NYQEAK*DAFL
351 GSFLYEYSRR HPEYAVSVLL RLAK*EYEATL EECCAKDDPH ACYSTVFDKL
401 KHLVDEPQNL IKQNCDQFEK* LGEYGFQNEL IVRYTRK*VPQ VSTPTLVEVS
451 RSLGK*VGTRC CTK*PESERMP CAEDYLSLIL NRLCVLHEKT PVSEK'VTKCC
501 TESLVNRRPC FSALTPDETY VPKAFDEKLF TFHADICTLP DTEKQIKK*QT
551 ALVELLKHKP KATEEQLKTV MENFVAFVGK CCAADDKEAC FAVEGPKLVV
601 STQTALA
1 MKWVTFISLL LLFSSAYSRG VFRRDTHK*SE IAHRFKDLGE EHFKGLVLIA
51 FSQYLQQCPF DEHVKLVNEL TEFAKTCVAD ESHAGCEK' SL HTLFGDELCK
101 VASLRETYGD MADCCAK'QEP ERNECFLSHK DDSPDLPKLK* PDPNTLCDEF
151 KADEKK' FWGK YLYEIARRHP YFYAPELLYY ANK* YNGVFQE CCQAEDKGAC
201 LLPK*IETMRE K*VLTSSARQR LRCASIQK*FG ERALK*AWSVA RLSQK*FPKAE
251 FVEVTKLVTD LTKVHi\ ECCH GDLLECADDR ADLAKYICDN QDTISSKLKE
301 CCDKPLLE!\ S HCIAEVEKDA IPENLPPLTA DFAEDKDVCK NYQEAK'DAFL
351 GSFLYEYSRR HPEYAVSVLL RLAK*EYEATL EECCAKDDPH ACYSTVFDKL
401 KHLVDEPQNL IKQNCDQFEK* LGEYGFQNEL IVRYTRK*VPQ VSTPTLVEVS
451 RSLGK*VGTRC CTK*PESERMP CAEDYLSLIL NRLCVLHEK'T PVSE" VTK*CC
501 TESLVNRRPC FSALTPDETY VPKAFDEKLF TFHADICTLP DTE . QIKK*QT
551 ALVELLKHKP K*ATEEQLKTV MENFVAFVGK CCAADDKEAC FAVEGP" LVV
601 STQTALA
1 MKWVTFISLL LLFSSAYSRG VFRRDTHKSE IAHRFK* DLGE EHFKGLVLIA
51 FSQYLQQCPF DEHV LVNEL TEFAKTCVAD ESHAGCE SL HTLFGDELC
101 VASLRETYGD MADCCA QEP ERNECFLSHK DDSPDLPKLK* PDPNTLCDEF
151 KADEK FWG YLYEIARRHP YFYAPELLYY AN YNGVFQE CCQAEDKGAC
201 LLPK*IETMRE K*VLTSSARQR LRCASIQK*FG ERALK*AWSVA RLSQK*FPKAE
251 FVEVT LVTD LTKVH . ECCH GDLLECADDR ADLAKYICDN QDTISSKLKE
301 CCDK* PLLE S HCIAEVE . DA IPENLPPLTA DFAEDKDVCK NYQEA" DAFL
351 GSFLYEYSRR HPEYAVSVLL RLAK* EYEATL EECCAKDDPH ACYSTVFDKL
401 KHLVDEPQNL IKQNCDQFEK* LGEYGFQNEL IVRYTRK*VPQ VSTPTLVEVS
451 RSLGK*VGTRC CTK*PESERMP CAEDYLSLIL NRLCVLHEK*T PVSE VTK*CC
501 TESLVNRRPC FSALTPDETY VPKAFDEKLF TFHADICTLP DTE QIKK*QT
551 ALVELLKHKP K* ATEEQLKTV MENFVAFVG CCAADDKEAC FAVEGP LVV
601 STQTALA
Figure S.4. Neoglycoconjugate model sequences where the glycation sites are indicated
by an asterisk (red = identified on tryptic digests, blue = identified on GluC V8 digests
and red and underlined = identified on both tryptic and GluC V8 digests) for the
neoglycoconjugates with a hpaten-BSA ratio of (a) 4.3: I. (b) 6.6: I and (c) 13.2: I.
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Figure 5.5. 3-D structure of the neoglycoconjugate model vaccines. The glycated
lysine residues are highlighted in red (Swiss-Pdb Viewer software) for the
neoglycoconjugates with a hapten:BSA ratio of (a) 4.3: I, (b) 6.6: 1 and (c) 13.2: I.
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5.3.2. Mass spectrometry determination of the glycation sites on the
neoglycoconjugate possessing a hapten:BSA ratio of6.6:1
The LC-ESI-QqTOF-MS/MS analysis of the tryptic digests of the
neoglycoconjugate with a hapten:BSA ratio of 6.6:1 allowed identification of 16
glycation sites on the following glycopeptides (Table 5.1): SLGK*VGTR (Lys 455) at
m/z 665.8694 (+2), EK*VLTSSAR (Lys 211) at m/z 752.4114 (+2), ALK*AWSVAR
(Lys 235) at m/z 757.9189 (+2), K*QTALVELLK (Lys 548) at m/z 828.4872 (+2),
CCTK*PESER (Lys 463) at m/z 840.3788 (+2), LK*PDPNTLCDEFKADEK (Lys 140)
at m/z 845.0839 (+3), DTHK*SEIAHR (Lys 28) at m/z 853.9366 (+2),
GACLLPK*IETMR (Lys 204) at m/z 951.5014 (+2), K*VPQVSTPTLVEVSR (Lys 437)
at m/z 1077.0985 (+2), LAK*EYEATLEECCAK (Lys 374) at m/z 1164.5613 (+2),
QNCDQFEK*LGEYGFQNALlVR (Lys 420) at m/z 1014.8390 (+3), HKPK*ATEEQLK
(Lys 561) at m/z 607.9966 (+3), LSQK*FPK (Lys 245) at m/z 680.8722 (+2),
LCVLHEK*TPVSEK (Lys 489) at m/z 685.0256 (+3), CAS1QK*FGER (Lys 228) at m/z
854.9284 (+2) and VTK*CCTESLVNR (Lys 498) at m/z 990.4813 (+2).
Figure 5.1 (c) displays an example of a glycopeptide which was identified during
the CID-MS/MS analysis of the tryptic digests of the neoglycoconjugate with a
hapten:BSA ratio of6.6:1: VTK*CCTESLVNR (Lys 498) at m/z 990.4813 (+2).
The neoglycoconjugate with a hapten:BSA ratio of 6.6: I was also digested with
the GluC V8 endoproteinase and subsequently analyzed by LC-ESI-QqTOF-MS/MS. The
following glycated peptides were discovered in this way after manual sequencing of the
peptides which were suspected to be glycated (same mass than a "peptide + carbohydrate
linker") and these are listed in Table 5.3: K*SHCIAE (Lys 309) at m/z 679.3343 (+2),
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LTKYHK*E (Lys 266) at m/z 684.3851 (+2), K*YTKCCTE (Lys 495) at m/z 769.8720
(+2), K*QEPER E (Lys 117) at m/z 771.8795 (+2), K*SLHTLFGDE (Lys 88) at m/z
830.4246 (+2), DKGACLLPK*IE (Lys 204) at m/z 878.9669 (+2), AK*DAFLGSFLYE
(Lys 346) at m/z 937.4759 (+2), KK*FWGKYLYE (Lys 156) at m/z 937.9862 (+2),
LLYYA K*YNGYFQE (Lys 183) at m/z 1118.0587 (+2), YSRSLGK*YGTRCCTKPE
(Lys 455) at m/z 816.7583 (+3), K*TPYSE (Lys 489) at m/z 587.3103 (+2),
GPK*LVYSTQTALA (Lys 597) at m/z 899.5080 (+2), LLKHKPK*ATEE (Lys 561) at
m/z 904.0190 (+2) and K*QIKKQTALYE (Lys 544) at m/z 900.0234 (+2).
The LC-ESI-QqTOF-MS/MS analysis of the GluC Y8 digests of the
neoglycoconugate with a hapten:BSA ratio of 6.6: I allowed us to identify 14 glycation
sites. Moreover, the combination of the identified glycation sites from both the tryptic
and GluC V8 digests gives us a total of 27 glycation sites with total sequence coverage of
90 % [Figure 5.4(b)].
In addition, Figure 5.5(b) which shows the 3-D structure of the BSA, with the
glycated lysine residues highlighted in red, enabled us to conclude that the glycated
lysine residues are located on the outer surface of the BSA.
5.3.3. Mass spectrometry determination of the glycation sites on the
neoglycoconjugate possessing a hapten:BSA ratio of 13.2:1
The neoglycoconjugate with a hapten:BSA ratio of 13.2: I was also digested with
trypsin and LC-ESI-Qq-TOF-MS/MS analysis of the digests allowed the identification of
the following glycopeptides (Table 5.1): SLGK*YGTR (Lys 455) at m/z 665.8699 (+2),
EK*YLTSSAR (Lys 211) at 111/: 752.3971 (+2), ALK*AWSYAR (Lys 235) at m/z
757.9248 (+2), K*QTALYELLK (Lys 548) at m/z 828.4857 (+2), CCTK*PESER (Lys
186
463) at m/z 840.3769 (+2), LK*PDPNTLCDEFKADEK (Lys 140) at m/z 845.0911 (+3),
GACLLPK*IETMR (Lys 204) at m/z 951.5006 (+2), K*VPQVSTPTLVEVSR (Lys 437)
at m/z 1077.0975 (+2), LAK*EYEATLEECCAK (Lys 374) at m/z 1164.5540 (+2),
QNCDQFEK*LGEYGFQ ALlVR (Lys 420) at m/z 1014.8534 (+3), HKPK*ATEEQLK
(Lys 561) at m/z 608.0033 (+3), LSQK*FPK (Lys 245) at m/z 680.8755 (+2),
LCVLHEK*TPVSEK (Lys 489) at m/z 685.0310 (+3), CASIQK*FGER (Lys 228) at m/z
854.9290 (+2), VTK*CCTESLVNR (Lys 498) at m/z 990.4930 (+2), FK*DLGEEHFK
(Lys 36) at m/z 881.9491 (+2) and LKECCDK*PLLEK (Lys 304) at m/z 1023.5348 (+2).
Total of 17 glycation sites were thus discovered. Figure 5.1 (d) an example of identified
glycopeptides, which were only discovered on the neoglycoconjugate with a hapten:BSA
ratio of 13.2:1: FK*DLGEEHFK (Lys 36) at m/z 881.9491 (+2).
Finally, the analysis by LC-ES1-QqTOF-MS/MS of the GluC V8 digests
permitted identification of the following gIycopeptides (Table 5.3): K*SHCIAE (Lys
309) at m/z 679.3284 (+2), LTKVHK*E (Lys 266) at m/z 684.3795 (+2), K*VTKCCTE
(Lys 495) at m/z 769.8668 (+2), K*QEPER E (Lys 117) at m/z 771.8883 (+2),
K*SLHTLFGDE (Lys 88) at m/z 830.4196 (+2), DKGACLLPK*IE (Lys 204) at m/z
878.9643 (+2), AK*DAFLGSFLYE (Lys 346) at m/z 937.4798 (+2), KK*FWGKYLYE
(Lys 156) at m/z 937.9648 (+2), LLYYANK*YNGVFQE (Lys 183) at m/z 1118.0511
(+2), VSRSLGK*VGTRCCTKPE (Lys 455) at m/z 816.7483 (+3), K*TPVSE (Lys 489)
at m/z 587.3041 (+2), GPK*LVVSTQTALA (Lys 597) at m/z 899.5092 (+2),
LLKHKPK*ATEE (Lys 561) at m/z 903.9916 (+2), K*QIKKQTALVE (Lys 544) at /11/Z
900.0165 (+2), VTK*LVTD (Lys 256) at /11/z 644.8498 (+2), HVK*LVNE (Lys 65) at
m/z 676.3647 (+2), VEK*DAIPE (Lys 318) at /11/z 707.3578 (+2), CCDK*PLLE (Lys
187
304) at m/z 774.3662 (+2), LCK*YASLRE (Lys 100) at m/z 794.9163 (+2) and
NFYAFYDK*CCAADDKE (Lys 580) at m/z 1201.5350 (+2). Moreover, we also
observed glycopeptides carrying two carbohydrate-linker residues:
YSRSLGK*YGTRCCTK*PE (Lys 455, Lys 463) at m/z 987.8313 (+3) and
KK*FWGK*YLYE (Lys 156, 160) at m/z 1194.5626 (+2).
It is important to note in this connection, that we have identified glycopeptides
which contained two diagnostic glycation sites. Unquestionably, two glycopeptides with
the following peptide sequence YSRSLGKYGTRCCTKPE were detected containing one
glycation site on Lys 455, YSRSLGK*YGTRCCTKPE (Lys 455) at m/z 816.7483 (+3),
and also with two glycation sites on each of Lys 455 and Lys 463 residues:
YSRSLGK*YGTRCCTK*PE (Lys 455, Lys 463) at m/z 987.8313 (+3). This observation
supports the fact that the sample was composed of glycofonns. Figure 5.3(d) displays the
spectra obtained during the CID-MS/MS analysis of the glycated peptide
YSRSLGK*YGTRCCTK*PE (Lys 455, Lys 463) at m/z 987.8313 (+3), while the
observed product ions and their mass-to-charge ratios are listed in Table 5.5.
In the product ion scan of the precursor ion at m/z 987.8313 (+3), we observed the
product ion y 2+ at m/z 1350.6416, which was fonned by loss of the carbohydrate moiety
from one of the glycated lysine residues. The product ion [Y - 8]2+ at m/z 1220.0900 was
initiated by the loss of the carbohydrate portions of the two glycated lysine residues. It is
important to mention that the following series of diagnostic product ions: 8+ at m/z
262.1259, [8 - H20t at m/z 244.1156, [8 - 2H20t at m/z 226.1058, [2.5A - 2H20t at m/z
152.0673, [8 - C4H60 3t at m/z 142.0837, [2.5A - CH403t at m/z 124.0733,
[CI7H26N304t at m/z 336.1890 and [CIIHI6N302t at m/z 222.1170 were fonned
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specifically from both the carbohydrate portions and the spacer moieties of the
glycopeptide precursor ion. Furthermore, we have observed "proper" peptide product
ions during this CID-MS/MS analysis, which were identified as follows: [b 14 - st at m/z
1814.8000, [b ll - st at m/z 1393.8366, [Y9 - st at m/z 1360.5399, [b1o - st at m/z
1237.6267, [Y7 - st at m/z /202.6109, [b9 - st at m/z 1136.6248, [bs - st at m/z
1079.5776, [b7 - st at m/z 980.5371, [b 14 - S]2+ at m/z 907.9442, [bl2 - sf+ at m/z
777.4165, [b ll - S]2+ at m/z 697.3653, [CTK* - st at m/z 642.2561, [YJ - st at m/z
625.3205, [K*VG - st at m/z 537.2682, [TK* - st at m/z 482.2529, [GK* - st at m/z
438.2285 and [K* - st at m/z 381.1820. All of these product ions were fonned by the
loss of the carbohydrate moiety exclusively, which allowed us to localize unambiguously
the two different glycation sites.
Thus the CID-MS/MS sequencing of the previously mentioned glycopeptides
allowed us to identify 22 glycation sites. Moreover, the combination of the CID-MS/MS
analysis of the tryptic and GluC V8 digests enabled us to discover a total of 33 glycation
sites with total sequence coverage of88% [Figure 5.4(c)]. As previously observed for the
neoglycoconjugates with hapten:SSA ratios of 4.3:1 and 6.6:1, the glycated lysine
residues for the hapten-SSA glycoconjugate with a ratio of 13.2: I are positioned on the
outer surface of the protein [Figure 5.5(c)].
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Table 5.5. LC-ESI-QqTOF-MS/MS analysis of the glycated peptide
YSRSLGK*YGTRCCTK*PE (Lys 455, Lys 463) at m/z 987.8313 (+3).
Molecular ion Calculated Experimental Deviation
mlz mlz Da
[b I4 -Bt 1814.9000 1814.8000 0.1000
[bll-Bt 1393.7910 1393.8366 -0.0456
[Y9- Br 1360.5973 1360.5399 0.0574
yZ+ 1350.6700 1350.6416 0.0284
[blO-Bt 1237.6899 1237.6267 0.0632
[Y_B]z+ 1220.1091 1220.0900 0.0191
[Y7- Bt 1202.5282 1202.6109 -0.0827
[b9 -Bt 1136.6422 1136.6248 0.0174
[bs-Br 1079.6208 1079.5776 0.0432
[b7-Br 980.5524 980.5371 0.0153
[b I4 -B]z+ 907.9539 907.9442 0.0097
[b IZ - B]z+ 777.4148 777.4165 -0.0018
[bll-B]z+ 697.3994 697.3653 0.0341
[CTK* - Bt 642.2910 642.2561 0.0349
[y,-Br 625.3181 625.3205 -0.0024
b6+ 600.3469 600.3531 -0.0062
bs+ 543.3255 543.3561 -0.0306
[K*VG-Bt 537.3026 537.2682 0.0344
[TK*-Bt 482.2604 482.2529 0.0075
[GK*-Bt 438.2342 438.2285 0.0057
b/ 430.2414 430.2185 0.0229
[K*- Br 381.2127 381.1820 0.0307
b/ 343.2094 343.2214 -0.0120
CI7Hz6N,04+ 336.1918 336.1890 0.0028
B+ 262.1290 262.1259 0.0031
[B-HzOr 244.1179 244.1156 0.0023
[B-2HzOr 226.1079 226.1058 0.0021
CII HI6N,O/ 222.1237 222.1170 0.0067
bz+ 187.1083 187.1118 -0.0035
eSA -2HzOr 152.0706 152.0673 0.0033
[Yl-Hzr 146.0453 146.0758 -0.0305
[B -C4H6O,t 142.0863 142.0837 0.0026
[Z5 A - CH4O,r 124.0757 124.0733 0.0024
190
S.4. Conclusion
The LC-ESI-QqTOF-MS/MS analysis of the tryptic and GluC V8 digests
allowed identification of a higher number of glycation sites than previously reported for
the neoglycoconjugates with a hapten:BSA ratio of 4.3: 1,6.6: 1 and 13.2: IJ11J Therefore,
the present approach can be considered as a refinement of the previous analysis. As
expected, the number of glycation sites in the neoglycoconjugates increases with the
hapten:BSA ratio. Indeed, 20 glycation sites were observed for the neoglycoconjugate
with a hapten:BSA ratio of 4.3: 1,27 for the neoglycoconjugate with a hapten:BSA ratio
of 6.6: I and 33 for the neoglycoconjugate with a hapten:BSA ratio of 13.2: I. Moreover,
it was found that the glycated lysine residues are situated on the outer surface of the BSA.
[n a future work, we plan to apply this method to find glycation sites on a
synthetic neoglycoconjugate models formed by the conjugation of an antigenic
hexasaccharide hapten of V. cholerae 0 I serotype Ogawa and tetanus toxin protein
carrier.
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CHAPTER 6: Determination of glycation sites by tandem mass spectrometry in a
synthetic lactose-BSA conjugate, a vaccine model prepared by dialkyl squarate
chemistry
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Abstract
Covalent attachment of lactose to BSA with a hapten:BSA ratio of 20: I was
prepared by a known method. The carbohydrate antigen (hapten)-BSA ratio in two
different lactose-BSA glycoconjugate vaccine models obtained at different reaction times
was determined by MALDl-TOF/TOF-MS to be 5.1:1 and 19.0:1. The glycation sites in
the neoglycoconjugates were determined using nano-LC-ESI-QqTOF-MS/MS analysis of
the trypsin and GluC V8 digests of the conjugates. Analysis of the digests gave
complementary structural information and maximized the number of recognized
glycation sites. For the neoglycoconjugate vaccine with a hapten:BSA ratio of 5.1: 1, a
total of 15 glycation sites were identified all located on the BSA lysine residues. The
nano-LC-ESI-QqTOF-MS/MS of the tryptic and GluC V8 digests of the hapten-BSA
glycoconjugate with a hapten:BSA ratio 19.0: 1 allowed the identification of 30 glycation
sites. Considering the average hapten:BSA ratio found in the neoglycoconjugate and the
number of glycation sites identified, we concluded that the glycoconjugation results in
formation of various glycoforms.
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6.1. Introduction
Synthesis of carbohydrate-protein neoglycoconjugates has become an important
avenue towards treatment of infectious diseases, as exemplified by the synthesis of
carbohydrate based vaccines.[l-4] Different methods have been applied for the synthesis of
neoglycoconjugate vaccines. One of the most efficient methods for the synthesis of
glycoconjugates is provided by the squaric acid chemistry, which allows single point
attachment of the antigen to the protein carrier; it avoids the formation of cross-linking
reactions, and allows recovery of the non-reacted squaric acid derivative (usually used in
excess at the onset of the conjugation).[5l Kamath et al. were first to monitor the
conjugation using MALDI-TOF-MSJ6] The first step in the conjugation process is the
synthesis of the hapten in the form of a glycoside whose aglycone contains a primary
amino group. The latter can react at pH 7.0 with a squaric acid diester at pH 7.0 to
produce the corresponding amide ester. Subsequent reaction of the monoester with amine
groups in the carrier protein at pH 9.0 forms the carbohydrate-protein glycoconjugate.
More recently, KovaC's group developed a strategy that enables a one-pot preparation of
a series of neoglycoconjugates with pre-determined carbohydrate:protein ratios.[7-9] They
were then able to make conjugates from fragments of the O-PS of Vibrio cholerae 01
serotype Ogawa[9. IOl, and of Inaba['1.'2] with BSA to investigate the immunogenicity of
these hapten-BSA glycoconjugates.
While the hapten:protein ratio has been generally measured using MALDl-TOF
or SELDl-TOF mass spectrometry,[lO.13] the localization of the carbohydrate occupancies
and the sites of conjugation has been more difficult to achieve.
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We reported our first attempt to localize the conjugation sites in the hapten-BSA
glycoconjugate made from the monosaccharide antigen of the O-PS of V cholerae
serotype Ogawa.[14 j The glycoconjugate was first digested with trypsin and the suspected
glycated digests were then analyzed by MALDI-TOF/TOF-MS/MS. However, presence
of only three glycation sites were identified, despite the average molecular mass of the
conjugate evidenced that it contained -5 moles of the ligand per mole of the carrier, as
determined by MALDI-TOF-MS. This discrepancy was attributed to the poor ionization
of the glycated peptides. Analysis of the tryptic digests by MS/MS also showed the
presence of numerous carbohydrate fragment ions which markedly complicated the
MS/MS sequencing of the glycopeptides.However, it is recognized that the glycosylation
of the carbohydrate haptens always occurs on lysine residues of the carrier BSA. Thus,
we have previously proposed that the trypsin digestion of the glycoconjugate is not
efficient to cleave the glycated lysines and this may affect the total digestion of the
glycoconjugateJl5]
In a separate study, we have investigated the location of glycation sites in an
experimental neoglycoconjugate vaccine for anthrax by MALDI-TOF/TOF-CID-MS/MS
and LC-ESI-QqTOF-tandem mass spectrometry.lI6] The carbohydrate portion of the
neoglycoconjugate was the synthetic tetrasaccharide side chain of the Bacillus anthracis
exosporium, 2-0-methyl-~-D-glucopyranosyl-(1->3)-a-L-rhamnopyranosyl-( 1->3)-a-L-
rhamnopyranosyl-(1->2)-a-L-rhamnopyranoside, and the protein carrier was BSA[16.17j
The hapten:BSA ratio in the neoglycoconjugate was 5.4: 1, as showed independently by
MS. The conjugate was digested with either trypsin or GluC V8 before MS analysis. The
advantage of using two different proteases results in more complete sequence coverage.
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A total of 30 glycation sites were discovered when perfonning LC-ESI-QqTOF-MS/MS
analysis of the digests, which is many more than was indicated by MALDI-TOF/TOF-
CID-MS/MS analysis of the digests. Additionally, we also observed carbohydrate
fragment ions characteristic of the tetrasaccharide portion.
Based on these observations, and to further explore power of MS in combination
with enzymatic digestion in glycoconjugate analysis, here we use a glycoconjugate
composed of a simple model carbohydrate, the milk sugar lactose, composed of two 0-
hexosyl residues and BSA as carrier. We hypothesize that the gas-phase reactivity of the
~-lactose portion of the neoglycoconjugate should be different than that of the 4-(3-
deoxY-L-glycero)-2-0-methyl-a-D-perosamine and of the tetrasaccharide 2-0-methyl-~­
D-glucopyranosyl-( 1---->3)-a-L-rhamnopyranosyl-( 1---->3)-a-L-rhamnopyranosyl-( 1---->2)-a-
L-rhamnopyranoside which we used previously.[14.16] In addition, here we have used a
combination of two different proteases, namely trypsin and the GluC V8, for the
digestion of various glycoconjugates. It is well known that at pH 7.8, GluC V8
endoprotease cleaves peptide bonds at the C-tenninus of glutamic acid and aspartic acid
residues [18.1 91. Finally, the protease digests were analyzed using nano-LC-ESI-QqTOF-
MS/MS.
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6.2. Material and Methods
6.2.1. Hapten-BSA glycoconjugate preparation
Conjugation of B-D-galactopyranosyl-(1->4)-B-D-glucopyranose (B-lactose) to
BSA was carried out by the standard protocol.[8] Briefly, commercial B-Iactose
octaacetate was converted to 5-methoxycarbonylpentyl B-Iactoside which was
transformed to a squaric acid monoester before conjugation. The conjugations were
carried out in 0.5 M borate buffer (pH 9.0) at the initial hapten:BSA ratio of 20: I and
using BSA (Sigma Aldrich, Saint Louis, MO, USA) as carrier protein. The conjugation
times were 3 and 24 hours.[7] Isolation of the neoglycoconjugate was carried out by
centrifugal ultrafiltration using filtration devices with a cut-off30,000 DaY]
It has been already established that when the foregoing protocol is applied, the
carbohydrate-spacer moiety covalently attaches to the f:-amino group of the lysine residue
in BSA.[14.l61 Figure 6.1 shows a representation of the synthesized carbohydrate hapten-
BSA glycoconjugate.
6.2.2. Digestion
The digestions of the lactose-BSA glycoconjugates were carried out with trypsin
and Glu-C V8 protease (Sigma Aldrich, Saint Louis, MO, USA). Thus, 100 ~lg of the
glycoconjugate was dissolved in a mixture of 0.1 % RapiGest SF Surfactant (I ~lg,
Waters, USA) in 50 mM of NH4HC03 (I 00 ~lL) at a pH of 8.0 and reduced by treatment
with 2 ~lL of 10 mM OTT (Sigma Aldrich, Saint Louis, MO, USA) for 30 min at room
temperature, followed by alkylation with 2 ~IL of a 50 mM iodoacetamide (Sigma
Aldrich, Saint Louis, MO, USA) for I h at room temperature. A portion (50 ~lg) of the
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BSA glycoconjugate was digested with trypsin using a 20 ng/ml of trypsin dissolved in
NH4HC03 (50 mM, 1 mL) at a trypsin:glycoprotein ratio of 1:25 (w/w) and incubated at
37°C overnight with shaking. The other 50 f.lg of the BSA glycoconjugate was digested
using the GluC V8 endoprotease protease:glycoprotein ratio of 1:25 (w/w) and incubated
at 37°C overnight with shaking. The sample was then dried under vacuum and the
residue was dissolved in 20 f.lL of 1% acetic acid (Sigma-Aldrich, Oakville, ON,
Canada). An aliquot of each sample (10 f.lL) was then cleaned up using ZipTip CI8
(Millipore, Bedford, MA, USA) before mass spectral analysis.
= B-cellepitope
=squaricacid
diamide
Figure 6.1. Schematic representation of the lactose-BSA glycoconjugate.
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6.2.3. MALDI-TOF-MS analysis
Mass spectrometry analyses were carried out on an ABI 4800 with TOF-TOF
optics (Applied Biosystems Foster City, CA) and a 200-Hz frequency Nd:YAG laser. a-
Cyano-4-hydroxycinnamic acid was used as matrix for the analysis of BSA and hapten-
BSA conjugates with an average of 5000 to 8000 laser shots per spectra. Briefly, I ~L of
a 20 mg/mL solution ofa-CHCA (dissolved in acetone, O.I%TFA) was spotted on the
MALO! plate and dried at room temperature. Then, an aliquot of I ~L of sample was
spotted on the top of the dried matrix and let to dry before the MALOl-MS experiments.
The analysis was achieved in the linear mode and the MALDI-TOF-MS was calibrated
using BSA.
6.2.4. LC-ESI-QqTOF-MS/MS analysis
The peptides were separated on a D10NEX UltiMate3000 ano LC System
(Gennering, Gennany). 250 finol of digested glycoprotein was dissolved in 0.1 % TFA
and loaded onto a precolumn (300 ~mi.d. x 5 mm, C I8 PepMaplOO, 5 ~m (LC Packing,
Sunnyvale, CA» in order to desalt and concentrate the sample. After their elution from
the precolumn, the peptides and glycopeptides mixtures were separated on a nanoflow
analytical column (75 ~lm i.d. x 15 cm, C I8 PepMap 100, 3 ~lIn, 100 A, (LC Packing,
Sunnyvale, CA» at a flow rate of 180 nL/min. The elution of the peptides and
glycopeptides was achieved using the following mobile phases: 0.1 % FA/O.O I% TFA/2%
ACN (A) and 0.08% FA/O.008% TFA/98% ACN (B). The elution started with 0% B for
10 min, followed by a gradient of 0-60% B in 55 min and 60-90% B in 3 min and was
kept at 90% B for 3 min. The MS/MS analysis of the eluted peptides and glycopeptides
was accomplished using an Applied Biosystems API-QSTAR XL quadrupole 011hogonal
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time-of-flight (QqTOF)-MS/MS hybrid tandem mass spectrometer (Applied Biosystems
Intemational-MDS Sciex, Foster City, CA, USA) equipped with a nanoelectrospray
source (Protana XYZ manipulator) which produces the electrospray through a PicoTip
needle (10 ~lm i.d., ew Objectives, Woburn, MA, USA) carrying a voltage of 2400 V.
The TOF analyzer was calibrated using a renin solution (I pmol/l-lL) and looking for the
ions at m/z 586.9815 and m/z 879.9723. The collision energies used during the CID-
MS/MS analyses were detennined automatically using the Infonnation Dependent
Acquisition method integrated in the Analyst software.
6.3. Results
As previously indicated, the covalent attachment of lactose to BSA was carried
out at an initial hapten:BSA ratio of 20: I and the conjugation reaction was allowed to
proceed for either 3 hours or 24 hours. Thus, two p-Iactoside-BSA glycoconjugate
vaccine models were produced.
6.3.1. MALDI-TOF-MS analysis ofthe hapten-BSA glycoconjugates.
In order to detennine the average number of carbohydrate-spacer moieties linked
to BSA (hapten:BSA ratio), the two glycoconjugates were analyzed using MALDI-
TOF/TOF-MS (single stage). Molecular masses and hapten:BSA ratios were calculated
by comparing the molecular mass of the conjugate to the molecular mass of the stal1ing
BSA. Thus, MALDI-TOF/TOF-MS revealed that the two neoglycoconjugates fonned
had hapten:BSA ratios 5.1: I (reaction time: 3 hours) and 19.0: I (reaction time: 24 hours).
These hapten:BSA ratios were found to be identical to those previously detennined by
SELDI-TOF-MS.17]
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The molecular mass calculations of these glycoconjugates were based on the
presumption that squaric acid covalently links to the EO-amino groups of the lysine
residues in BSA by loss of an ethanol molecu!e[13,15j and that the molecular mass of the
fragment of disaccharide-spacer-squaric acid which will bond to the BSA is 577.22 Da
(Table 6.1).
Figure D.l (Appendix D) and Table 6.1 display the mass spectra and the m/z
values of (a) BSA, (b) the synthetic neoglycoconjugate vaccine obtained after a reaction
time of 3 hours and (c) the synthetic neoglycoconjugate vaccine obtained after a reaction
timeof24 hours.
Table 6.1. Molecular ions identified during the MALDI-TOF/TOF-MS analysis of the
1actose-BSA glycoconjugates obtained with different reaction times.
Observed ion I1I/Z Calculated
I
Reaction IM+2HJ2+ I IM+H( Lactose:BSAtime ratio
I BSA 33161.81 I 66318.88
I 3h 34619.44 I 69307.96 5.1
I 24 h 38683.93 I 77258.62 19.0
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6.3.2. LC-ESI-QqTOF-MS/MS analyses of the tryptic and GluC V8 digests of the
neoglycoconjugate with a lactose:BSA ratio of5.1:1and 19.0:1
Nano-LC-ESI-QqTOF-MS/MS analysis was carried out on both tryptic and GluC
V8 digests of glycoconjugates with a hapten:protein ratio of 5.1: I and 19.0: I. The
MS/MS spectra obtained were submitted to the Mascot library in order to identify the
peptides fonned from BSA. The Mascot reports of LC-ESI-QqTOF-MS/MS data of the
tryptic digest of the glycoconjugates demonstrated the identification of two serum
albumin isofonns from the Bos taurus species. The serum albumin precursor
(giI1351907) was identified with the following sequence coverage: 45% and 47%, for the
neoglycoconjugates with a lactose:BSA ratio of respectively 5.1: I and 19.0: I. The serum
albumin protein (giI74267962) was also identified for the analysis of the tryptic digests of
the glycoconjugates with a hapten:protein ratio of 5.1: I (sequence coverage = 41 %) and
19.0:1 (sequence coverage = 43%).
Similarly, the data of the LC-ESI-QqTOF-MS/MS analysis of the GluC V8
digests of the glycoconjugates with ratios of 5.1: I and 19.0: I were submitted to the
Mascot library which gave a match to the same two serum albumin proteins from the 80S
taurus species mentioned previously: the serum albumin precursor (giI1351907) and the
serum albumin (giI74267962). The sequence coverage for the albumin precursor
(giI1351907) for the neoglycoconjugates with hapten:BSA ratios of 5.1: I and 19.0: I was
found to be 39% and 37%, respectively. Finally, serum albumin protein (giI74267962)
was identified with the following sequence coverage: 40% for the hapten-BSA
glycoconjugate 5.1: I and 33% for the hapten-BSA glycoconjugate 19.0: I.
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Most importantly, the reports obtained also contained a list of ions that did not
match any protein; these were considered to be potentially glycated BSA peptides. These
ions were selected and subjected to CID-MS/MS sequencing, in order to identify the
correct sequences ofthe glycated peptides and their exact glycation sites.
6.3.3. Mass spectrometry determination of the glycation sites on the
neoglycoconjugate with a hapten:BSA ratio of5.1:1
LC-ESI-QqTOF-MS/MS analysis ofthe tryptic digests
The LC-ESI-QqTOF-MS/MS analysis of the tryptic digests of the
neoglycoconjugate with a hapten:BSA ratio of 5.1: I allowed us to identify nine
glycopeptides having lysine residues occupied on different glycation sites designed with
an asterisk. These were identified as follows (Table 6.2): SLGK*YGTR (Lys 455) at /11/z
697.3748 (+2), LSQK*FPK (Lys 245) at /11/z 712.3812 (+2), EK*YLTSSAR (Lys 211) at
m/z 783.8877 (+2), ALK*AWSYAR (Lys 235) at m/z 789.4228 (+2),
LAK*EYEATLEECCAK (Lys 374) at m/z 797.7141 (+3), CASIQK*FGER (Lys 228) at
/11/z 886.4299 (+2), CCTK*PESER (Lys 463) at /11/z 871.8738 (+2), YTK*CCTESLVNR
(Lys 498) at m/z 1021.9941 (+2) and K*YPQYSTPTLYEYSR (Lys 437) at m/z
1108.5900 (+2). Figure 6.2 displays the following examples of different glycopeptides
obtained by tryptic digests of the lactose-BSA glycoconjugate: (a) SLGK*YGTR (Lys
455) at m/z 697.3748 (+2) and (b) LSQK*FPK (Lys 245) at m/z 712.3812 (+2), (c)
EK*YLTSSAR (Lys 211) at m/z 783.8877 (+2) and (d) ALK*AWSYAR (Lys 235) at
m/z 789.4228 (+2). The CID-MS/MS fragmentation pathways obtained by the isolated
precursor glycopeptide ions enabled us to unambiguously detennine the various glycation
sites.
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Table 6.2. Tryptic glycopeptides identified in the bovine serum albumin protein by LC-ESI-QqTOF-MS/MS analysis of the lactose-
BSA glycoconjugates.
Peptide Missed Lactose:BSAS.l:l Lactose:BSA19.0:1Sequence (asterisk = glycation Calculated Observed Deviation Observed Deviation
site) lIl/z (char e) cleavage lIl/z (charge) (Da) lIl/z(charge) (Da)
SLGK*YGTR (Lys 455) 697.3568(+2) 1 697.3748 (+2) 0.0181 697.3567(+2) -0.0001
LSQK*FPK (Lys 245) 712.3640(+2) 2 712.3812(+2) 0.0172 712.3673 (+2) 0.0033
EK*YLTSSAR (Lys 211) 783.8912(+2) 1 783.8877 (+2) -0.0035 783.8900(+2) -0.0012
ALK*AWSYAR (Lys 235) 789.4068 (+2) 1 789.4228(+2) 0.0161 789.4125 (+2) 0.0058
LAK*EYEATLEECCAK (Lys 374) 797.6874(+3) 2 797.7141 (+3) 0.0267 797.6954(+3) 0.0080
CAS1QK*FGER (Lys 228) 886.4066(+2) 1 886.4299(+2) 0.0233 886.4033 (+2) -0.0033
CCTK*PESER (Lys 463) 871.8587(+2) 1 871.8738(+2) 0.0151 871.8000(+2) -0.0587
YTK*CCTESLVNR (Lys 498) 1021.9667(+2) 1 1021.9941 (+2) 0.0274 1021.9741 (+2) 0.0074
K*FWGK(Lys 156) 621.3007(+2) 1
TPYSEK*YTK (Lys 495) 782.8959(+2) 2 782.8995 (+2) 0.0036
K*YPQVSTPTLVEYSR (Lys 437) 1108.5811 (+2) 0 1108.5854(+2) 0.0043
SLHTLFGDELCK*VASLR (Lys 841.4162 (+3) 1 841.4000 (+3) -0.0162100)
la. CsH17N20i
100% 173.1251
Y3'
333.1B87'~
SOO 1000
WZ
~ 521Yi~80 EK'VLTSSAR
:: iiJi ~J~li
600 800
WZ
LSQK*FPK
800 1000
WZ
Figure 6.2. LC-QqTOF-MS/MS spectra of the tryptic glycated peptides (a)
SLGK*YGTR (Lys 455) at mlz 697.3567 (+2), (b) LSQK*FPK (Lys 245) at mlz
712.3673 (+2), (c) EK*YLTSSAR (Lys 211) at mlz 783.8900 (+2) and (d)
ALK*AWSYAR (Lys 235) at mlz 789.4125 (+2).
208
During the CID-MS/MS analyses, we used the pre-existing peptide nomenclature
involving the detection of the x-, y-, z-ions and the a-, b-, c-ions for the individual peptide
sequence.[20,21] For the glycopeptide product ions, we used the nomenclature established
by Domon and Costello for the carbohydrate portion as: A, 8, C, X, Y and Z.[22]
The CID-MS/MS analysis of the doubly charged glycated peptide SLGK*YGTR
(Lys 455) at m/z 697.3748 (Figure 6.2(a), Table 0.1) afforded a series of product ions
corresponding to the entire peptide chain formed by loss of the p-o-galactopyranosyl
moiety: Y 1+ at m/z 1231.6639, and the entire p-o-galactopyranosyl-(I-->4)-P-O-
glucopyranoside: Yo+ at m/z 1069.6055, Yo2+ at m/z 535.3109 and [Yo - H20]2+ at m/z
526.3004 (representation in Figure 6.3). Additionally, we have noted the formation of
product ions corresponding to the galactopyranosyl moieties: 8 1+ at m/z 163.0556, [8 1 -
H20t at m/z 145.0441 and [8 1 - 2H20t at m/z 127.0377. Clearly, these carbohydrate
fragments confinned the identity of the carbohydrate conjugated to the 8SA and were an
epitome of chemical stability of these cations in gas phase. We also noted the fonnation
of the product ions corresponding to the squaric acid-spacer: C17H26N30/ at m/z
336.1908, CIIHI6N30/ at m/z 222.1271 and CgH17N202+ at m/z 173.1251 (product ions
displayed in Figure 6.3). As expected, we observed a propensity of the gas-phase loss of
the carbohydrate disaccharide portion during the MS/MS analysis. For example, the
following peptide product ions were observed and fonned by the loss of the carbohydrate
moiety: [b7 - 8 2t at m/z 895.4260, [Y6 - 8 2t at m/z 869.4918, [Ys - 8 2t at m/z 812.4715,
[b6 - 82t at m/z 794.4752, [bs - 8 2t at m/z 737.4277, [bs - 8 2 - H20t at /11/z 719.3841,
[as - 82t at m/z 709.4391, [b4 - 82t at m/z 638.3549 and [Y6 - 82 - H20f+ at m/z
426.2460.
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Finally, we also noted the presence of the conventional y- and b- product ions
corresponding to the fragmentation of the peptide backbone, which allowed us to cover
the sequence of each entire glycated peptide.
HO*~+A Y'B'+_jrQ-i OH Yo+
y 2+
(detecledinsomeproduca ;0 0 2+
;=~"'''''=I ,- ~ .,-"PI
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I Y4 Y3Y2Y'
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b/b3+
f OHC~'
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Figure 6.3. Product ions resulting from the tandem mass spectrometry analysis of the
glyctated peptide SLGK*YGTR (Lys 455) at m/z 697.3567 (+2) extracted from the LC-
ESI-Qq-TOF-MS/MS analysis of the tryptic digests of the hapten-BSA glycoconjugate
with a lactose:BSA ratio of 5.1: I.
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LC-ESI-QqTOF-MS/MS analysis a/the GluC V8 digests
The manual sequencing of the spectra that were not assigned to a peptide of the B.
taurus protein on the Mascot report, enabled us to identify eight glycopeptides containing
different lysine residue glycation sites at different lysine residues (Table 6.3): K*TPYSE
(Lys 489) at m/z 618.7989, HYK*LVNE (Lys 65) at m/z 707.8591, K*LFTFHAD (Lys
528) at m/z 777.9566 (+2), LCK*YASLRE (Lys 100) at m/z 826.4216 (+2),
YSRSLGK*YGTRCCTKPE (Lys 455) at m/z 837.7418 (+3),
YSRSLGK*YGTRCCTKPESE (Lys 455) at m/z 909.7741 (+3), DKGACLLPK*IE (Lys
204) at m/z 910.4582 (+2), YAYSYLLRLAK*E (Lys 374) at m/z 969.5187 (+2),
LLYYANK*YNGYFQE (Lys 183) at m/z 1149.5413 (+2) and K*LFTFHADICTLPDTE
(Lys 528) at m/z 1242.5946 (+2) (Table 6.3). Figure 6.4(a) and 6.4(b) display several
examples of the identified glycopeptides during the LC-ESI-QqTOF-MS/MS analysis of
the GluC Y8 digests: (a) YSRSLGK*YGTRCCTKPE (Lys 455) at m/z 837.7418 (+3)
and (b) DKGACLLPK*IE (Lys 204) at m/z 910.4582 (+2).
The MS/MS analysis of the precursor glycopeptide ion
YSRSLGK*YGTRCCTKPE (Lys 455) at m/z 837.7418 (+3) shown in Figure 6.4(a)
(Table D.2) adopted a CID-fragmentation pathway similar to the other tryptic digested
glycopeptides ions. These CID-MS/MS fragmentations appear to be initiated by loss of
the entire disaccharide moiety. Thus the following product ions were identified: the entire
peptide ion produced by loss of the ~-D-galactopyranosyl moiety, the product ion y 12+ at
m/z 1175.0537 and the intact disaccharide product (~-D-galactopyranosyl-(1->4)-~-D­
glucopyranoside) ion, Yo2+ at m/z 1094.0196 and Yo3+ at m/z 729.6955. It is important to
point out the formation of the diagnostic product ions, which were created specifically by
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the carbohydrate-spacer moiety: the mixed product ions containing a fragment of lysine
and the squaric acid-spacer assigned as [C17HZ6 304t at m/z 336.1871 and
[C 11 H16 30Zt at m/z 222.1181. In addition, we were also able to detect the product ions
corresponding to monosaccharide galactopyranosyl moiety: B1+ at m/z 163.0527 and [B 1 -
HzOt at m/z 145.0423.
Additionally, some peptide fragment ions formed by loss of the entire 13-lactose
moiety were also detected: [b 13 - Bz]z+ at m/z 857.3536, [b16 - BZ]3+ at m/z 680.9973 and
[b 15 - BZ]3+ at m/z 648.3185. Furthermore, other product ions covering the sequence of the
glycopeptide are displayed in Figure 6.4(a) and Table 0.2. Another example of a
glycopeptide identified during the LC-ES1-QqTOF-MS/MS analysis of GluC V8 digests
of the precusor DKGACLLPK*IE ion (Lys 204) at m/z 910.4582 (+2) is shown in Figure
6.4(b).
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Table 6.3. Glycopeptides identified in the bovine serum albumin protein by LC-ESI-QqTOF-MS/MS analysis of the GluC V8 digests
of the lactose-BSA glycoconjugates.
Peptide Lactose:BSAS.1:1 Lactose:BSA 19.0:1
Sequence (star=glycation site) Calculated ~ Observed Deviation Observed Deviation
m/z(chan!e) cleavage m/z(charge) (Da) m/z(chan!e) (Da)
K*TPYSE (L s 489) 618.7904(+2) 0 618.7989(+2) 0.0085 618.7940(+2) 0.0036
HYK*LYNE (Lys 65) 707.8513 (+2) 0 707.8591 (+2) 0.0078 707.8565 (+2) 0.0052
K*LFTFHAD (Lys 528) 777.8644(+2) 0 777.9566(+2) 0.0922 777.9564 (+2) 0.092
LCK*yASLRE (Lys 100) 826.4087(+2) 0 826.4216(+2) 0.0129 826.4137(+2) 0.005
YSRSLGK*YGTRCCTKPE (Lys 455) 837.7407(+3) 0 837.7418(+3) 0.0011 837.7468 (+3) 0.0061
YSRSLGK*YGTRCCTKPESE (Lys 455) 909.7656 (+3) 1 909.7741 (+3) 0.0085 909.7714 (+3) 0.0058
DKGACLLPK*IE (Lys 204) 910.4480(+2) 1 910.4582(+2) 0.0103 910.4539(+2) 0.0059
YAYSYLLRLAK*E (Lys 374) 969.5198 (+2) 0 969.5187(+2) -0.0011 969.4790(+2) -0.0408
LLYYANK*YNGYFQE (Lys 183) 1149.5389(+2) 0 1149.5413 0.0024 1149.5565 (+2) 0.0176(+2)
K*LFTFHADICTLPDTE (Lys 528) 1242.5726(+2) 2 1242.5946 0.022 1242.5876(+2) 0.0150(+2)
K*SHCIAE (Lys 309) 710.8113 (+2) 0 710.8039 (+2) -0.0074
K*SLHTLFGD (Lys 88) 797.3804(+2) 0 797.3361 (+2) -0.0443
CCDK*PLLE (Lys 304) 805.8445 (+2) 1 805.8449 (+2) 0.0004
FAK*TCYADE (Lys 75) 808.8481 (+2) 1 808.8551 (+2) 0.007
GPK*LYYSTQTALA (Lys 597) 930.9883 (+2) 0 931.0042(+2) 0.0159
IAHRFK*DLGEE (Lys 36) 945.9523 (+2) 2 945.9632(+2) 0.0109
AK*DAFLGSFLYE (Lys 346) 968.9514(+2) 1 968.9538 (+2) 0.0024
YSRSLGK*YGTRCCTK*PE (Lys 455, 1029.8153 (+3) 0 1029.8239(+3) 0.0086Lys463)
K*DAIPE (Lys 318) 624.7904(+2) 1 624.8000(+2) 0.0096
YTK*LYTD (Lys 256) 676.3402(+2) 0 676.3457(+2) 0.0055
:;
K*SHCIAEYE (Lys 309) 824.8668(+2) 1 824.8706(+2) 0.0038
LTK*YHK*E (Lys 263, Lys 266) 1003.9750(+2) 0 1003.9831 (+2) 0.0081
K*YTK*CCTE (Lys 495, Lys 498) 1089.4619(+2) 0 1089.4600(+2) -0.0019
YSRSLGK*YGTRCCTK*PESE (Lys 455, 1101.8402 (+3) 1 1101.8476(+3) 0.0074Lys463)
DK*GACLLPK*IE (Lys 197, Lys 204) 1198.5599(+2) 1 1198.5604(+2) 0.0005
KK*FWGK*YLYE(Lys 156, 160) 1257.5868(+2) 0 1257.5983 (+2) 0.0115
ta) 245Y12~56 VSRSLGK'YGTRCCTKPE tb) J~~:3~~;
;f?
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~ ~
~
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~ ar
,£ .... ~
~ .~~
-" ~
400 BOO 800 1000 12001400
rrVz
400 BOO 800 1000 1200
rrVz
Figure 6.4. LC-QqTOF-MS/MS spectra of the GluC V8 digests glycated peptides (a)
VSRSLGK*VGTRCCTKPE (Lys 455) at mlz 837.7418 (+3), (b) DKGACLLPK*IE (Lys
204) at mlz 910.4582 (+2), (c) VSRSLGK*VGTRCCTK*PE (Lys 455, Lys 463» at mlz
1029.8189 (+3) and (d) DK*GACLLPK*IE (Lys 197, Lys 204) at mlz 1198.5604 (+2).
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Tus, a total of 15 glycation sites were identified during the LC-ESI-QqTOF-
MS/MS analysis of tryptic and GluC V8 digests of the lactose-BSA glycoconjugate,
which are displayed in Figure 6.5(a). When we compare the average number of glycation
sites determined by the foregoing analysis (15 glycation sites) to the ratio of 5.1: I
determined for the lactose-BSA conjugate, the difference can be explained by the
formation of a mixture of glycoforms during conjugation. Finally, the total sequence
coverage of the glycoconjugate obtained by the trypsin and GluC V8 digestion was found
to be 86%.
(a)
1 MKWVTFISLL LLFSSAYSRG VFRRDTHKSE IAHRFKDLGE EHFKGLVLIA
51 FSQYLQQCPF DEHVK LVNEL TEFAKTCVAD ESHAGCEKSL HTLFGDELC!,
101 VASLRETYGD MADCCAKQEP ERNECFLSHK DDSPDLPKLK PDPNTLCDEF
151 KADEKKFWGK YLYEIARRHP YFYAPELLYY AN,,'YNGVFQE CCQAEDKGAC
201 LLP'" IETMRE K*VLTSSARQR LRCASIQK*FG ERALK*AWSVA RLSQK*FPKAE
251 FVEVTKLVTD LTKVHKECCH GDLLECADDR ADLAKYICDN QDTISSKLKE
301 CCDKPLLEKS HCIAEVEKDA IPENLPPLTA DFAEDKDVCK NYQEAKDAFL
351 GSFLYEYSRR HPEYAVSVLL RLAK*EYEATL EECCAKDDPH ACYSTVFDKL
401 KHLVDEPQNL IKQNCDQFEK LGEYGFQNEL IVRYTRK*VPQ VSTPTLVEVS
451 RSLGK*VGTRC CTK*PESERMP CAEDYLSLIL NRLCVLHEK'T PVSEKVTK*CC
501 TESLVNRRPC FSALTPDETY VPKAFDEK' LF TFHADICTLP DTEKQIKKQT
551 ALVELLKHKP KATEEQLKTV MENFVAFVGK CCAADDKEAC FAVEGPKLVV
601 STQTALA
(b) 1 MKWVTFISLL LLFSSAYSRG VFRRDTHKSE IAHRFK' DLGE EHFKGLVLIA
51 FSQYLQQCPF DEHVi\' LVNEL TEFAi\' TCVAD ESHAGCEv' SL HTLFGDELC' '
101 VASLRETYGD MADCCAKQEP ERNECFLSHK DDSPDLPKLK PDPNTLCDEF
151 KADEKK* FWG, YLYEIARRHP YFYAPELLYY ANK' YNGVFQE CCQAEDi" GAC
201 LLP, IETMRE K*VLTSSARQR LRCASIQK*FG ERALK*AWSVA RLSQK*FPKAE
251 FVEVTi\' LVTD LTK'VH!,' ECCH GDLLECADDR ADLAKYICDN QDTISSKLKE
301 CCD,,' PLLE\ S HCIAEVEK' DA IPENLPPLTA DFAEDKDVCK NYQEAK' DAFL
351 GSFLYEYSRR HPEYAVSVLL RLAK*EYEATL EECCAKDDPH ACYSTVFDKL
401 KHLVDEPQNL LGEYGFQNEL IVRYTRK*VPQ VSTPTLVEVS
451 RSLGK*VGTRC CAEDYLSLIL NRLCVLHEK' T PVSEK*VTK*CC
501 TESLVNRRPC VPKAFDE:, LF TFHADICTLP DTEKQIKKQT
551 ALVELLKHKP KATEEQLKTV MENFVAFVGK CCAADDKEAC FAVEGP LVV
601 STQTALA
Figure 6.5. BSA sequence where the glycation sites are indicated by an asterisk (red =
identified on tryptic digests, blue = identified on GluC V8 digests and red and underlined
= identified on both tryptic and GluC V8 digests) for the neoglycoconjugates with a
lactose:BSA ratio of (a) 5.1:1 and (b)19.0:1.
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6.3.4. Mass spectrometry determination of the glycation sites on the
neoglycoconjugate with a hapten:BSA ratio of 19.0:1
LC-ESI-QqTOF-MS/MS analysis ofthe tryptic digests
The following glycated peptides were identified allowing the detennination of I I
glycation sites (Table 6.2) and these were assigned as follows: SLGK*YGTR (Lys 455)
at m/z 697.3567 (+2), LSQK*FPK (Lys 245) at m/z 712.3673 (+2), TPYSEK*YTK (Lys
495) at m/z 782.8995 (+2), EK*YLTSSAR (Lys 211) at m/z 783.8900 (+2),
ALK*AWSYAR (Lys 235) at m/z 789.4125 (+2), LAK*EYEATLEECCAK (Lys 374) at
/11/z 797.6954 (+3), SLHTLFGDELCK*YASLR (Lys 100) at /11/z 841.4000 (+3),
CASIQK*FGER (Lys 228) at m/z 886.4033 (+2), CCTK*PESER (Lys 463) at /11/z
871.8000 (+2), YTK*CCTESLVNR (Lys 498) at m/z 1021.9741 (+2) and
K*YPQYSTPTLYEYSR (Lys 437) at /11/z 1108.5854 (+2).
LC-ESI-QqTOF-MS/MS analysis ofthe GluC V8 digests
The LC-ESI-QqTOF-MS/MS analysis of the GluC Y8 digests of the
neoglycoconjugate with a hapten:BSA ratio of 19.0:1 pennitted us to detennine 24
glycation sites through the identification of the following glycated peptides (Table 6.3):
K*TPYSE (Lys 489) at /11/z 618.7940 (+2), K*DAIPE (Lys 318) at /11/z 624.8000 (+2),
YTK*LYTD (Lys 256) at m/z 676.3457 (+2), HYK*LVNE (Lys 65) at m/z 707.8565
(+2), K*SHCIAE (Lys 309) at /11/z 710.8039 (+2), K*LFTFHAD (Lys 528) at m/z
777.9564 (+2), K*SLHTLFGD (Lys 88) at m/z 797.3361 (+2), CCDK*PLLE (Lys 304)
at /11/z 805.8449 (+2), FAK*TCYADE (Lys 75) at /11/z 808.8551 (+2), K*SHCIAEYE
(Lys 309) at /11/z 824.8706 (+2), LCK*YASLRE (Lys 100) at /11/z 826.4137 (+2),
YSRSLGK*YGTRCCTKPE (Lys 455) m/z 837.7468 (+3),
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YSRSLGK*YGTRCCTKPESE (Lys 455) at m/z 909.7714 (+3), DKGACLLPK*IE (Lys
204) at m/z 910.4539 (+2), GPK*LYYSTQTALA (Lys 597) at m/z 931.0042 (+2),
IAHRFK*DLGEE (Lys 36) at m/z 945.9632 (+2), AK*DAFLGSFLYE (Lys 346) at m/z
968.9538 (+2), YAYSYLLRLAK*E (Lys 374) at m/z 969.4790 (+2),
LLYYANK*YNGYFQE (Lys 183) at m/z 1149.5565 (+2) and K*LFTFHADlCTLPDTE
(Lys 528) at m/z 1242.5876 (+2).
In this case, it is worth mentioning that we were able to scrutinize 6 glycopeptides
which carry two nearby glycation sites. These were assigned as follows: LTK*YHK*E
(Lys 263, Lys 266) at m/z 1003.9831 (+2), YSRSLGK*YGTRCCTK*PE (Lys 455, Lys
463) at m/z 1029.8239 (+3), K*YTK*CCTE (Lys 495, Lys 498) at m/z 1089.4600 (+2),
YSRSLGK*YGTRCCTK*PESE (Lys 455, Lys 463) at /11/z 1101.8476 (+3),
DK*GACLLPK*IE (Lys 197, Lys 204) at m/z 1198.5604 (+2) and KK*FWGK*YLYE
(Lys 156, 160) at m/z 1257.5983 (+2). An interesting example to discuss is the diagnostic
peptide YSRSLGKYGTRCCTKPE, which was detected with either one single glycation
site on the Lys 455 residue affording the glycopeptide at m/z 837.7468 (+3) or with two
glycation sites on the Lys 455 and Lys 463 residues, producing the glycated peptide at
m/z 1029.8239 (+3). The ClD-MS/MS analysis of the precursor ions containing two
glycation sites YSRSLGK*YGTRCCTK*PE (Lys 455, Lys 463) at m/z 1029.8239 (+3)
is shown in Figure 6.4 (c) and Table D.3. The ClD-fragmentation pathway of this
precursor glycated peptide ion afforded peptide product ions formed by loss of only one
entire ~-D-galactopyranosyl-(1----t4)-~-D-glucopyranoside. Thus, we detected the y-
product ions obtained by the loss of the entire carbohydrate moiety on the Lys 463
residue. The majority of the remaining product ions were identified as follows: [Ylo - 82t
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at m/z 1459.6788, [Y9 - B2t at m/z 1360.5324, [Ys - B2t at m/z 1303.5839, [Y7 - B2t at
m/z 1202.4761, [Y4 - B2t at m/z 726.3182 and [Y3 - B2t at m/z 625.3054. However, it is
interesting to note that the loss of the entire ~-D-galactopyranosyl-(1--->4)-~-D­
glucopyranoside on the Lys 455 residue was also observed on the following b-product
ions: [bs - B2t at m/z 1079.6271, [b7 - B2t at m/z 980.5238, [b 14 - B2]2+ at m/z 907.9193,
[b 13 - Bd+ at m/z 857.3852, [b 12 - B2]2+ at m/z 777.3857, [b ll - Bd+ at m/z 697.3887, [b9
- B2]2+ at m/z 568.7979 and [b7 - B2f+ at m/z 490.7766. Finally, during the product ion
scan of the precursor YSRSLGK*YGTRCCTK*PE ion (Lys 455, Lys 463) at m/z
1029.8239 (+3), we identified a product ion formed by the loss of the two ~-D­
galactopyranosyl-( 1--->4)-~-D-glucopyranosidescarried on Lys 455 and Lys 463 residues:
[b ls - 2B2f+ at m/z 1098.0119. In addition, another series of diagnostic product ions,
which were decribed earler were detected and assigned as: [C17H26N304t at m/z
336.1852 and [CIIHI6N302t at m/z 222.1174. The galactopyranosyl [Bit production at
m/z 163.0559 was also observed.
Thus, it is important to note, that the observation of peptides having the same
sequence which were glycosylated with either one and/or two carbohydrate haptens,
confirms the fact that the fonned glycoconjugate was indeed a mixture of glycofonns.
Figure 6.4(d) displays the LC-ES1-QqTOF-MS/MS analysis of glycopeptide
DK*GACLLPK*IE at m/z 1198.5604 (+2), derivatized at the Lys 197 and Lys 204
residues, and the product ions with their m/z values are reported in Table D.4. Moreover,
the peptides with the following sequences YSRSLGKYGTRCCTKPE and
YSRSLGKYGTRCCTKPESE were also observed with one glycosylation on the Lys 455
residue and two glycosylations on the Lys 455 and Lys 463 residues (Table 6.3).
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When combining the data of the LC-ESI-QqTOF-MS/MS analysis of the tryptic
and GluC V8 digests, a total of 30 glycation sites were identified [displayed in Figure
6.5(c)], and the total sequence coverage was evaluated to be 89 %.
Figure 6.6 displays the 3-D structure (obtained using Swiss-Prot pdb viewerl23.241)
of the lactose-BSA glycoconjuagtes with a hapten:BSA ratio of (a) 5.1:1 and (b) 19.0:1,
where the glycated lysines are highlighted in red. We can thus observe that the majority
of the glycated lysine residues are located on the outer-surface of the protein.
(a)
(b)
Figure 6.6. 3-D structure of the lactose-BSA glycoconjugates with a lactose:BSA ratio
of (a) 5.1:1 and (b) 19.0:1.
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6.4 Conclusion
The MALDI-TOF/TOF-MS analysis of the different lactose-BSA
glycoconjugates allowed us to detennine the different hapten:BSA ratios fonned during
conjugation: 5.1: I and 19.0: I. The LC-ES1-QqTOF-MS/MS analysis identified 15
glycation sites for the neoglycoconjugate with a hapten:BSA ratio of 5.1: I and 30
glycation sites for the neoglycoconjugate with a hapten:BSA ratio of 19.0: I, showing that
the conjugates were mixtures of glycofonns. This could be deduced from a higher
number of glycation sites compared to the average number of haptens present in
conjugates per mol of the carrier. The presence of glycofonns was also confinned by the
fact that for the same glycoconjugate with a hapten:BSA ratio of 19.0: I, glycopeptides of
the same amino acid sequence were detected containing either one or two different
glycation sites.
As expected, it was observed that the number of identified glycation sites
increased when the hapten:BSA ratio of glycoconjugate fonnation increased and that the
location of the glycation sites appears to be mainly on the outer-surface of the BSA
carrier molecule (Figure 6.6), which is in line with the assumption that the sterically more
accessible lysine residues, namely those located on the outer-surface of the BSA, would
be conjugated preferentially.
As also observed during the LC-ESI-QqTOF-MS/MS analysis of the digested
Bacillus anthracis exosporium specific tetrasaccharide-BSA glycoconjugate, [16] we were
able to detect various conventional diagnostic carbohydrate fragment ions ([Bit, [B 1 -
H20t and [B I - 2H20t). We also noted the fonnation ofYo+ product ions and, in some
glycopeptides, the loss of the neutral B2 product ions (fonnation of[y - B2t and [b - B2t
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ions). These findings seem to indicate the gas-phase fragility of these ions and inclination
of the glycosylated oxygen-carbon spacer bond to rupture. Therefore, we conclude that
regardless of the nature the carbohydrate portion in the synthetic neoglycoconjugates
under investigation, the glycosylated 0-6-C-1 bond, between the aglycone and the
carbohydrate portion, is easy to rupture in the gas-phase.
Appendix D. Supplementary data
Supplementary data are associated with this chapter (page 267)
222
References
[I] P. Kovac. Synthetic oligosaccharides. Indispensable probes in the life sciences, Ed.;
ACS Symposium Series 560; American Chemical Society: Washington, DC, 1994.
[2] Y. C. Lee, R. T. Lee. In Synthetic glycoconjugates; H. J. Allen, E. C. Kisailus, Eds.;
Marcel Dekker: ew York, 1992, p. 121.
[3] D. P. Galonic, D. Y. Gin. Chemical glycosylation in the synthesis of glycoconjugate
antitumor vaccines. Nature 2007,446, 1000.
[4] W. E. Dick Jr., M. Beurret. Glycoconjugates of Bacterial Carbohydrate Antigens. In
Conjugate vaccines. J. M. Cruise, R. E. Jr. Lewis (Eds.) Switzerland: Basel, Krager, vol.
10,1989, p. 48.
[5] L. F. Tietze, M. Arlt, M. Beller, K. H. GJusenkamp, E. Jahde, M. F. Rajewsky.
Anticancer agents, 15. Squaric acid diethyl ester: a new coupling reagent for the
formation of drug biopolymer conjugates. Synthesis of squaric acid ester amides and
diamides. Chern. Ber. 1991,124,1215.
[6] V. P. Kamath, P. Diedrich, O. Hindsgaul. Use of diethyl squarate for the coupling of
oligosaccharide amines to carrier proteins and characterization of the resulting
neoglycoproteins by MALDI-TOF mass spectrometry. Glycoconj. 1. 1996, 13,315.
[7] S. J. Hou, R. Saksena, P. Kovac. Preparation of glycoconjugates by dialkyl squarate
chemistry revisited. Carbohydr. Res. 2008, 343, 196.
[8] J. Zhang, A. Yergey, J. Kowalak, P. Kovac. Studies towards neoglycoconjugates
from the monosaccharide detemlinat of Vibrio chlerae 0: 1 serotype Ogawa, using the
diethyl squarate reagent. Carbohydr. Res. 1998,313, 15.
223
[9] R. Saksena, X. Ma, P. Kovac. One-pot preparation of a series of glycoconjugates with
predetermined antigen-carrier ratio from oligosaccharides that mimic the O-PS of Vibrio
cholerae 0: I, serotype Ogawa. Carbohydr. Res. 2003, 338, 2591.
[10] A. Chemyak, A. Karavanov, Y. Ogawa, P. Kovac. Conjugating oligosaccharides to
proteins by squaric acid diester chemistry: rapid monitoring of the progress of
conjugation, and recovery of the unused ligand. Carbohydr. Res. 2001,330,479.
[II] X. Ma, R. Saksena, A. Chemyak, P. Kovac. Neoglycoconjugates from synthetic
tetra- and hexasaccharides that mimic the terminus of the O-PS of Vibrio cholerae 0: I,
serotype Inaba. Org. Biomo!. Chem. 2003, J, 775.
[12] R. Saksena, A. Chemyak, A. Karavanov, P. Kovac, in Methods Enzymol. Vol. 362,
Y. C. Lee and R. Lee (eds), Academic press, New York, 2003, p. 125.
[13] Hegediis G, Belai I, Szekacs A. Development of an enzyme-linked immunosorbent
assay (ELISA) for the herbicide trifluralin. Anal. Chim. Acta 2000, 421, 121.
[14] F. Jahouh, R. Saksena, D. Aiello, A. Napoli, G. Sindona, P. Kovac, 1. H. Banoub.
Glycation sites in neoglycoconjugates from the tenninal monosaccharide antigen of the
O-PS of Vibrio cho!erae 01, serotype Ogawa, and BSA revealed by matrix-assisted laser
desorption-ionization tandem mass spectrometry. 1. Mass Spectrom. 2010,45, 1148.
[15] N. D. Rawlings, A. J. Barrett. Families of serine peptidases. Methods Enzymol. 1994,
244,19.
[16] F. Jahouh, S. .J. Hou, P. Kovac, Banoub J. H. Determination of the glycation sites of
Bacillus anthracis neoglycoconjugate vaccine by MALDI-TOF/TOF-CID-MS/MS and
LC-ESI-QqTOF-tandem mass spectrometry. 1. Mass Spec/rom. 2011,46,993.
224
[17] J. M. Daubenspeck, H. Zeng, P. Chen, S. Dong, C. T. Steichen, . R. Krishna, D. G.
Pritchard, C. L. Turnbough. 1. BioI. Chern. 2004,279, 30945.
[18] G. R. Drapeau, Y. Boily, J. Houmard. Purification and properties of an extracellular
protease of StaphylococcLls aureus. 1. Bioi. Chern. 1972,247,6720.
[19] J. J. Birktoft, K. Breddam. Proteolytic enzymes: Glutamyl endopeptidases. Methods
Enzyrnol. 1994,244, 114.
[20] P. Roepstorff, J. Fohlman. Letter to the editors. BioI. Mass Spectrorn. 1984, 11,601.
[21] R.S. Johnson, S. A. Martin, K. Biemann, J. T. Stults, J. T. Watson. Novel
fragmentation process of peptides by collision-induced decomposition in a tandem mass
spectrometer: differentiation ofleucine and isoleucine. Anal. Chern. 1987,59,2621.
[22] B. Domon, C. Costello. A systematic nomenclature for carbohydrate fragmentations
in FAB-MS/MS spectra ofglycoconjugates. Glycoconj. 1. 1988,5,397.
[23] K. Arnold, L. Bordoli, J. Kopp, T. Schwede. The SWISS-MODEL Workspace: A
web-based environment for protein structure homology modelling. Bioin!orrnatics 2006,
22,195.
[24] M. C. Peitsch. Protein modeling by E-mail. BioI. Technol. 1995, 13,658.
225
CHAPTER 7: General conclusion
In this study, tandem mass spectrometry has been used for the analysis of
oligonucleotides and synthetic carbohydrate-protein neoglycoconjugate vaccines.
The ESl-QqTOF-MS analysis of the three constitutional isobaric I8-mer D A
oligomers (GATTCATAGCTACGAATC 1, AATTCGTAGCTACGAATC 2, and
AATTCGTACCTACGAATG 3) produced the same multiply-charged molecular ions.
We have shown that the CID-MS/MS analysis of the deprotonated molecular ions [M -
8H]8- at m/z 683.9881 and [M - 9H]9- at m/z 607.8775 pennitted us to establish their
sequences and the verification of the product ions obtained were confinned by using the
Mongo Oligo Mass Calculator. Furthennore, we reported that the CID-MS/MS of the
precursor ions isolated from each distinct oligonucleotide created characteristic product
ions which pennitted their differentiation and characterization. The CID-MS/MS studies
allowed us to define the mass spectrometry fingerprint of these three isobaric
oligonucleotides. This described work on these three oligonucleotides, was also
undertaken, for the elucidation of the adduction site of guanine by the carcinogen
retrorsine. The detection and quantification of the important biomarkers DNA adducts
obtained during the reaction between carcinogen and DNA (adduction reaction) reveals
the identity of the carcinogenic substances.!I] Thus, DNA adducts analysis is complicated
by their low abundance in DNA sample. This was found to range from 10 to 100
picomoles of adduct per milligram of DNA in animals, after treatment with tumorigenic
doses of carcinogensYJ It was found that mass spectrometry is a reliable technique for the
detennination, characterization and sequencing of intact DNA oligomer adducts, and thus
can be applied in routine analyses. l3]
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The second category of molecules that we analyzed pertained to synthetic
bacterial vaccines consisting of carbohydrate haptens conjugated to the BSA, which were
prepared by using the squaric acid chemistry. The development of carbohydrate
glycoconjugate vaccines against bacteria is considered to be a major advance in modem
medicine, since they are able to induce the eradication of the target disease.[4]
The main scientific "raison d'etre" and purpose for the analytical determination
of the glycation sites of the hapten-BSA glycoconjugate vaccines are for analytical
quality purposes, for checking the purity and to help to reveal the effect of the
localisation of the glycation sites on the induced immune response and the production of
specific well targeted antibodies. In addition, novel conjugation methods have been
developed for site-specific protein modification which can be applied for the production
ofvaccines.[5] The MS method that we used can thus be applied for the verification of the
conjugation at specific sites of the protein in these new vaccines.
The three models were studied: the Vibrio cholerae 0 I antigenic specific hapten
conjugated to the BSA, the tetrasaccharide side chain of the Bacillus anfhracis
exosporium conjugated to the BSA, and finally the model ~-D-galactopyranosyl-(1-+4)­
~-D-glucopyranoside(~-D-Iactoside) conjugated to the BSA.
The MALDI-TOF/TOF-MS analysis of the different synthetic carbohydrate-
protein neoglycoconjugates allowed us to reveal the average carbohydrate hapten:BSA
ratios.
The studies that we can'ied out for the glycation sites detennination in hapten-
protein glycoconjugate vaccines can be considered as innovative in the field of
carbohydrate-protein glycoconjugate vaccines characterization. The detennination of the
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glycation sites of the neoglycoconjugates was attempted using different strategies. We
have preferred the LC-ESI-QqTOF-MS/MS analysis to MALDI-TOF/TOF-MS/MS
analysis the of the trypsin and GluC V8 digests for the sequencing of the glycated
peptides. The sequencing of the glycated peptides was perfonned on the selected
precursor ions that did not match the peptides formed by the serum albumin protein in the
Mascot library.
In this thesis, it was always observed that the synthetic glycoconjugates were
composed of glycofonns. This was due to the reality that the number of glycation sites
was always higher than the average carbohydrate hapten:BSA ratios. For example, the
glycoconjugate consisting in the conjugation of the tetrasaccharide side chain of the
Bacillus anfhracis exosporium to the BSA with a hapten:BSA ratio of 5.4 revealed 30
glycation sites. The mass spectrometry analysis of the neoglycoconjugate formed by
conjugation of the antigenic monosaccharide hapten of Vibrio cholerae 0 I serotype
Ogawa to the BSA possessing a hapten:BSA ratio of 13.2: I revealed 33 glycation sites,
which was the highest number of glycation sites that we have observed amongst all the
different neoglycoconjugates. Finally, a total of 30 glycation sites were also observed for
the ~-D-Iactoside-BSA glycoconjugate vaccine model with a hapten:BSA ratio of 19.0: I.
We can thus conclude that an average of 30 glycation sites appears to be the maximum
number that we can detennine in the glycoconjugate vaccines prepared with the squaric
acid chemistry, regardless the hapten:BSA ratio.
In addition, we have observed in the GluC V8 digestion of the f3-D-lactoside-BSA
and the Vibrio cholerae 01 serotype Ogawa glycoconjugates, the fomlation of
glycopeptides having the same peptidic sequences, which can carry either one and/or two
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carbohydrate-haptens. This observation confinns the presence of glycofonns in the
synthetic neoglycoconjugates. It is noteworthy to mentjon that these di-glyctaed peptides
were fonned only when the hapten:BSA ratio was the highest during the synthesis of
each of these glycoconjugates. Therefore, we propose that this extra glycosylation of the
peptide occurs despite of the possible steric hindrance imposed by the presence on the
original neighboring glycosylated residue on the peptide.
It was also observed that the majority of the glycation sites in the three studied
vaccines were located in the outer surface of the BSA. The importance of this discovery
relies on the fact that the carbohydrate antigens are thus exposed and accessible to
interact with specific receptors located at the surface of B cells.
The carrier protein BSA was successfully identified after the submission of the
MS data to the Mascot library. The total sequence coverage for the hapten:BSA
glycoconjugates, which is an important parameter to consider in the proteomics field, was
found to be in the range of 90 % and sometimes higher. We thus concluded that our
method was reliable for the mass spectrometry analysis of carbohydrate-protein
glycoconjugate vaccines.
The CID-MS/MS analysis of the glycated peptides of each neoglycoconjugate
also exposed product ions specific to the carbohydrate-hapten portion carried by the
BSA, as well as product ions attributed to the fragmentation of the spacer [(C17H26N30/)
at m/z 336.19 and (CIIHI6N302f at m/z 222.11). It is interesting to note that the latter
were observed in the three different glycoconjugates and can constitute the fingerprint of
neoglycoconjugates prepared using the squaric acid chemistry.
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We propose in future work to use different activation methods to initiate the
fragmentation of the digested neoglycoconjugates, such as Electron Capture Dissociation
(ECD with a FTICR-MS) and Electron Transfer Dissociation (ETD with an Orbitrap MS)
which are known to fragment the glycopeptides only at their peptide backbone and leave
the carbohydrate portion intact.
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APPENDIX A
Additional Figures and tables for
CHAPTER 2: Differentiation and sequencing ofthree constitutional isobaric IS-mer
DNA oligomers using low-energy collision tandem mass spectrometry.
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[M.9HJ"
[M-8Hf
[M.10Hj'O-
mil
Figure A.1. ESI-QqTOfMS (negative mode) of the oligomer 1.
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Table A.I. Different specific product ions of the oligomer 1 obtained during the MSfMS
analysis of the [M - 8Ht anion at m/z 683.9881 and the [M - 9H]9- anion at m/z
607.8775.
100
Calculated Deviatioofor Deviatioofor
III/Z 1M - 8H)8- (ppm) 1M - 9H19- (ppm)
[d l -H20r 328.0016 50 9
[G9:c lOf 397.0420 -6 -4
W4' 411.3970 -7
W6 462.8200 -4
Ws 521.0810 -8
[T3:Csf 536.5610 -16
[a6- B( 544.7530 -23
[G9:T\,f 549.0650 -6
[G9:C\3( 566.4080 1
[T7:T\\( 571.4080 -16
[CS:G9(
[A6:CIO(
[T7:T\I)"" 574.4120 -2 -29
[As:A\2(
[T\\:A 1s(
[C\3:T17(
Y/ 577.6170 23
Ws4- 617.0960 -7
W6 617.4300 19
[a7- B( 649.1050 -4 -13
[M_A]s- 667.2300 -21 -22
[M-CHt 670.1060 -23
[as-Bf 673.1100 -13
[G9:G\4( 676.0920 -9
[aI2- Bt 696.9090 52 -15
YIO 751.6290 -16
[ds -H20f 768.6150 -3 -12
[a\6- Bt 787.9580 -I -1
[A\s:A\6r 803.1080 -11
[a6- Bf 817.6330 -16
[aI2- Bt 871.3890 -16
[d6 -H20f 925.1440 -15
W6 926.6490 -14
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[d.1- H20r 945.1470 -3 -9
[arSf 974.1620 -25
[T4:G9f
[~:Tl1f 1014.1450 -5
[T7:A 12f
[~:Asr 1107.1540 10 -9
[AI5:T17r
[as-Sf 1126.1850
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Table A.2. Different specific product ions of the oligomer 2 obtained during the MS/MS
analysis of the [M - 8H]8- anion at m/z 683.9881 and the [M - 9H]9- anion at m/z
607.8775.
Calculated Deviation for Deviation for
Ion
m/z IM-8HI8- IM-9HJ9-(DDm) (DDm)
[T4:Cst 384.539
[C1o:T11t
[T3:T4t 392.038 -21
[Az:TJt
[T7:Ast 396.544 12
[T11:Adz-
[A I6:Tl7lz-
[CS:G6t
[G9:C lOt 397.042
[C JJ :G I4t
[G 6:T7t 404.542
yz 530.127 -15
[Az:T4t 548.567
[G6:Ast 561.07 -49
[T7:G9t
[G I4:A I6t 565.576 4
[G9:C lJt 566.408 -3
[As:Ad1•
[T11:A1St 574.412
[C 1J :Tl7lJ-
[d4 - 616.095Hzof
[M- 665.105 -9GHls-
[Az:T7t 672.757 -6
[T,:Ast
[CS:C1ot
676.092
[G9:G I4t
[CIO:CIJt 685.59 8
Y7 695.127 -28
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[T,:G6f
701.088
[T4:T7f
[a,-Br 723.142 -9
[G6:G9f 725.596 -3
Y7 1043.195 -14
[G I4 :AI6r 1132.161 13 17
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Table A.3. Different specific product ions of the oligomer 3 obtained during the MS/MS
analysis of the [M - 8H]8- anion at mlz 683.9881 and the [M - 9Ht anion at mlz
607.8775_
Ion
Calculated Deviation for Deviation for
mlz 1M - 8H)8- (ppm) 1M - 9H1 9- (ppm)
[T,:T4f 392.0380 II
[T3 :T7t" 426.0510 -31
W6 472.8220 33
W7 551.0860
[G6:Asf 561.0700
[ag-st 562.5880 13
WI/- 616.9280 73
W105- 617.0950 -26
[G6:C I3t
651.0910 17 17
[T7:G I4t
WI5 660.3860 23
[M-AHt 667.1040
[aI5- S t 729.1140 -30
[M-At 762.6930 -15
[T4:C lOt
764.1050 -23
[C5:T11 t
WIO4- 771.6210 12
[A2:Ast 777.1090
[A I2 :C 13r 779.0970 -36
[A2:T11 t
803.1140
[T3:A I2t
Y9 906.1600 -7
[G6:T11 f
1002.1390 -28
[T4:c9f
[C9:T11 r 1059.1320 -14
[AI~:GI4r
1108.1490 12
[CI.1:A I5r
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Table A.4. Product ions common (isobarics and non isobarics) to the three oligomers
obtained during the MS/MS analysis of the [M - 8Ht anion at m/z 683.9881.
Oligomer] Oligomer 2 Oligomer 3
Ion Experimental Deviation Experimental Deviation Experimental Deviation
mass (ppm) Mass (ppm) mass (ppm)(Daltons) (Daltons) (Daltons)
[pd(T)r 303.0392 303.0396 -2 303.0470 -27
w/ 304.5429 304.5430 324.5523 19
WI 306.0488 306.0479 346.0610 20
[pd(A)r 312.0491 312.0490 312.0586 -27
[a2- Sr 426.0820 410.0818 -8 410.0853
2· 461.0687 -5 461.0684 -6 481.0689 -11W.1
[pd(C)pf)' 466.0367 -7 466.0402 466.0437
[pd(T)pf)' 481.0406 481.0410
[pd(A)pf)' 490.0512 490.0507 490.0594 17
[pd(G)pfT 506.0459 506.0474 506.0498
ws.1- 521.0813 521.0792 -3 534.4272 19
[T.1:c sf 536.5706 18 536.5631
[CS:T7f 541.0725 10 549.0629 -4 549.0675
[C,.1: A,sf
553.5673 -7 553.5689 -4 553.5813 19
[A I2:G I4f
[T7:G9t 561.0526 -31 561.0698
[C IO:G 14l" 568.4007 -13 566.4138 10
[T7:T1d.1- 571.4004 -13 571.4099
y/ 577.6099 -12 577.6193
W2 610.0910 -3 610.0934 650.0968 -5
W6 617.4181 -19 617.4261 -6 630.7709
[dr H20r 641.0936 -12 625.0860 -32
[M-CHt 670.0987 -11 670.0938 -18
[as-Sf 673.1054 -7 665.1079 -8 665.1061 -10
[T4:G9l" 675.7594 681.0911
[T11 :G I4f 705.5935 705.5939 705.5994
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[C 13:A I6f
710.0807 -26 710.0962 -4
[A I2 :A lSf
[a3- Sr 739.1342 -4 723.1356 -9
yt 742.1333 -13 742.1423
WI1 748.5498 748.5771 44
[ag-st 750.4478 -8 750.4530 750.4395 -19
[ClO:Tllr
770.0776 -II 770.0856 770.0639 -29
[T4:CSr
2· 782.1231 -4 782.1239 -3 802.1492 25Ws
[T,:T4r 785.0812 -5 785.0850 785.1037 24
[al6- S t 787.9272 -39 781.2867 -6
[A2:TJr
[T7:Agr
794.0972 794.1016 794.1041
[Tll :A l2r
[A 16:T17r
[C 13 :G I4r 795.0934 795.0970 795.0943
[a6- Sf 817.6290 -5 809.6368
[G I4:A lSr 819.1000 -4 819.1023
YJ 843.1699 -18 843.1886 883.1763 -17
[T3:T7f 845.1041 -II 853.1149
[C lO:G 14f 850.1224 850.1313 18
[T7:Tll f 857.6094 -8 857.6186 837.6124
[Ag:A 12f
862.1096 -27 862.1236
[Tll:AlSf
[al2- St 871.3856 -4 861.3868
Yo 886.6554 -12 886.6712
W, 923.1469 -4 923.1490 -2 963.1609
W6 926.6393 -10 926.6501
[a7-Bf 974.1417 -21 974.1552 -7
[A2:T7f
1001.6314 -II 1009.6401
[TJ:Agf
[a4- Br 1043.1860 1027.1830 -4
[T,:Csr 1074.1331 1074.1372 1074.1335
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[C IO:A I2r
1083.1411 -2 1083.1433 1083.1198 -21
[T11 :C J3r
[A2:T4r 1098.1627 18 1098.1458 1098.1663 21
[C Jl :A I5r
1108.1528 1108.1628 12
[A I2 :G I4r
[T7:G9r 1123.1372 -II 1123.1597 10
lag-Sf 1126.1601 -22 1126.1752 -9
Y4 1156.2282 -12 1156.2388 -3
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Table A.S. Product ions common (isobarics and non isobarics) to the three oligomers
obtained during the MS/MS analysis of the [M - 9Ht anion at m/z 607.8775.
Oligomerl Oligomer] Oligomer 3
Ion Experimental Deviation Experimental Deviation Experimental Deviation
mass (ppm) Mass (ppm) mass (ppm)(Daltons) (Daltons) (Daltons)
[pd(T)r 303.0392 303.0389 303.0364
2· 304.5428 304.5426 324.5525 20W2
WI 306.0502 306.0476 346.0505 -10
[pd(A)r 312.0483 312.0498 312.0489
[32- Br 426.0780 -5 410.0795 -13
WI 461.0683 -6 461.0740
[pd(C)pfT 466.0372 -6 466.0410 466.0392 -2
[pd(T)pfT 481.0394 481.0434 481.0419
[pd(A)pfT 490.0458 -11 490.0536 490.0536
[pd(G)pfT 506.0415 -9 506.0486 506.0497
[CS:T7f 541.0697 549.0676
W2 610.0859 -12 610.0950 650.0981 -3
Ws 617.0860 -16 617.0913 -8
[d2 -H20r 641.0889 -19 625.1073 625.0925 -22
[T4:T7f 693.0824 -11 701.0920
[T1, :G ,4f 705.5829 -14 705.5988 705.5646 -40
[A ,2 :A,sf
710.0799 -27 710.0987
[C\):A ,6f
(3)- Br 739.1292 -11 723.1482 723.1172 -34
Ys 742.1295 -18 742.1401 -4
[T4:CSr
770.0816 -6 770.0897 770.0782 -10
[C IO:T1d'
2- 782.1193 -9 782.1170 -12Ws
[T):T4r 785.0712 -18 785.0929 10 785.0917
[A2:T1r 794.0880 -II 794.0977 794.1093 15
[T7:AsJ'
[T I1 :A I2J'
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[A 16:T17r
[C13 :G I4r 795.0903 -2 795.0998 10 795.1089 21
[A1S:AI6r 803.1005 -9 803.1113
[G6:T7r 810.1019 12 810.1115 24
[G I4:A1Sr 819.1042 819.1064 819.0710 -39
Y3 843.1642 -25 843.1850 883.1971
[T3:T7f 845.1009 -14 853.1120
[C IO:G I4f 850.1005 -18 850.0952 -24
[T7:T11f 857.6033 -15 857.6394 27
[As:A 12f
862.1038 -21 862.1391 20
[T 11 :A 1Sf
Y6 886.6485 -20 886.6599 -7
W3 923.1414 -10 923.1549 963.1358 -22
[a4- 8 r 1043.1532 -29 1027.1883
[T.,:Csr 1074.1156 -14 1074.1291 -2 1074.1153 -15
[C IO:AI2r 1083.1379 -5 1083.1436 1083.1611 17
[A2:T4r 1098.1356 -7 1098.1530
[G9:T11 r 1099.1149 -18 1099.1452
[As:ClOr
[A12 :G I4r 1108.1247 -22 1108.1650 14
[C 13 :A 1Sr
[T7:G9r 1123.1278 -19 1123.1557
Y4 1156.2161 -22 1156.2549
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APPENDIX B
Additional Figures and Tables for
CHAPTER 3: Glycation sites in neoglycoconjugates from the terminal
monosaccharide antigen ofthe O-PS of Vibrio cholerae OJ, serotype Ogawa, and
BSA revealed by matrix-assisted laser desorption-ionization tandem mass
spectrometry
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Figure B.1. MALDI-TOF/TOF-MS analysis of the hapten-BSA neoglycoconjugates
with a hapten:protein ratio of6.6 (a) and 13.2 (b).
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Table B.1. MALDI-TOF/TOF-MS/MS of the glycated peptide SLGK*YGTR at m/z
1330.72.
Observed Calculated Deviation
Ion
mlz mlz (Da)
[M+Hf 1332.4247 1330.7213 1.7034
[M +H -cH4f 1314.6834 1314.69 -0.0066
[M + H - CIIHI9N06f 1069.5933 1069.6 -0.0067
[M + H - CIIHI9N06 - NHJf 1052.5676 1052.5623 0.0053
[Ys-CH20 2f 1027.5660 1027.5782 -0.0122
[Z6 - CIlHl9N06f 852.4828 852.4579 0.0249
[bs - CIlHl9N06f 737.4564 737.4198 0.0366
[b4- CIIHl9N06f 638.3859 638.3513 0.0346
[a4 - ClsH2gN07r· 537.3314 537.2905 0.0409
[K*YGT - CI9HJ4N20gf 438.2656 438.2347 0.0309
Y4 432.2989 432.2565 0.0424
C,sHJoNO/ 336.2110 336.2017 0.0093
YJ 333.2013 333.1881 0.0132
Y2 276.1725 276.1666 0.0059
CIIH20N06+ 262.1366 262.1290 0.0076
CIlHlgNO/ 244.1309 244.1179 0.0130
YI 175.1199 175.1190 0.0009
C6HgNOJ+ 142.0679 142.0499 0.0180
[YI-CH20 2f 129.1205 129.1135 0.0070
[zl-CH20 2r 112.0758 112.0869 -0.0111
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Table B.2. MALDI-TOFITOF-MS/MS of the glycated peptide ALK* AWSVAR at m/z
1514.82.
Ion
Observed Calculated Deviation
mlz mlz (Da)
[M+HJ' 1517.8384 1514.8213 3.0171
[M + H - C.1H60 2J' 1440.0994 1440.7845 -0.6851
[M + H - CIIHI9N06f 1253.6884 1253.7001 -0.0117
[M + H - CIIH20N07·r 1236.6424 1236.6973 -0.0549
[M + H - C19H36N20SJ' 1092.5640 1092.5585 0.0055
[C7 - C17H3INOsf 909.5271 909.4941 0.0330
[bs - CIIHI9N06f 822.5058 822.4514 0.0544
[as - CIIHI9N06f 794.4930 794.4565 0.0365
[a6 - CI9H3SN1OSr- 723.4375 723.3704 0.0671
Y6 689.3879 689.3729 0.0150
[as - Cl9H3SN20sf 636.4226 636.3384 0.0842
Ys 618.3445 618.3358 0.0087
[b3- CIIHI9N06J' 565.3745 565.3350 0.0395
Y4 432.2845 432.2565 0.0280
Y3 345.2283 345.2245 0.0038
ClsH30N07' 336.2042 336.2017 0.0025
CIIH20N06+ 262.1406 262.1290 0.0116
Y2 246.1630 246.1561 0.0069
C,IHISNOs+ 244.1282 244.1179 0.0103
YI 175.1198 175.1190 0.0008
[YI-C02r 129.1129 129.1135 -0.0006
[zl-CH101f 112.0862 112.0869 -0.0007
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Table 8.3. MALDI-TOFffOF-MS/MS ofthe glycated peptide K*VPQVSTPTLVEVSR
atm/z2153.16.
Ion Observed Calculated Deviation
mlz mlz (Da)
[M+Hf 2153.6801 2153.1700 0.5101
[M + H - C2HsOJ' 2108.1530 2107.1281 1.0249
[M + H - CIIHI9N06J' 1892.0073 1892.0487 -0.0414
YIJ 1412.7814 1412.7744 0.0070
ZIJ 1396.8246 1396.7562 0.0684
YII 1187.7466 1187.6630 0.0836
YIO 1088.6348 1088.5946 0.0402
Y9 1001.6400 1001.5626 0.0774
Ys 900.5673 900.5149 0.0524
Zs 884.5682 884.4967 0.0715
[bs - C7HuNOJJ' 804.5096 804.4620 0.0476
Y7 803.5045 803.4621 0.0424
[b4- CI1HI9N06J' 705.4496 705.3935 0.0561
Y6 702.4599 702.4145 0.0454
Ys 589.3736 589.3304 0.0432
C2.1HJsNJOIO+· 513.3080 513.2317 0.0763
C23HJJNJ09+' 495.2560 495.2211 0.0349
Y4 490.2816 490.2620 0.0196
[b2- CII HI9N06J' 480.3265 480.2817 0.0448
[b4- C2JHJ6NJOlOr· 452.3134 452.2742 0.0392
CI9HJoN.107- 412.2450 412.2078 0.0372
YJ 361.2359 361.2194 0.0165
C1s H.1oNO/ 336.2131 336.2017 0.0114
[bJ - C2.1HJsNJOIOJ' 325.2255 325.2234 0.0021
CISH26NJO/ 312.2119 312.1918 0.0201
raj - C2JH.1SNJOIOJ' 297.2130 297.2285 -0.0155
Y2 262.1570 262.1510 0.0060
C11H1SNO/ 244.1331 244.1179 0.0152
[b2- C2.1H.17NJO IOJ' 226.1504 226.1556 -0.0052
Yl 175.1199 175.1190 0.0009
[YI-CH20 2J' 129.1108 129.1135 -0.0027
[zl-CH20 2J' 112.0833 112.0869 -0.0036
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APPENDIX C
Additional Figures and Tables for
CHAPTER 4: Determination of the glycation sites of Bacillus aflfhracis
neoglycoconjugate vaccine by MALDI-TOFrrOF-CID-MS/MS and LC-ESI-
QqTOF-tandem mass spectrometry
248
(a) BSA
100
[M + 2Ht
33161.81
[M + Hj+
56318.88
(b) Hapten-BSA
100
.~ 60
] 50
[M + H]
71448.36
Figure c.1. MALDI-TOF/TOF-MS analysis of (a) the BSA and (b) the hapten-BSA glycoconjugate.
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Figure C.2. MALDI-TOF/TOF-MS/MS spectra of the glycated peptide VTK*CCTESLVNR (Lys
498) at m/z 2416.1372.
250
[M+H-N~r
3461.6979
200400600 800 10001200140016001800200022002400260028003000320034003600
mlz
Figure C.3. MALDI-TOF/TOF-MS/MS spectra of the glycated peptide
QNCDQFEK*LGEYGFQNALIVR (Lys 420) at m/z 3478.6429.
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Figure CA. MALDI-TOF/TOF-MS/MS spectra of the glycated peptide LCK*YASLRE (Lys
100) at mlz 2025.0186.
252
vJdv~vJ~~'~YKjE
a,' b; b: b: b6' ba' b,' b,o' bll '
a; a,' a;
100%
95%
90%
85%
80%
75%
70%
65%
60%
55%
50% 5" ~
45% I ,_
40% ,rS:::~~i~ ~
25%2i~;:!;~
20% g~
15% ;~
10% ~
5%
;:-
-;
>=' co
"
8
[))
il: ~if)
·146~ " -}[))
" '£ '"2J co ~J ~
~ cDr. ~ -146
'+
.!! 1;6
[M+Hr
2311.5595
200 400 600 800 1000 1200 1400 1600 1800 2000 2200 2400
mlz
Figure C.S. MALDI-TOF/TOF-MS/MS spectra of the glycated peptide
YAVSVLLRLAK*E (Lys 374) at m/z 2311.2476.
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Figure C.6. MALDI-TOF/TOF-MS/MS spectra of the glycated peptide
YAVSVLLRLAK*EYE (Lys 374) at m/z 2603.3484.
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Table C.l. Tryptic peptides identified in the two serum albumin protein isofonns by MALDI-TOF/TOF-MS analysis of the hapten-
BSA glycoconjugate. The experimental values were obtained after recalibration of the spectra.
Serum
Observed Calculated Accuracy Missed Serum albumin
albumin precursor Unique Peptide
mlz mlz ppm cleavage Bostaurus Bostaurus(giI74267962) (giI1351907)
847.5055 847.5041 -2 1 ,j ,j LSQKFPK
898.4808 898.4820 I 0 ,j ,j LCVLHEK
922.4853 922.4885 4 0 ,j ,j AEFVEVTK
927.4940 927.4940 0 0 ,j ,j YLYEIAR
1014.6208 1014.6199 -I 0 ,j ,j QTALVELLK
1138.5020 1138.4985 -3 0 ,j ,j CCTESLVNR
1142.7170 1142.7149 -2 1 ,j ,j KQTALVELLK
1163.6336 1163.6312 -2 0 ,j ,j LVNELTEFAK
1193.6064 1193.6027 -3 I ,j ,j DTHKSEIAHR
1249.6228 1249.6217 -I I ,j ,j FKDLGEEHFK
1283.7148 1283.7112 -3 0 ,j ,j HPEYAVSVLLR
1305.7177 1305.7167 -I 0 ,j ,j HLVDEPQNLIK
1419.6945 1419.6942 0 0 ,j ,j SLHTLFGDELCK
1439.8139 1439.8123 -I I ,j ,j RHPEYAVSVLLR
1479.7977 1479.7960 -I 0 ,j LG EYGFQNALI VR
1532.7783 1532.7816 2 1 ,j ,j LKECCDKPLLEK
1537.8041 1537.8014 -2 0 ,j U LGEYGFQNELIVR
1554.6639 1554.6535 -7 0 ,j ,j DDPHACYSTVFDK
1567.7471 1567.7433 -2 0 ,j ,j DAFLGSFLYEYSR
1576.7635 1576.7681 3 0 V V LKPDPNTLCDEFK
1639.9417 1639.9383 -2 1 V V KVPQVSTPTLVEVSR
1661.9224 1661.8718 -30 2 V V GACLLPKJETMREK
1694.8245 1694.8246 0 0 V U MPCAEDYLSLILNR
1724.8353 1724.8351 0 0 V MPCTEDYLSLILNR
1880.9275 1880.9216 -3 0 V V RPCFSALTPDETYVPK
1901.8758 1901.8703 -3 1 V V NECFLSHKDDSPDLPK
1907.9231 1907.9213 -1 0 V V LFTFHADICTLPDTEK
1927.8001 1927.7988 -I 1 V V CCAADDKEACFAVEGPK
1951.0130 1951.0158 1 1 V V ALK*AWSVAR (Lys 235)
2019.9644 2019.9697 3 1 V V LKPDPNTLCDEFKADEK
2045.0307 2045.0285 -I 1 V V RHPYFYAPELLYYANK
2113.8960 2113.8853 -5 1 V V VHKECCHGDLLECADDR
2247.9470 2247.9433 -2 1 V V ECCHGDLLECADDRADLAK
2416.1372 2416.1357 -1 1 V V VTK*CCTESLVNR (Lys 498)
2458.1766 2458.1812 2 1 V V DAIPENLPPLTADFAEDKDVCK
2492.2653 2492.2648 0 0 V V GLVLIAFSQYLQQCPFDEHVK
2541.1679 2541.1680 0 2 V V QEPERNECFLSHKDDSPDLPK
2612.1872 2612.1655 -8 2 V V VHKECCHGDLLECADDRADLAK
3250.5163 3250.4681 -15 2 V TVMENFVAFVGKCCAADDKEACFAVEGPK
3478.6429 3478.6458 1 1 V QNCDQFEK*LGEYGFQNALIVR(Lys420)
3511.6771 3511.6725 -1 2 V V SHCIAEVEKDAIPENLPPLTADFAEDKDVCK
Table C.2. Peptides identified in the two serum albumin protein isofonns by MALDl-TOFrrOF-MS analysis of the digested hapten-
BSA glycoconjugate with the endoproteinase Glue V8. The experimental values were obtained after recalibration of the spectra.
Serum SerumObserved Calculated Accuracy Missed albumin
albumin precursor Unique Peptide
1/1/: m/z ppm cleavage Bostaurus Bostaurus(giI74267962) (giI1351907)
838.4787 838.4787 0 0 HVKLVNE
844.4019 844.3987 -4 0 KSHCIAE
848.4568 848.346 -131 1 PNTLCDE
854.5126 854.51 -3 0 LTKVHKE
944.4718 944.4702 -2 0 YSRRHPE
978.505 978.5049 0 0 KLFTFHAD
1003.3963 1003.3977 1 1 CCHGDLLE
1017.4364 1017.5369 99 0 KSLHTLFGD
1025.4248 1025.4032 50 0 KYTKCCTE
1029.4978 1029.4965 -I 2 KQEPERNE
1034.4639 1034.4651 1 1 CCDKPLLE
1040.4626 1040.4722 9 1 FAKTCYADE
1069.5166 1069.5206 4 1 ETYYPKAFD1069.5206 4 1 TYVPKAFDE
1075.5958 1075.5934 -2 0 LCKYASLRE
1146.5792 1146.5795 0 1 KSLHTLFGDE
1243.6739 1243.672 -2 1 DKGACLLPKIE
1284.7502 1284.7527 2 0 GPKLYYSTQTALA
1293.7541 1293.753 -I 1 LLKHKPKATEE
1314.6833 1314.6806 -2 2 IAHRFKDLGEE
1315.7303 1315.6316 -75 1 KSHCIAEYEKD
1360.6739 1360.6789 4 1 AKDAFLGSFLYE
1383.6659 1383.6466 -14 2 LTEFAKTCYADE
1519.7811 1519.781 0 0 IARRHPYFYAPE
1653.9224 1653.9216 0 1 YAVSVLLRLAKEYE
1721.8452 1721.8539 5 0 LLYYANKYNGVFQE
1742.8396 1742.9627 71 0 YLSLlLNRLCVLHE
1857.9968 1857.9897 -4 I DYLSLlLNRLCVLHE
1907.9236 1907.9213 -1 2 KLFTFHADICTLPDTE
1934.9962 1934.9904 -3 0 VSRSLGKVGTRCCTKPE
1962.0323 1962.037 2 1 ACFAVEGPKLVVSTQTALA
2025.0186 2025.0195 0 0 LCK*VASLRE (Lys 100)
2311.2476 2311.2418 -3 0 YAVSVLLRLAK*E (Lys 374)
2467.1422 2467.1451 1 4 NLPPLTADFAEDKDVCKNYQE
2603.3484 2603.3477 0 1 YAVSVLLRLAK*EYE (Lys 374)
2879.5814 2879.5783 -I 0 U YGFQNALIVRYTRKVPQVSTPTLVE
2912.4256 2912.4252 0 3 "j SLVNRRPCFSALTPDETYVPKAFDE
2941.348 2941.3752 9 2 VSRSLGKVGTRCCTKPESERMPCTE
Table C.3. MALDI-TOF/TOF-MS/MS analysis of the glycated peptide ALK*AWSVAR
(Lys 235) at m/z 1951.0130.
Molecular ion Calculated Experimental Deviation (Da)
mlz mlz
[M+Hf 1951.0158 /951.0180 0.0022
[M+H-CH20r 1921.0052 1921.0932 0.0880
[M + H - CHIOO,r 1880.9528 1881.1765 0.2237
y. 1691.8738 1691.8829 0.0091,
Y2· 1545.8159 1545.8376 0.0217
Y I+ 1399.758 1399.7768 0.0188
[Y7- B2r 1361.6947 1361.7265 0.0318
Yo· 1253.7001 1253.7010 0.0009
[YO -NH3r 1236.6735 1236.6813 0.0078
[b.l- CSHI1 N02r 1145.5711 1145.5757 0.0046
[b4 -B4r 636.3715 636.2715 -0.1000
Ys 618.3558 618.2805 -0.0753
[b3-B4r 565.3442 565.2661 -0.0781
Y.l 345.2245 345.1345 -0.0900
C17H26N30/ 336.1918 336.1242 -0.0676
BI+ 260.1492 260.0739 -0.0753
Y2 246.1561 246.0775 -0.0786
[BI-Hpr 242.1387 242.0709 -0.0678
2.sAI + 230.1387 230.0719 -0.0668
Z2 229.1306 229.0569 -0.0737
CIIHI6N30/ 222.1237 222.0670 -0.0567
[CI -C3H70r 202.1074 202.0350 -0.0724
YI 175.119 175.0651 -0.0539
[CI - CsHII N02r 159.0652 159.0486 -0.0166
[YI-CH20 2r 129.1134 129.0679 -0.0455
[zl-CH20 2f 112.0869 112.0527 -0.0342
[zl-CH40 2f 110.0713 110.0414 -0.0299
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Table CA. MALDI-TOFrrOF-MS/MS analysis of the glycated peptide LCK*YASLRE
(Lys 100) at mlz 2025.0186.
Molecular ion Calculated Experimental Deviation
mlz mlz Da
[M+Hr 2025.0195 2024.5149
-0.5046
[M + H - CH20 2f 1979.0141 1978.9469
-0.0672
[M + H - C4HIOO - CH4f 1934.9151 1935.0632 0.1481
Zg 1894.9089 1894.9465 0.0376
Y/ 1765.8776 1765.8924 0.0148
Y/ 1619.8197 1619.8220 0.0023
Y I+ 1473.7618 1473.7520
-0.0098
Yo+ 1327.7038 1327.7091 0.0053
[Yo-NH,l' 1310.6773 1310.6732
-0.0041
[b6-B4f 911.4661 911.4274
-0.0387
[bs -B4f 824.434 824.3805
-0.0535
[b4-B4f 753.3969 753.3832
-0.0137
Y6 674.3832 674.3556
-0.0276
[b,-B4f 654.328 654.3269
-0.0011
Ys 575.3148 575.3475 0.0327
[zs-NH,f 541.2617 541.2237
-0.0380
Y4 504.2776 504.2357
-0.0419
[K*V-B4l' 452.2867 452.3055 0.0188
y, 417.2456 417.2095
-0.0361
CI7H16N,04- 336.1918 336.2023 0.0105
Yl 304.1615 304.1637 0.0022
Zl 287.135 287.1116
-0.0234
B I + 260.1492 260.1505 0.0013
[B I -H2O]' 242.1387 242.1599 0.0212
C I1 HI6N,Ol+ 222.1237 222.1627 0.0390
[C I -C,I-l70r 202.1074 202.1093 0.0019
C7H1.10 1+ 129.091 129.1094 0.0184
[bl - H1r 112.0757 112.0950 0.0193
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Table C.S. Tryptic peptides identified in the two serum albumin protein isofonns by LC-ESI-QqTOF-MS/MS analysis of the hapten-
BSA glycoconjugate.
Precursor Serum SerumDeviation Missed albumin
mlz Mr(expt) Mr(calc) albumin precursor Unique Peptide
(charge) Da cleavage Bostaurus Bostaurus(giI74267962) (gil13S1907)
507.8123 (+2) 1013.6101 1013.6121 -0.0020 0 'Ii QTALYELLK
571.8600(+2) 1141.7055 1141.707 -0.0015 1 --J KQTALYELLK
625.3159(+2) 1248.6172 1248.6139 0.0033 1 --J FKDLGEEHFK
642.3654(+2) 1282.7162 1282.7034 0.0128 0 --J HPEYAYSYLLR
653.3464(+2) 1304.6783 1304.7088 -0.0305 0 'Ii HLYDEPQNLIK
671.3491 (+2) 1340.6836 1340.6799 0.0037 0 U TYMENFYAFYGK
700.3522(+2) 1398.6899 1398.6853 0.0045 0 'Ii TYMENFYAFYDK
708.3502 (+2) 1414.6859 1414.6803 0.0057 0 ~ TYMENFYAFYDK + Oxidation(M)
710.3493 (+2) 1418.6841 1418.6864 -0.0023 0 'Ii 'Ii SLHTLFGDELCK
710.7665 (+2) 1419.5184 1419.5105 0.008 0 'Ii U ETYGDMADCCAK
720.4098(+2) 1438.805 1438.8045 0.0006 1 'Ii 'Ii RHPEYAYSYLLR
722.3251 (+2) 1442.6356 1442.6347 0.0009 0 --J --J YICDNQDTISSK
739.7664(+2) 1477.5182 1477.516 0.0023 0 --J ETYGDMADCCEK
756.4284(+2) 1510.8422 1510.8355 0.0066 0 'Ii YPQYSTPTLYEYSR
769.4033 (+2) 1536.7921 1536.7936 -0.0016 0 U LGEYGFQNELIYR
516.3047(+2) 1545.8924 1545.8878 0.0046 1 'Ii LKHLYDEPQNLIK
777.8271 (+2) 1553.6396 1553.6457 -0.0061 0 'Ii DDPHACYSTYFDK
784.377(+2) 1566.7395 1566.7354 0.0041 0 'Ii DAFLGSFLYEYSR
788.8923 (+2) 1575.7701 1575.7603 0.0098 0 --J LKPDPNTLCDEFK
820.4754(+2) 1638.9363 1638.9305 0.0058 1 --J KYPQYSTPTLYEYSR
847.9184(+2) 1693.8223 1693.8167 0.0055 0 U MPCAEDYLSLILNR
862.9237(+2) 1723.8328 1723.8273 0.0055 0 'Ii MPCTEDYLSLILNR
870.9194(+2) 1739.8243 1739.8222 0.0021 0 ,j MPCTEDYLSLILNR + Oxidation(M)
874.3575 (+2) 1746.7004 1746.6978 0.0027 0 YNGVFQECCQAEDK
583.8934(+2) 1748.6585 1748.6553 0.0033 0 ECCHGDLLECADDR
599.2800(+2) 1794.8182 1794.8247 -0.0065 1 DDPHACYSTVFDKLK
940.9644(+2) 1879.9142 1879.9138 0.0004 0 RPCFSALTPDETYVPK
944.9757(+2) 1887.9368 1887.9195 0.0173 0 HPYFYAPELLYYANK
634.6273 (+3) 1900.8601 1900.8625 -0.0025 1 NECFLSHKDDSPDLPK
636.6473 (+3) 1906.92 1906.9135 0.0065 0 LFTFHADICTLPDTEK
643.2729 (+3) 1926.797 1926.791 0.006 1 CCAADDKEACFAVEGPK
673.9933 (+3) 2018.9582 2018.9619 -0.0037 1 LKPDPNTLCDEFKADEK
682.3489(+3) 2044.0249 2044.0206 0.0042 1 RHPYFYAPELLYYANK
705.2984(+3) 2112.8733 2112.8775 -0.0042 1 VHKECCHGDLLECADDR
706.6155 (+3) 2116.8246 2116.8136 0.011 1 U ETYGDMADCCEKQEPER
749.9835 (+3) 2246.9288 2246.9354 -0.0067 1 v ECCHGDLLECADDRADLAK
820.0702(+3) 2457.1887 2457.1733 0.0153 1 v AIPENLPPLTADFAEDKDVCK
831.4255(+3) 2491.2546 2491.257 -0.0024 0 -V GLVLIAFSQYLQQCPFDEHVK
1013.4318 (+3) 3037.2735 3037.2416 0.0319 1 ,j ,j YEATLEECCAKDDPHACYSTVFDK
Table C.6. LC-QqTOF-MS/MS analysis of the glycated peptide CCTK*PESER (Lys
463) at m/z 1058.4652 (+2).
Production Calculated Observed Deviation
mlz mlz (Da)
V/ 1856.7776 1856.7628 -0.0148
V2+ 1710.7197 1710.7332 0.0135
V I- 1564.6618 1564.6742 0.0124
Vo' 1418.6039 1418.6321 0.0282
[Y7- B4f 1098.5426 1098.5412 -0.0014
[Y6- B4f 997.4949 997.4909 -0.0040
[b4- B4f 802.3228 802.3246 0.0018
Ys 617.2889 617.2909 0.0020
Y4 520.2362 520.2245 -0.0117
b/ 422.1168 422.1208 0.0040
B/ 406.2077 406.2071 -0.0006
Y.1 391.1936 391.1922 -0.0014
C17H26N.10 / 336.1918 336.1908 -0.0010
b/ 321.0681 321.0646 -0.0035
Y2 304.1615 304.1593 -0.0022
C1- 276.1442 276.1435 -0.0007
B1+ 260.1492 260.1460 -0.0032
[B 1 -H2t 258.1336 258.1313 -0.0023
[B I -H2Of 242.1387 242.1354 -0.0033
CII H I6N.10 2- 222.1237 222.1184 -0.0053
[C I -C.1H70f 202.1074 202.1034 -0.0040
2.4AI + 184.0968 184.0928 -0.0040
YI 175.1190 175.1144 -0.0046
[B I - CSHg0 2r 160.0968 160.0945 -0.0023
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Table C.7. Peptides identified in the two serum albumin protein isofonns by LC-ESI-QqTOF-MS/MS analysis of the hapten-BSA
glycoconjugate digested with the endoproteinase GluC V8.
Precursor Serum SerumDeviation Missed albumin
mlz Mr(expt) Mr(calc) albumin precursor I Unique Peptide
(charge) Da cleavage Bosfaurus Bosfaurus(giI74267962) (giI1351907)
489.7625 977.5104 977.4971 0.0134 0
" "
KLFTFHAD(+2)
535.2620 1068.5095 1068.5128 -0.0033 1
" "
TYVPKAFDE(+2)
573.7933 1145.5720 1145.5717 0.0003
" "
KSLHTLFGDE(+2)
0\
611.2009 1220.3872 1220.3784 0.0088 2
"
TYGDMADCCE
~ (+2)
622.3434 1242.6723 1242.6642 0.0081
" "
DKGACLLPKIE(+2)
642.8832 1283.7519 1283.7449 0.007 0
" "
GPKLVVSTQTALA(+2)
680.8517 1359.6888 1359.6711 0.0177 1
" "
AKDAFLGSFLYE(+2)
681.3677 1360.7208 1360.7179 0.0029 0
" "
KKFWGKYLYE(+2)
760.3999 1518.7853 1518.7731 0.0122 0
" "
IARRHPYFYAPE(+2)
773.3853 1544.7561 1544.7358 0.0202 3
" "
NLPPLTADFAEDKD(+2)
537.6603 1609.9591 1609.9403 0.0188
" "
VTKLVTDLTKVHKE(+2)
861.4378 1720.8611 1720.8460 0.0151 0
" "
LLYYANKYNGVFQE(+2)
6109461 1829.8163 1829.8077 0.0087 2
"
U NFVAFVGKCCAADDKE(+3)
931.4739 1860.9332 1860.9152 0.018 1 "j "j SLVNRRPCFSALTPDE(+3)
630.2817 1887.8233 1887.8131 0.0102 3 "j NFVAFVDKCCAADDKE(+3)
954.4680 1906.9214 1906.9135 0.0079 2 "j "j KLFTFHADICTLPDTE(+3)
973.3785 1944.7424 1944.7441 -0.0017 "j "j CCAKDDPHACYSTVFD(+3)
709.3707 2125.0901 2125.0725 0.0177 2 "j "j LAKYICDNQDTISSKLK(+3) E
725.3025 2172.8856 2172.8510 0.0346 3 "j U TYGDMADCCAKQEPER(+3) NE
730.6347 2188.8822 2188.8459 0.0362 3 "j U TYGDMADCCAKQEPER(+3) NE + Oxidation (M)
0\ 1866.1225 2595.3457 2595.3115 0.0342 2 "j "j KLKHLVDEPQNLIKQNC(+3) DQFE
960.5398 2878.5976 2878.5705 0.0271 0 "j u YGFQNALIVRYTRKVPQ(+3) VSTPTLVE
971.4907 2911.4504 2911.4174 0.033 3 "j "j SLVNRRPCFSALTPDETY(+3) VPKAFDE
Table e.s. LC-QqTOF-MS/MS analysis of the glycated peptide K*YTKCCTE (Lys 495)
at m/z 987.9658 (+2).
Production Calculated Observed Deviation
m/z m/z (Da)
Y/ 1569.7023 1569.6618 -0.0405
YI+ 1423.6443 1423.6440 -0.0003
Yo' 1277.5854 1277.5919 0.0065
[YO-H20f 1259.5764 1259.5710 -0.0054
[b7 -B4f 1130.5338 1130.5222 -0.0116
[bs -B4f 869.4555 869.4469 -0.0086
Yo 798.312 798.3099 -0.0021
[b4 -B4f 709.4243 709.4351 0.0108
Ys 697.2644 697.2727 0.0083
[b3 -B4f 581.3293 581.3174 -0.0119
Y4 569.1694 569.1620 -0.0074
[b2 -B4f 480.2817 480.2884 0.0067
Y3 409.1388 409.1308 -0.0080
B/ 406.2077 406.2084 0.0007
C17H2oN3O/ 336.1918 336.1892 -0.0026
CI+ 276.1442 276.1415 -0.0027
BI+ 260.1492 260.1460 -0.0032
[B I -H2f 258.1336 258.1307 -0.0029
Y2 249.1081 249.1040 -0.0041
[B I -H2Of 242.1387 242.1380 -0.0007
[C I -C3H70f 202.1074 202.1047 -0.0027
2.4
AI
+ 184.0968 184.0948
-0.0020
[B I - cSHSo2f 160.0968 160.0912 -0.0056
YI 148.0604 148.0559 -0.0045
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APPENDIX D
Additional Figures and Tables for
CHAPTER 6: Determination of glycation sites by tandem mass spectrometry in a
synthetic lactose-BSA conjugate, a vaccine model prepared by dialkyl squarate
chemistry
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Figure 0.1. MALDI-TOF/TOF-MS analysis of the BSA (a) and the lactose-BSA
glycoconjugates at the following ratios: 5: I (b) and 19: 1 (c).
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Table 0.1. LC-ESI-QqTOF-MS/MS analysis of the glycated peptide SLGK*YGTR (Lys
455) at mlz 697.3748 (+2).
Molecular ion Calculated Experimental Deviation
mlz mlz Da
YI + 1231.6529 1231.6639 0.0110
Yo+ 1069.6000 1069.6055 0.0055
[b7 -B2l' 895.4889 895.4260 -0.0629
[Y6- B2l' 869.4839 869.4918 0.0079
[Ys- B2r 812.4625 812.4715 0.0090
[b6-B2l' 794.4412 794.4752 0.0340
[bs -B2l' 737.3198 737.4277 0.1079
[bs -B2-H20l' 719.4087 719.3841 -0.0246
[as-B2l' 709.4243 709.4391 0.0148
[b4 -B2l' 638.3514 638.3549 0.0035
Yo2+ 535.3037 535.3109 0.0072
[YO -H2OJ2+ 526.2984 526.3004 0.0020
Y4 432.2565 432.2579 0.0014
[Y6- B2- H2OJ2+ 426.2404 426.2460 0.0056
C17H26N3O/ 336.1918 336.1908 -0.0010
Y3 333.1881 333.1887 0.0006
Y2 276.1666 276.1634 -0.0032
b+ 258.1454 258.1401 -0.00533
CIIHI6N30/ 222.1237 222.1271 0.0034
b/ 201.1239 201.1187 -0.0052
YI 175.1190 175.1165 -0.0025
CgH17N2O/ 173.1285 173.1251 -0.0034
BI+ 163.0606 163.0556 -0.0050
[B I -H20l' 145.0495 145.0441 -0.0054
[B I -2H20f 127.0390 127.0377 -0.0013
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Table D.2. LC-ESI-QqTOF-MS/MS analysis of the glycated peptide
YSRSLGK*YGTRCCTKPE (Lys 455) at mlz 837.7418 (+3).
Molecular ion
Calculated Experimental Deviation
mlz mlz Da
yt 1175.0802 1175.0537 -0.0265
yo2+ 1094.0538 1094.0196 -0.0342
Ys 1051.4654 1051.6035 0.1381
[bn - B2]2+ 857.4301 857.3536 -0.0765
Y6 794.3166 794.3500 0.0334
Y n+ 783.7226 783.7090 -0.0136
Yo"+ 729.7050 729.6955 -0.0095
[b ,6 -B2l'+ 680.6874 680.9973 0.3099
[b ls -B2l'+ 648.3365 648.3185 -0.0180
Ys 634.2859 634.2903 0.0044
b6+ 600.3469 600.3686 0.0217
bs+ 543.3255 543.3232 -0.0023
b/ 430.2414 430.2353 -0.0061
YJ 373.2076 373.2002 -0.0074
b+ 343.2094 343.2020 -0.0074
.'
CI7H26NJ04+ 336.1918 336.1871 -0.0047
Y2 245.1126 245.1056 -0.0070
CIIHI6NJO/ 222.1237 222.1181 -0.0056
b2+ 187.1083 187.1043 -0.0040
BI- 163.0606 163.0527 -0.0079
YI 148.0599 148.0601 0.0002
[B I -H20r 145.0495 145.0423 -0.0072
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Table 0.3. LC-ESI-QqTOF-MS/MS analysis of the glycated peptide
YSRSLGK*YGTRCCTK*PE (Lys 455, Lys 463) at m/z 1029.8189 (+3).
Molecular Calculated Experimental Deviation
ion III/Z III/Z Da
[YIO-B2f 1459.6657 1459.6788 0.0131
[Y9- B2f 1360.5973 1360.5324 -0.0649
[Yg-B2f 1303.5758 1303.5839 0.0081
[Y7- B2f 1202.5281 1202.4761 -0.0520
[b IS -2B2t 1098.0566 1098.0119 -0.0447
[bg-B2f 1079.6208 1079.6271 0.0063
[b7-B2f 980.5524 980.5238 -0.0286
[b I4 -B2]2+ 907.9539 907.9193 -0.0346
[bl)-B2]2+ 857.4301 857.3852 -0.0448
[b t2 -B2]2+ 777.4148 777.3857 -0.0290
[Y4- B2f 726.3657 726.3182 -0.0475
[b tt -B2]2+ 697.3994 697.3887 -0.0107
[Y.1- B2f 625.3180 625.3054 -0.0126
b6+ 600.3469 600.3208 -0.0261
[b9 -B2]2+ 568.8250 568.7979 -0.0271
bs+ 543.3255 543.3021 -0.0234
[b7- B2]2+ 490.7801 490.7766 -0.0034
b+ 343.2094 343.2091 -0.0003
.1
C17H26N3O/ 336.1918 336.1852 -0.0066
Y2 245.1126 245.1060 -0.0066
CltHt6N.102+ 222.1237 222.1174 -0.0063
Bt+ 163.0606 163.0559 -0.0047
Yt 148.0599 148.0556 -0.0043
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Table D.4. LC-ESI-QqTOF-MS/MS analysis of the glycated peptide DK*GACLLPK*IE
at m/z 1198.5604 (+2).
Molecular ion Calculated Experimental Deviation
III/Z III/Z Da
[b7 -B2t 1010.4975 1010.4840 -0.0135
[b6-B2t 897.4135 897.4186 0.0051
[Ys-B2t 851.4862 851.4950 0.0088
[bs -B2t 784.3294 784.3192 -0.0102
[Y4- B2t 738.4021 738.3985 -0.0036
[Y4-C2t 720.3913 720.3922 0.0009
[YJ-B2f 641.3494 641.3512 0.0018
[b4-B2t 624.2988 624.2894 -0.0094
[PK*I-B2f 591.3495 591.3327 -0.0168
[PK*I- B2- cot 563.3551 563.3495 -0.0056
[b,-82t 553.2617 553.2575 -0.0042
[bJ -C2l' 535.2509 535.2567 0.0058
[K*GA- 82t 509.2713 509.2603 -0.0110
[b2-82t 496.2402 496.2263 -0.0139
[K*I-82t 494.2968 494.2911 -0.0057
[PK*-B2l' 478.2655 478.2529 -0.0126
CI7H26NJ04+ 336.1918 336.1881 -0.0037
Y2 261.1439 261.1394 -0.0045
CIIHI6N302+ 222.1237 222.1187 -0.0050
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